A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Phase: PHASE2
Conditions: Hidradenitis Suppurativa (HS)
Sponsor: InflaRx GmbH

 
 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 1 of 109  
IFX-1 
InflaRx GmbH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLINICAL STUDY PROTOCOL 2.0 
GLOBAL AMENDMENT 1.1 
 
Study Title: 
 
A randomized, double-blind, placebo-controlled, 
multicenter Phase II study to determine efficacy and 
safety of IFX-1 in subjects with moderate to severe 
hidradenitis suppurativa  
Study Number: 
IFX-1-P2.4 
Study Product: 
IFX-1 
IND Number: 
136470 
EudraCT Number: 
2017-004501-40 
Sponsor: 
 
InflaRx GmbH  
Winzerlaer Str. 2 
07745 Jena 
Germany  
Version and Date of 
Study Protocol 
Version 2.0 
Final 16 November 2018 
 
Global Amendment 
Version 1.1 

PROTOCOL AMENDMENT SIGNATURES
Confirmation of the Final Protocol Amendment
We hereby certify that this is the final version of the protocol amendment:
Protocol Number
IFX-1-P2.4
Study Title
A randomized, double-blind, placebo-controlled, multicenter Phase
II
study to determine efficacy and safety of IFX-1 in subjects with moderate
to severe hidradenitis suppurativa
Sponsor
OthmarZenker, MD
3j (O18
Chief Medical Officer
(Date)
(Signature)
IFX-1-P2.4
Global Amendment 1.1 [Final V2.0, 16 November 2018]
page 2 of 109
IFX-1
lnflaRx GmbH

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 5 of 109 
IFX-1  
InflaRx GmbH 
SIGNATURE OF INVESTIGATOR 
GLOBAL AMENDMENT 1.1 
 
Protocol Number 
IFX-1-P2.4 
 
Study Title 
A randomized, double-blind, placebo-controlled, multicenter Phase II 
study to determine efficacy and safety of IFX-1 in subjects with moderate 
to severe hidradenitis suppurativa  
_________________________________________________________________ 
 
Herewith I declare that I have read and understood the present protocol and agree to honor 
each part of it. By signing this study protocol, I agree to conduct the clinical study, following 
approval by an Ethics Committee, in accordance with the study protocol, the current 
International Council for Harmonisation (ICH) Guideline for Good Clinical Practice (GCP), and 
applicable regulatory requirements. I will ensure that all the subjects enrolled in the study by 
my site will be treated, observed, and documented in accordance with this protocol. I will 
ensure that all persons assisting with the study under my supervision are adequately informed 
about the protocol, the investigational product, and their duties.   
 
Investigator 
 
<<TBD>> 
 
 
 
 
 
________________________ 
_______________________________________ 
(Date [DD/MM/YYYY]) 
 
(Signature) 
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 6 of 109 
IFX-1  
InflaRx GmbH 
TABLE OF CONTENTS 
PROTOCOL AMENDMENT SIGNATURES ........................................................................... 2 
PROTOCOL AMENDMENT SIGNATURES ........................................................................... 3 
SIGNATURE OF COORDINATING INVESTIGATOR ............................................................ 4 
SIGNATURE OF INVESTIGATOR ......................................................................................... 5 
TABLE OF CONTENTS ......................................................................................................... 6 
LIST OF TABLES .................................................................................................................. 9 
ABBREVIATIONS ................................................................................................................ 10 
DEFINITION OF TERMS ...................................................................................................... 12 
GENERAL INFORMATION .................................................................................................. 14 
List of Personnel and Organizations Responsible for Conduct of Study ............................... 14 
Synopsis .............................................................................................................................. 15 
Schedules of Assessments .................................................................................................. 24 
1 
INTRODUCTION .................................................................................................... 29 
1.1 
Background Information on the Indication ............................................................... 29 
1.2 
Background Information on IFX-1 ........................................................................... 30 
1.3 
Rationale for the Phase II Study ............................................................................. 31 
1.4 
Risk-Benefit Assessment ........................................................................................ 32 
2 
OBJECTIVES ......................................................................................................... 35 
2.1 
Primary Objective ................................................................................................... 35 
2.2 
Secondary Objectives ............................................................................................. 35 
3 
STUDY DESIGN ..................................................................................................... 35 
3.1 
Overall Design ........................................................................................................ 35 
3.2 
Study Sites and Number of Subjects ...................................................................... 36 
3.3 
Expected Duration of the Study .............................................................................. 36 
4 
STUDY POPULATION ........................................................................................... 37 
4.1 
Inclusion Criteria ..................................................................................................... 37 
4.2 
Exclusion Criteria .................................................................................................... 37 
4.3 
Lifestyle Considerations .......................................................................................... 40 
4.4 
Screen Failures ...................................................................................................... 40 
4.5 
Rationale for Gender Distribution ............................................................................ 41 
5 
STUDY INTERVENTION ........................................................................................ 41 
5.1 
Investigational Medicinal Product ............................................................................ 41 
5.2 
Packaging and Labeling ......................................................................................... 42 
5.3 
Supply, Storage, and Accountability ....................................................................... 42 
5.4 
Reconstitution and Administration of the Investigational Medicinal Product ............ 43 
5.5 
Randomization and Blinding ................................................................................... 47 
5.6 
Procedures in Case of Specific Side Effects ........................................................... 48 
5.7 
Overdose ................................................................................................................ 49 
5.8 
Prior and Concomitant Therapy .............................................................................. 49 
6 
DISCONTINUATION OF STUDY INTERVENTION ................................................ 53 
6.1 
Discontinuation of Study ......................................................................................... 53 
6.2 
Discontinuation of Individual Subject Participation .................................................. 53 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 7 of 109 
IFX-1  
InflaRx GmbH 
7 
STUDY ASSESSMENTS AND PROCEDURES ..................................................... 55 
7.1 
Screening ............................................................................................................... 55 
7.2 
Main Period (16 Weeks) ......................................................................................... 56 
7.3 
Extension Period (28 Weeks) ................................................................................. 58 
7.4 
Unscheduled Visits ................................................................................................. 61 
8 
STUDY VARIABLES AND METHODS OF ASSESSMENT ................................... 62 
8.1 
Study Subjects ........................................................................................................ 62 
8.2 
Efficacy Variables ................................................................................................... 63 
8.3 
Safety Variables ..................................................................................................... 67 
8.4 
Pharmacokinetics and Pharmacodynamics ............................................................ 70 
9 
ADVERSE EVENTS ............................................................................................... 71 
9.1 
Adverse Events ...................................................................................................... 71 
9.2 
Serious Adverse Events.......................................................................................... 75 
9.3 
Adverse Events of Special Interest ......................................................................... 76 
9.4 
Suspected Unexpected Serious Adverse Reactions ............................................... 76 
9.5 
Therapeutic Procedures.......................................................................................... 76 
9.6 
Pregnancy .............................................................................................................. 77 
10 
STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE ................ 77 
10.1 
General Considerations .......................................................................................... 77 
10.2 
Determination of Sample Size ................................................................................ 77 
10.3 
Analysis Sets .......................................................................................................... 78 
10.4 
Endpoints ............................................................................................................... 78 
10.5 
Analysis of Endpoints ............................................................................................. 80 
10.6 
Demographics and Baseline Characteristics ........................................................... 83 
10.7 
Prior and Concomitant Therapies ........................................................................... 83 
10.8 
Subject Disposition ................................................................................................. 83 
10.9 
Treatment Exposure ............................................................................................... 83 
10.10 
Handling of Missing Data ........................................................................................ 83 
10.11 
Interim Analysis ...................................................................................................... 83 
11 
ETHICAL, LEGAL, AND ADMINISTRATIVE ASPECTS ........................................ 84 
11.1 
Good Clinical Practice Statement ........................................................................... 84 
11.2 
Submission to the Ethics Committee and Responsible Regulatory Authority .......... 84 
11.3 
Subject Information and Informed Consent ............................................................. 84 
11.4 
Protocol Amendments ............................................................................................ 85 
12 
DOCUMENTATION ................................................................................................ 85 
12.1 
Electronic Case Report Forms ................................................................................ 85 
12.2 
Archiving ................................................................................................................. 86 
13 
SUPERVISION OF THE CLINICAL STUDY ........................................................... 86 
13.1 
Access to Source Data ........................................................................................... 86 
13.2 
Monitoring ............................................................................................................... 86 
13.3 
Independent Data Monitoring Committee ................................................................ 87 
13.4 
Audits ..................................................................................................................... 87 
13.5 
Inspections ............................................................................................................. 87 
14 
DATA PROTECTION AND CONFIDENTIALITY .................................................... 88 
14.1 
Declaration Regarding Data Protection ................................................................... 88 
14.2 
Declaration Regarding the Anonymized Transfer of Personal Data ........................ 88 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 8 of 109 
IFX-1  
InflaRx GmbH 
15 
ADMINISTRATIVE AGREEMENTS ....................................................................... 88 
15.1 
Adherence to the Protocol/Protocol Violations ........................................................ 88 
15.2 
Financing and Insurance......................................................................................... 88 
15.3 
Notification of the Local Authorities ......................................................................... 89 
15.4 
Publication Policy and Registration ......................................................................... 89 
16 
REFERENCES ....................................................................................................... 90 
17 
APPENDIX ............................................................................................................. 92 
17.1 
Hurley Stages ......................................................................................................... 92 
17.2 
Hidradenitis Suppurativa-Physician’s Global Assessment ....................................... 93 
17.3 
Modified Sartorius Score......................................................................................... 94 
17.4 
Erythema Assessment ............................................................................................ 96 
17.5 
Patient’s Assessment of Drainage .......................................................................... 97 
17.6 
Patient’s Global Assessment of Skin Pain .............................................................. 98 
17.7 
The Dermatology Life Quality Index ........................................................................ 99 
17.8 
The Hospital Anxiety and Depression Scale ......................................................... 101 
17.9 
The 36-Item Short Form Survey ............................................................................ 102 
17.10 
The EuroQol-5 Dimensions Survey ....................................................................... 108 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 9 of 109 
IFX-1  
InflaRx GmbH 
LIST OF TABLES 
Table 1 Exposure and Safety Margins ..................................................................................32 
Table 2 Dosing Schedule by Cohort in Main Period (Double-Blind) ......................................43 
Table 3 Dosing Schedule by Cohort in Extension Period ......................................................45 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 10 of 109 
IFX-1  
InflaRx GmbH 
 ABBREVIATIONS 
 
ADA 
 
Antidrug antibody 
AE 
 
Adverse event 
AESI  
Adverse event of special interest 
AN 
 
Total abscess and inflammatory nodule count 
ANCOVA 
Analysis of covariance 
BDRM  
Blind Data Review Meeting 
bw 
 
Body weight 
CI 
 
Confidence interval 
CRF 
 
Case Report Form 
CRO  
Clinical Research Organization 
CRP 
 
C-reactive protein 
CS 
 
Clinically significant 
DLQI  
Dermatology Life Quality Index 
DMC  
Data Monitoring Committee 
ECG  
Electrocardiogram 
ED50 
 
Median effective dose 
ELISA  
Enzyme-linked immunosorbent assay  
Emax 
 
Maximum possible effect for the agonist 
EQ-5D-5L 
EuroQol-5 Dimensions survey 
FAS 
 
Full analysis set 
FUV 
 
Follow-up visit 
GCP  
Good Clinical Practice 
HADS  
Hospital Anxiety and Depression Scale 
HBsAb  
Hepatitis B virus surface antibody 
HBV 
 
Hepatitis B virus 
HiSCR  
Hidradenitis Suppurativa Clinical Response 
HIV 
 
Human immunodeficiency virus 
HRQL  
Health-related quality of life 
HS 
 
Hidradenitis suppurativa 
HS-PGA 
Hidradenitis Suppurativa- Physician’s Global Assessment 
ICH 
International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use 
IgM anti HBc IgM-antibody against hepatitis B core antigen 
IL 
 
Interleukin 
IMP 
 
Investigational medicinal product 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 11 of 109 
IFX-1  
InflaRx GmbH 
IRT 
 
Interactive Response Technology 
iv 
 
Intravenous 
LPS 
 
Lipopolysaccharide 
MAC  
Membrane attack complex 
MCP-Mod 
Multiple comparisons procedure-modelling 
MED  
Minimum effective dose 
MedDRA 
Medical Dictionary for Regulatory Activities 
mSS  
Modified Sartorius Score 
NRS 
 
Numeric Rating Scale 
NYHA  
New York Heart Association 
PD 
 
Pharmacodynamic(s) 
PK 
 
Pharmacokinetic(s) 
PPS 
 
Per protocol set 
q2w 
 
every two weeks 
q4w 
 
every four weeks 
SAE 
 
Serious adverse event 
SAS 
 
Safety analysis set 
SF-36v2 
36-Item Short Form Survey (version 2) 
SUSAR 
Suspected unexpected serious adverse reaction 
TEAE  
Treatment-emergent adverse event 
TNF 
 
Tumor necrosis factor 
USV 
 
Unscheduled visit 
UVA 
 
Ultra-violet A 
UVB 
 
Ultra-violet B 
VAS 
 
Visual analog scale 
WBC  
White blood cell count 
WOAI  
Worsening or Absence of Improvement 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 12 of 109 
IFX-1  
InflaRx GmbH 
DEFINITION OF TERMS 
Baseline 
A value or quantity that serves as a reference for comparisons 
over time. 
Investigational 
medicinal product (IMP) 
Any drug product that is to be administered in the current study. 
Case Report Form 
(CRF) 
A printed or electronic (eCRF) form for recording study 
participants’ data during the study, as required by the protocol. 
Central laboratory 
A laboratory where all subject-derived samples (e.g., serum, 
plasma) are centrally analyzed.   
Compliance 
Adherence to all the study-related requirements, Good Clinical 
Practice (GCP) requirements, and the applicable regulatory 
requirements. 
Consent 
The act of obtaining informed consent for participation in a 
clinical study from subjects deemed eligible or potentially eligible 
to participate in the clinical study. Subjects entered into a study 
are those who sign the informed consent form directly or through 
their legally acceptable representatives. 
End of study  
Overall study completion: the day of the last visit of the last 
subject enrolled in the study.  
Individual subject: the time point after which no further 
study-related procedures are performed. 
Endpoint 
Key measurement or observation used to measure the effect of 
experimental variables in a study. 
Enrollment 
The time point at which a subject formally starts to participate in 
the study after signing of informed consent form.  
Hidradenitis 
Suppurativa Clinical 
Response (HiSCR) 
• 
An at least 50% reduction in total abscess and inflammatory 
nodule count (AN) 
• 
No increase in number of abscesses 
• 
No increase in number of draining fistulas compared to 
baseline 
Loss of response 
For subjects who achieve HiSCR at the end of the Main Period: 
a loss of at least 50% of the improvement (reduction) in the AN 
count achieved from baseline to Week 16. 
AN count > ½ × (Baseline AN count + Week 16 AN count) 
Screening 
The predetermined series of procedures with which each 
investigator selects an appropriate and representative sample of 
subjects for enrollment into the study. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 13 of 109 
IFX-1  
InflaRx GmbH 
Study start 
The time point at which the first subject gives written informed 
consent; equivalent to first subject’s first visit at the first study 
site which has enrolled a subject into the study. 
 
Worsening or Absence 
of Improvement (WOAI) 
For subjects who do not achieve HiSCR at the end of the Main 
Period: AN count at 2 consecutive visits ≥ Baseline AN count. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 14 of 109 
IFX-1  
InflaRx GmbH 
GENERAL INFORMATION 
List of Personnel and Organizations Responsible for Conduct of 
Study 
A list of personnel responsible for the conduct of the study will be supplied to study sites as 
part of the investigator site file. As needed, this list will be updated by the sponsor or delegate 
and provided to study sites. 
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 15 of 109 
IFX-1  
InflaRx GmbH 
Synopsis 
Title of study 
A randomized, double-blind, placebo-controlled, multicenter 
Phase II study to determine efficacy and safety of IFX-1 in 
subjects with moderate to severe hidradenitis suppurativa. 
Protocol / study number 
IFX-1-P2.4 
EudraCT number 
2017-004501-40 
Type of study 
Dose-range finding 
Phase of development 
II 
Indication 
Treatment of patients with moderate or severe hidradenitis 
suppurativa (HS) 
Sponsor 
InflaRx GmbH  
Winzerlaer Str. 2  
07745 Jena 
Germany 
Coordinating investigator 
Prof. Dr. med. Evangelos J. Giamarellos-Bourboulis 
ATTIKON University Hospital, Athens, Greece 
Study site(s) 
Planned: approximately 50 sites in approximately 8 countries 
Primary objective 
To evaluate a dose-response signal of IFX-1 in subjects with 
HS according to the Hidradenitis Suppurativa Clinical 
Response (HiSCR) at Week 16 
Secondary objectives 
• 
To assess the efficacy of IFX-1 using additional outcome 
measures 
• 
To assess the safety and tolerability of IFX-1 
• 
To generate data for pharmacokinetic (PK) and 
pharmacodynamic (PD) modelling 
• 
To assess patient-reported outcomes 
• 
To evaluate the long-term efficacy and safety of IFX-1 
Study design 
Prospective, randomized, 2-period, double-blind and placebo-
controlled (Main Period) and open-label (Maintenance Phase 
of Extension Period) multicenter study 
Sample size 
175 subjects (randomized to receive double-blind treatment in 
1 of 5 treatment cohorts in a ratio of 1:1:1:1:1) 
Study population 
Key inclusion criteria at Screening: 
• 
Male or female, ≥ 18 years of age 
• 
Written informed consent obtained from subject 
• 
Diagnosis of HS for at least 1 year 
• 
Moderate or severe HS, as indicated by HS lesions in at 
least 2 distinct areas, 1 of which must be at least Hurley 
Stage II or Stage III 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 16 of 109 
IFX-1  
InflaRx GmbH 
• 
Stable HS for at least 2 months before Screening, as 
determined by the investigator through subject interview 
and review of medical history 
• 
Inadequate response to at least 3 months of oral 
antibiotics, or intolerance to antibiotics 
• 
Total abscess and inflammatory nodule (AN) count of ≥ 3 
Key exclusion criteria at Screening: 
• 
Body weight < 60 or > 130 kg  
• 
Any other skin disease that may interfere with 
assessment of HS  
• 
More than 20 draining fistulas 
• 
Prior treatment with adalimumab or another biologic 
product during the 24 weeks before Screening 
• 
Prior treatment with IFX-1 
• 
Subjects on permitted oral antibiotic treatment for HS 
(doxycycline or minocycline only) who have not been on 
a stable dose during the 28 days before Screening 
• 
Subject received systemic non-biologic therapy for HS 
with potential therapeutic impact for HS during the 
28 days before Screening (other than permitted oral 
antibiotics) 
• 
Prior treatment with any of the following medications 
during the 28 days before Screening: 
o Any other systemic therapy for HS 
o Any iv anti-infective therapy 
o Phototherapy (ultra-violet B [UVB] or psoralen 
and ultra-violet A [UVA]) 
• 
Prior treatment with any of the following medications 
during the 14 days prior to IMP administration: 
o Analgesics (including opioids) for HS-related pain 
o Prescription-only topical therapies for HS 
o Oral anti-infectives for infections other than HS 
• 
History of moderate to severe heart failure (New York 
Heart Association [NYHA] Class III or IV), 
cerebrovascular accident during the 24 weeks before 
Screening, history of malignancy except for successfully 
treated non-metastatic basal cell or squamous cell 
carcinoma or in situ carcinoma of the cervix 
• 
One of the following abnormal laboratory findings: 
o White blood cell count (WBC) < 2500/mm3 
o Neutrophil count < 1000/mm3 
o Serum creatinine > 3 × UNL 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 17 of 109 
IFX-1  
InflaRx GmbH 
o Total bilirubin > 3 × UNL 
o Alanine aminotransferase > 5 × UNL 
o Aspartate aminotransferase > 5 × UNL 
o Positive Screening test for human 
immunodeficiency virus (HIV)-1 or 2, or hepatitis 
B or C virus 
For Canada only: One of the following abnormal 
laboratory findings: 
o WBC < 2500/mm3 
o Neutrophil count < 1000/mm3 
o Serum creatinine > 3 × UNL 
o Total bilirubin > 1.5 × UNL 
o Alanine aminotransferase > 2.5 × UNL 
o Aspartate aminotransferase > 2.5 × UNL 
o Positive Screening test for HIV-1 or 2, or 
hepatitis B or C virus 
 
• 
Chronic and/or recurring systemic infections, history of 
invasive infections with atypical pathogens (i.e., which 
normally do not cause invasive infection, such as 
listeriosis), or known primary immunodeficiency 
• 
Subject is judged to be in poor general health, as 
determined by the investigator based upon medical 
history, physical examination, laboratory safety, and a 
12-lead electrocardiogram (ECG) 
• 
Female subjects of childbearing potential unwilling or 
unable to use a highly effective method of contraception 
(pearl index < 1%) such as complete sexual abstinence, 
combined oral contraceptive, vaginal hormone ring, 
transdermal contraceptive patch, contraceptive implant, 
or depot contraceptive injection in combination with a 
second method of contraception such as condom, 
cervical cap, or diaphragm with spermicide during the 
study and for at least 1 month after last administration of 
investigational medicinal product (IMP).  
For France only: the methods of contraception are 
applicable during the study and for at least 3 months 
after last administration of IMP. 
• 
History of drug or alcohol abuse during the 24 weeks 
before Screening 
• 
Pregnancy, as verified by a positive pregnancy test, or 
nursing woman 
• 
Evidence or suspicion that the subject might not comply 
with the requirements of the study protocol 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 18 of 109 
IFX-1  
InflaRx GmbH 
• 
Any other factor which, in the investigator’s opinion, is 
likely to compromise the subject’s ability to participate in 
the study 
• 
The subject is an employee or direct relative of an 
employee at the study site or sponsor 
• 
The subject is imprisoned or lawfully kept in an institution 
• 
The subject has participated in a clinical study during the 
3 months before Screening, or plans to participate in a 
clinical study 
• 
For Denmark only: Hypersensitivity to any excipients of 
IFX-1 
 
Investigational medical 
product(s) [IMP], dose, and 
mode of administration 
IFX-1 is provided in 10 mL vials containing 100 mg IFX-1 and 
will be infused over a period of 30 to 60 minutes (min) via an 
intravenous (iv) line. 
Placebo is provided in 10 mL vials containing sodium chloride, 
sodium phosphate, and Polysorbate 80. The placebo vials and 
content have the same appearance as the IFX-1 vials and 
additives. 
Main Period (16 weeks): 
For each cohort, the Main Period starts at Week 0 (Day 1, 
immediately before first administration of IMP) and consists of 
a 
2-week 
Induction 
Phase 
(ends 
immediately 
after 
administration of IMP at Week 2) followed by a 14-week 
Maintenance Phase through Week 16 (ends immediately after 
administration of IMP at Week 16). 
Cohort 1 (placebo): 
• 
Induction Phase: placebo at Weeks 0 (Days 1 and 4), 1, 
and 2 
• 
Maintenance Phase: placebo at Week 4 and every other 
week through Week 16 
Cohort 2 (IFX-1 400 mg q4w): 
• 
Induction Phase: IFX-1 400 mg at Week 0 (Days 1 
and 4), followed by placebo at Weeks 1 and 2 
• 
Maintenance Phase: IFX-1 400 mg at Week 4, followed 
by alternating infusions every other week of placebo or 
400 mg IFX-1 through Week 16 
Cohort 3 (IFX-1 800 mg q4w): 
• 
Induction Phase: IFX-1 800 mg at Weeks 0 (Days 1 
and 4) and 1, followed by placebo at Week 2 
• 
Maintenance Phase: IFX-1 800 mg at Week 4 followed 
by alternating infusions every other week of placebo or 
IFX-1 800 mg through Week 16 
Cohort 4 (IFX-1 800 mg q2w): 
• 
Induction Phase: IFX-1 800 mg at Weeks 0 (Days 1 and 
4), 1, and 2 
• 
Maintenance Phase: IFX-1 800 mg at Week 4 followed 
by IFX-1 800 mg every other week through Week 16 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 19 of 109 
IFX-1  
InflaRx GmbH 
Cohort 5 (IFX-1 1200 mg q2w): 
• 
Induction Phase: IFX-1 800 mg at Weeks 0 (Days 1 
and 4) and 1, followed by IFX-1 1200 mg at Week 2 
• 
Maintenance Phase: IFX-1 1200 mg at Week 4 followed 
by IFX-1 1200 mg every other week through Week 16 
PK substudy in Main Period: 
A PK substudy will be conducted in approximately 50 of the 
175 subjects participating in the Main Period. The subjects in 
Cohorts 1 to 5 will be included in the PK substudy, only after 
giving consent to participation. The PK substudy assessments 
will be made on 2 visits during the Main Period, at Weeks 2 
and 16. 
 
Extension Period (28 weeks) – HiSCR responders 
Subjects from all cohorts who are HiSCR responders at 
Week 16 will receive IFX-1 at a dose of 800 mg q4w, starting 
at Week 20 through Week 40. If they have a loss of response 
(see Definitions of Terms) during the Extension Period, they 
will have an optional visit 2 weeks later. Subjects who then 
have a loss of response at the subsequent (planned) visit will 
be discontinued from the study and will not switch to the non-
responder schedule. 
Extension Period (28 weeks) – HiSCR non-responders 
Subjects from all cohorts who are HiSCR non-responders at 
Week 16 will receive IMP during an Induction Phase (Weeks 
18 and 19), followed by IFX-1 at a dose of 800 mg q2w during 
the Maintenance Phase. 
Cohort 1:  
• 
Induction Phase: infusion of IFX-1 800 mg at Weeks 18 
(Days 127 and 130) and 19 
• 
Maintenance Phase: IFX-1 800 mg at Week 20 and 
every other week through Week 40 
Cohort 2: 
• 
Induction Phase: infusion of IFX-1 800 mg at Week 18 
(Day 127), placebo at Week 18 (Day 130), and IFX-1 
800 mg at Week 19 
• 
Maintenance Phase: IFX-1 800 mg at Week 20 and 
every other week through Week 40 
Cohorts 3, 4, and 5: 
• 
Induction Phase: infusion of IFX-1 800 mg at Week 18 
(Day 127), and placebo at Week 18 (Day 130) and 
Week 19 
• 
Maintenance Phase: IFX-1 800 mg at Week 20 and every 
other week through Week 40 
Subjects who experience Worsening or Absence of 
Improvement (WOAI) (see Definitions of Terms) at 
2 consecutive visits during the Maintenance Period of the 
Extension Period will be discontinued from the study. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 20 of 109 
IFX-1  
InflaRx GmbH 
Study duration 
 
The study duration for an individual subject will be up to 
48 weeks and includes the following study periods: 
• 
Screening Period: up to 18 days before first 
administration of IMP (Week −4 to Week −2 [Day -28 to 
Day -10) 
• 
Main Period: starts with the first infusion of IMP on 
Week 0 (Day 1) and ends at Week 16 (Day 113), after 
administration of IMP 
• 
Extension Period: starts after administration of IMP at 
Week 16 and ends at Week 44 
Criteria for evaluation 
Efficacy: 
The primary efficacy endpoint is the percentage of subjects 
with a response on the basis of the HiSCR determined at 
Week 16, before administration of IMP. 
The secondary efficacy endpoints include: 
• 
Percentage of subjects with a response on the basis of 
the HiSCR determined at Week 12, before administration 
of IMP 
• 
Number of subjects with flares analyzed in terms of 
≥ 25% increase in AN count among subjects with a 
minimum increase of 2 in AN count relative to Day 1  
• 
Absolute values and absolute and relative change in 
modified Sartorius Score (mSS) from Day 1 by time point 
• 
Absolute value and absolute and relative change in 
Patient’s Global Assessment of Skin Pain (Numeric 
Rating Scale [NRS]) from Day 1 by time point 
• 
Percentage of subjects achieving, by time point: 
o At least a 30% reduction and at least 1 unit 
reduction from Day 1 among subjects with 
baseline NRS ≥ 3 in Patient’s Global Assessment 
of Skin Pain (NRS30) 
o At least a 50% reduction and at least 2 units 
reduction from Day 1 among subjects with 
baseline NRS ≥ 3 in Patient’s Global Assessment 
of Skin Pain (NRS50) 
• 
Absolute values and absolute and relative change in 
Dermatology Life Quality Index (DLQI) score from Day 1 
by time point 
Exploratory efficacy endpoints: 
• 
Percentage of subjects with ≥ 50% reduction in AN count 
compared to Day 1 by time point 
• 
Percentage of subjects with no increase in number of 
abscesses compared to Day 1 by time point 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 21 of 109 
IFX-1  
InflaRx GmbH 
• 
Percentage of subjects with no increase in number of 
draining fistulas compared to Day 1 by time point 
• 
Percentage of (partial) responders measured by HiSCR 
and HiSCR25 by time point 
• 
Percentage of subjects with ≥ 25% relative and ≥ 2 
absolute increase in counts, using the abscess count, the 
inflammatory nodule count, and the draining fistula count 
by time point 
• 
Achievement of clear or minimal severity of Hidradenitis 
Suppurativa- Physician’s Global Assessment (HS-PGA) 
among subjects with at least 2 grades improvement 
(reduction) from Day 1 to each time point. 
 
All other efficacy endpoints will be exploratory. 
Safety endpoints: 
• 
The number and percentage of subjects who had a 
treatment-emergent adverse event (TEAE) as well as 
the number of TEAEs will be assessed for all TEAEs 
and serious adverse events (SAEs). 
 
Exploratory safety endpoints: 
• 
The number and percentage of subjects who have a 
TEAE as well as the number of TEAEs will be 
assessed for all causally related TEAEs, related 
SAEs, adverse events of special interest (AESIs), 
TEAEs leading to study discontinuation, related 
TEAEs leading to study discontinuation, TEAEs 
leading to IMP discontinuation, and related TEAEs 
leading to IMP discontinuation 
• 
Laboratory safety parameters will be assessed by 
time point and changes in routine laboratory 
parameters from baseline will be determined. Shifts in 
safety laboratory parameters outside of normal 
ranges compared with baseline will be investigated 
• 
Immunogenicity will be assessed by determining the 
number and percentage of subjects with detection of 
antidrug antibodies (ADAs) (before and after 
administration of IMP) 
PK: 
• 
PK will be assessed on the basis of IFX-1 
concentrations. The exposure to IFX-1 in all subjects 
will be measured as the plasma concentration of IFX-
1 determined on Day 4 and at all subsequent 
scheduled visits to the study site through Week 44. 
Actual PK sampling times will be determined and the 
plasma concentration of IFX-1 will be assessed by 
time point 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 22 of 109 
IFX-1  
InflaRx GmbH 
 
 
PD: 
• 
The PD of IFX-1 is primarily measured by plasma 
concentration of C5a at prespecified times after 
administration of IFX-1  
• 
Plasma concentrations of C5a and C3a and serum 
concentrations of CH50 will be assessed by time 
point and as change from Day 1 
• 
Serum concentrations of C-reactive protein (CRP) will 
be assessed by time point and as change from Day 1 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 23 of 109 
IFX-1  
InflaRx GmbH 
Statistical methods 
A total of 175 subjects are planned to be enrolled into the 
study (i.e., 35 subjects per cohort) to achieve at least 29 
subjects per cohort available for the primary analysis of the 
primary efficacy endpoint. The sample size is selected so that 
the multiple contrast test (as part of the multiple comparisons 
procedure-modelling [MCP-Mod] that will be used to analyze 
the primary efficacy endpoint) exceeds a power of 90%. With 
the planned sample size, the power criterion of the multiple 
contrast test is fulfilled because 29 subjects per cohort would 
yield a power of at least 90% to detect a dose-response signal 
if present. A 1-sided significance level of 𝛼𝛼 = 0.025 will be 
used. 
In general, data will be analyzed by cohort and study phase 
(Main Period and Extension Period) and may be differentiated 
further (e.g., by visit or by study site). 
The primary efficacy endpoint of the percentage of subjects 
with HiSCR at Week 16 will be analyzed using the MCP-Mod 
procedure.  
The secondary efficacy endpoint of the percentage of subjects 
with HiSCR at Week 12 will be analyzed in the same way as 
the primary endpoint using the MCP-Mod procedure.  
For all other continuous efficacy endpoints, the absolute 
values and changes from baseline (absolute and relative) will 
be analyzed by descriptive statistics (e.g., number of 
observations, mean, standard deviation, minimum, median, 
maximum, lower quartile, upper quartile, and upper and lower 
boundary of the 95% confidence interval [CI] for the mean) by 
time point. Model-based analyses (e.g., analysis of 
covariance [ANCOVA], Poisson, and logistic regression 
models) for continuous, count, and binary endpoints will be 
defined in the statistical analysis plan as deemed necessary 
and possible. 
All categorical efficacy endpoints will be summarized by time 
point using absolute and relative frequencies, including 95% 
exact CIs based on the binomial distribution. 
Sensitivity analyses will be defined for efficacy endpoints if 
deemed necessary. 
Continuous safety parameters will be analyzed by descriptive 
statistics for absolute values and changes from baseline 
(absolute and relative) by time point. Categorical safety 
parameters will be summarized by absolute and relative 
frequencies by time point. 
No formal interim analysis is planned for this study. 
An independent, unblinded Data Monitoring Committee 
(DMC) will be established to allow regular monitoring of the 
study data in order to detect and report early evidence of 
unanticipated harm to subjects. 
 
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 24 of 109 
IFX-1  
InflaRx GmbH 
Schedules of Assessments 
The Schedule of Assessments for Screening and the Main Period is applicable to all subjects. 
For the Extension Period, separate Schedules of Assessments are provided for subjects 
according to their responder status at Week 16. 
 

 
 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018]   
 
 
 
page 25 of 109 
IFX-1 
InflaRx GmbH 
Schedule of Assessments - Screening and Main Period (All Subjects)  
 
Screening
V1
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
USV
Week -4 to 
Week -2
Week 1
Week 2
Week 4
Week 6
Week 8
Week 10
Week 12
Week  14
Week 16
Day -28 to 
Day -10
Day 1
Day 4
Day 8
Day 15
Day 29
Day 43
Day 57
Day 71
Day 85
Day 99
Day 113
Accepted time window
±1 Day
±1 Day
±1 Day
±1 Day
±1 Day
±1 Day
±1 Day
±1 Day
±1 Day
±1 Day
Informed Consent Procedure
X
Inclusion/Exclusion Criteria
X
X (a)
Pregnancy Test
X 
(serum)
X (a) 
(urine)
X (j)
(urine)
X (j)
(urine)
X (j)
(urine)
X 
(urine)
Medical and Surgical History
X
X (a)
Demographics and Baseline Characteristics
X
HS Medical and Surgical History
X
X (a)
Prior Therapy
X
Physical Examination
X
X (a)
X
ECG
X
X
Vital Signs
X (f)
X (a)
X
X
X
X
X
X
X
X
X
X
X
HS Clinical Parameters
X
X (a)
X
X
X
X
X
X
X
X
X
Erythema Assessment
X
X
X
X
X
X
X
X
X
X
X
Patient's Global Assessment Skin Pain (NRS) (Daily)
Analgesic Therapy (Daily)
Patient's Assessment of Drainage  (Daily)
DLQI, HADS, SF-36v2, EQ-5D-5L
X
X
Photography
X
X
X
Randomization
X (l)
Administration of IMP (d)
X
X
X
X
X
X
X
X
X
X
X
Laboratory Parameters
Safety Laboratory (c)
X
X
X (j)
X (j)
X
HIV-1 or 2 / HBV / HCV Test
X
Plasma
C3a (c)
X
X
X
C5a (c)
X
X
X
X
X
Serum and plasma biomarkers (i)
X
X
X
Citrate plasma
IFX-1 (c)
X (g)
X
X (e, g)
X
X
X
X
X 
X
X (e)
Serum
CH50 (c)
X
X
X
CRP (c)
X
X
X (j)
X (j)
X (j)
X
Anti-drug Antibodies (c)
X
X
X
Continuous Documentation
Adverse Events
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant Therapy
X
X (a)
X
X
X
X
X
X
X
X
X
X
X
Induction Phase
Week 0
Main Period
Maintenance Phase
Unsch-
eduled 
Visit

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 26 of 109 
IFX-1  
InflaRx GmbH 
Schedule of Assessments - Extension Period (HiSCR Responders at Week 16)  
 
V1R
V2R
V3R
V4R
V5R
V6R
FUV
OVx
USV
Week 20
Week 24
Week 28
Week 32
Week 36
Week 40
Week 44 
(b)
Day 141
Day 169
Day 197
Day 225
Day 253
Day 281
Day 309
Accepted time window
± 1 Day
± 2 Days
± 2 Days
± 2 Days
± 2 Days
± 2 Days
+ 2 Days
Informed Consent Procedure
Inclusion/Exclusion Criteria
Pregnancy Test
X (j)
(urine)
X (j)
(urine)
X (j)
(urine)
X (j)
(urine)
X (j)
(urine)
X (j)
(urine)
X 
(serum)
Medical and Surgical History
Demographics and Baseline Characteristics
HS Medical and Surgical History
Prior Therapy
Physical Examination
X
X
ECG
X
X (h)
Vital Signs
X
X
X
X
X
X
X
X
X
HS Clinical Parameters
X
X
X
X
X
X
X
X
X
Erythema Assessment
X
X
X
X
X
X
X
X
X
Patient's Global Assessment Skin Pain (NRS) (Daily)
Analgesic Therapy (Daily)
Patient's Assessment of Drainage  (Daily)
DLQI, HADS, SF-36v2, EQ-5D-5L
X
X
Photography
X
X
X
Randomization
Administration of IMP (d)
X
X
X
X
X
X
Laboratory Parameters
Safety Laboratory (c)
X (j, k)
X (j)
X (j)
X
X (j)
X (j)
X
HIV-1 or 2 / HBV / HCV Test
Plasma
C3a (c)
X
X
C5a (c)
X
X
X
Serum and plasma biomarkers (i)
X
X
Citrate plasma
IFX-1 (c)
X
X
X
X
X
X
X
Serum
CH50 (c)
X
X
CRP (c)
X (j)
X (j)
X (j)
X
X (j)
X (j)
X
Anti-drug Antibodies (c)
X
X
X
Continuous Documentation
Adverse Events
X
X
X
X
X
X
X
X
X
Concomitant Therapy
X
X
X
X
X
X
X
X
X
Extension Period
Maintenance Phase
Optional 
Visit
Unsch-
eduled 
Visit

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 27 of 109 
IFX-1  
InflaRx GmbH 
Schedule of Assessments - Extension Period (HiSCR Non-Responders at Week 16)  
 
V1NR
V2NR
V3NR
V4NR
V5NR
V6NR
V7NR
V8NR
V9NR
V10NR
V11NR
V12NR
V13NR
V14NR
FUV
USV
Week 19
Week 20
Week 22
Week 24
Week 26
Week 28
Week 30
Week 32
Week 34
Week 36
Week 38
Week 40
Week 44 
(b)
Day 127
Day 130
Day 134
Day 141
Day 155
Day 169
Day 183
Day 197
Day 211
Day 225
Day 239
Day 253
Day 267
Day 281
Day 309
Accepted time window
± 1 Day
± 1 Day
± 1 Day
± 1 Day
± 2 Days
± 2 Days
± 2 Days
± 2 Days
± 2 Days
± 2 Days
± 2 Days
± 2 Day
± 2 Days
± 2 Days
+ 2 Days
Informed Consent Procedure
Inclusion/Exclusion Criteria
Pregnancy Test
X (j)
(urine)
X (j)
(urine)
X (j)
(urine)
X (j)
(urine)
X (j)
(urine)
X (j)
(urine)
X 
(serum)
Medical and Surgical History
Demographics and Baseline Characteristics
HS Medical and Surgical History
Prior therapy
Physical Examination
X
X
ECG
X
X (h)
Vital Signs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
HS Clinical Parameters
 
X
X
X
X
X
X
X
X
X
X
X
X
X
Erythema Assessment
X
X
X
X
X
X
X
X
X
X
X
X
X
Patient's Global Assessment Skin Pain (NRS) (Daily)
Analgesic Therapy (Daily)
Patient's Assessment of Drainage (Daily)
DLQI, HADS, SF-36v2, EQ-5D-5L
X
X
Photography
X
X
X
X
Randomization
Administration of IMP (d)
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Laboratory Parameters
Safety Laboratory (c)
X (j, k)
X (j)
X (j)
X
X (j)
X (j)
X
HIV-1 or 2 / HBV / HCV Test
Plasma
C3a (c)
X
X
C5a (c)
X
X
X
X
Serum and plasma biomarkers (i)
X
X
Citrate plasma
IFX-1 (c)
X
X (g)
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum
CH50 (c)
X
X
CRP (c)
X (j)
X (j)
X (j)
X
X (j)
X (j)
X
Anti-drug Antibodies (c)
X
X
X
X
Continuous Documentation
Adverse Events
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant Therapy
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Extension Period
Induction Phase
Maintenance Phase
Week 18
Unsch-
eduled 
Visit

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 28 of 109 
IFX-1  
InflaRx GmbH 
Footnote applies to all Schedules of Assessments 
AE = adverse event, CRP = C-reactive protein, DLQI = Dermatology Life Quality Index, ECG = electrocardiogram, 5D-5L = EuroQol-5 Dimensions survey, FUV = follow-up visit, h = hour, HADS = 
Hospital Anxiety and Depression Scale, HBV = hepatitis B virus, HCV = hepatitis C virus, HiSCR = Hidradenitis Suppurativa Clinical Response, HIV = human immunodeficiency virus, HS = 
hidradenitis suppurativa, IMP = investigational medicinal product, min = minute, OV = optional visit, PK = pharmacokinetic(s), TNF = tumor necrosis factor, USV = unscheduled visit, V = visit, 
VxR= Visit for HiSCR responders, VxNR= Visit for HiSCR non-responders. 
(a) 
Update some inclusion/exclusion criteria, prior and concomitant therapy, and HS/medical history and surgery information to confirm subject eligibility. 
(b) 
All assessments intended to be performed at Week 44 should also be performed at early discontinuation visits. For subjects who discontinue early, a Post-Treatment Follow-Up visit will take 
place 3 months after early discontinuation or another HS therapy has been started, whichever occurs first. At the Post-Treatment Follow-Up visit the same parameters as at Week 44 will be 
assessed.  
(c) 
Blood samples must be obtained before IMP administration. 
(d) 
IMP administered according to dosing schedules in Table 2 and Table 3. 
(e) 
PK substudy in 8 to 10 subjects from each cohort. Blood samples will be obtained for analysis of IFX-1 in citrate plasma before IMP administration (0 h), after end of IMP administration (+ 10 min) 
and at 2 h (± 10 min), 6 h (± 10 min), 24 h (± 2 h), and 48 h (± 2 h) after start of IMP administration, in all cases using a separate infusion line. 
(f) 
Height and body weight will be assessed at Screening only. 
(g) 
Blood sample for IFX-1 analysis will be taken before IMP administration and directly after IMP infusion using a separate infusion line, with a time window of + 10 min. 
(h) 
Subjects will have a repeat ECG at Week 44 or at an early discontinuation visit if the subject discontinues before Week 44. If in the opinion of the investigator, clinically relevant AEs have 
developed during the study that warrant a repeat ECG examination this can be performed at any time during the study. 
(i) 
Blood sampling of serum and plasma biomarkers for future research is not applicable for Denmark. 
(j) 
Test only applicable for France. 
(k) 
Test only applicable for Denmark. 
(l) 
The randomization can occur at every time point between Screening and Day 1 or at Day 1 after confirmation of the Principal Investigator that the patient fulfills the eligibility criteria. 
 

 
 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 29 of 109 
IFX-1 
InflaRx GmbH 
1 INTRODUCTION 
1.1 Background Information on the Indication 
Hidradenitis suppurativa (HS) is a chronic devastating skin disorder affecting areas rich in 
apocrine glands. Nodules appear in the affected areas, progressively become swollen, and 
rupture with the release of pus. This process occurs repeatedly leading to sinus tract formation 
and scars [1]. The disease course creates a frustrating situation for patients as well as for 
physicians. Treatments recommended by guidelines include dietary and behavioral changes, 
topical and systemic medications (including antibiotics), and timely surgical interventions [2, 
3]. Behavioral interventions and topical and systemic medications are most beneficial for 
preventing new lesions and reducing the inflammatory component of the disease. Surgical 
interventions are used to eliminate nodules, remove existing sinus tracts and scars, and 
prevent new sinus tract and scar formation. Despite treatment, relapse is very frequent, leading 
to severe impairment of the quality of life. The Dermatology Life Quality Index (DLQI) for HS 
is 8.9, and thereby higher than in any other skin disorder [4]. 
This devastating disorder has often been neglected and considered a rare condition. From an 
analysis of commercial health insurance reimbursement data for 2007 from a large group of 
patients in the United States, Cosmatos et al. determined a prevalence of 0.053% for clinically 
detected HS, and an estimated 146,000 to 162,000 patients in 2007 [5]. HS seems to 
indiscriminately affect the global population. A recent large epidemiological survey in France 
reported 0.97% disease prevalence[6]. However, the point prevalence is reported to range 
between 1% and 4%[7]. 
The exact pathophysiology of HS is unknown. Smoking, dietary habits, and genetic 
predisposition have all been linked with HS [8, 9]. However, a recent survey in 53 patients 
disclosed a severe derangement of the monocyte function and of subsequent antigen 
processing in these patients [10]. There the percentage of natural killer cells was increased 
and that of CD4-lymphocytes decreased compared to healthy controls, probably implying an 
autoimmune origin of the disorder. Additionally, a defective lipopolysaccharide (LPS)-induced 
production of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and 
interleukin (IL)-6 by blood monocytes was demonstrated in patients with HS. This down-
regulation of systemic cytokine production seems to be counter-regulatory to what happens in 
the inflamed skin: over-production of pro-inflammatory cytokines mainly TNF-α and IL-1β is ta 
distinctive feature that, nevertheless, does not seem to follow a specific pattern [11, 12].  
The wide range of possible pathogenic mechanisms suggested by different studies denotes 
that HS may be associated with host mechanisms rather than exogenous factors. Taking into 
account the paradox that both anti-infectious (e.g., antibiotics) and pro-infectious (e.g., anti-
TNF, corticosteroids, and immunosuppressive drugs) therapies may be effective, HS appears 
as an auto-inflammatory disease based on a defect in the hair follicle innate immunity [13]. The 
auto-inflammatory nature of HS is further supported by the evidence that pro-inflammatory 
cytokines such as IL-1β and TNF-α are markedly increased in lesional and perilesional 
skin[14]. 
As a consequence, the implication of some autoimmune or auto-inflammatory mechanism in 
the pathogenesis of HS has been speculated over the last years. The hypothesis is further 
reinforced by positive results from the administration of TNF antagonists such as adalimumab, 
which is approved for the treatment of patients with moderate to severe HS in prospective, 
placebo-controlled studies [15]. In the first study conducted with IFX-1 in subjects with HS 
(Study IFX-1-P2.3), in which subjects with moderate to severe HS were treated with 9 
consecutive infusions of IFX-1 800 mg over 50 days, 83.3% of subjects achieved a Hidradenitis 
Suppurativa Clinical Response (HiSCR).  

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 30 of 109 
IFX-1 
InflaRx GmbH 
1.2 Background Information on IFX-1 
IFX-1 is a monoclonal antibody which specifically binds to the soluble human complement split 
product C5a. Nonclinical studies have demonstrated that IFX-1 binds to its target rapidly and 
is capable of a nearly complete blockade of C5a-induced biological effects while not affecting 
cleavage of C5 and formation of the complement membrane attack complex (MAC) [16, 17].  
Single and repeated intravenous (iv) administration of IFX-1 at doses of up to 50 mg/kg body 
weight (bw) over 6 months in cynomolgus monkeys resulted in no related or relevant 
toxicological adverse findings within an extended core battery of safety pharmacology 
assessments. 
Various nonclinical studies have been conducted to assess pharmacological and toxicological 
aspects of IFX-1, none of which revealed any obvious toxicological or safety concerns for 
IFX-1. IFX-1 was well tolerated and did not show any toxicity with any of the doses tested. 
Therefore, the No Observed Adverse Effect Level was defined as the highest administered 
dose of 50 mg/kg bw (corresponding to a human equivalent dose of 16.13 mg/kg bw). 
IFX-1 is an investigational medicinal product (IMP) and is not approved in any country 
worldwide. To date, IFX-1 has been investigated in 1 Phase I study in healthy subjects and in 
3 Phase II studies in subjects with early septic organ dysfunction, in subjects undergoing 
complex cardiac surgery, and in subjects with moderate to severe HS.  
Study IFX-1-P1.1 (healthy subjects): in this Phase I study in 15 healthy subjects, 5 consecutive 
dose groups (IFX-1 0.02, 0.1, 0.5, 2, and 4 mg/kg bw) received single iv infusions of IFX-1 or 
placebo. IFX-1 was safe and well tolerated. The following adverse events (AEs) were reported 
by the investigator as at least possibly related to IFX-1: nausea, headache, nasopharyngitis, 
and C-reactive protein (CRP) increased.  
Study IFX-1-P2.1 (subjects with early septic organ dysfunction): in this Phase II study in 
subjects with early septic organ dysfunction caused by pulmonary or abdominal infection, the 
safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of IFX-1 were 
investigated in 3 different dose groups (IFX-1 2 × 2 mg/kg bw, 2 × 4 mg/kg bw, and 3 × 4 mg/kg 
bw, each with a placebo control). In total, 48 subjects were treated with IFX-1. IFX-1 was safe 
and well tolerated. The following AEs were reported by the investigator as at least possibly 
related to IFX-1: acute hepatic failure, hepatocellular injury, pulmonary embolism, 
hypertension, atrial fibrillation, and impaired healing.  
Study IFX-1-P2.2 (subjects undergoing complex cardiac surgery): in this Phase II study in 
subjects undergoing complex cardiac surgery, the efficacy, PK, PD, and safety of single doses 
of IFX-1 were investigated in 4 different dose groups (IFX-1 1, 2, 4, and 8 mg/kg bw, each with 
a placebo control). In total, 82 subjects were treated with IFX-1. IFX-1 was safe and well 
tolerated. The following AEs were reported by the investigator as at least possibly related to 
IFX-1: leukocytosis, impaired healing, blood pressure decreased, and heart rate decreased.  
Study IFX-1-P2.3 (subjects with moderate to severe HS): in this Phase II study in subjects with 
moderate to severe HS, the safety, PK, PD, and efficacy of IFX-1 were investigated after 
9 weekly infusions of 800 mg. In total, 12 subjects were treated with IFX-1. IFX-1 was safe and 
well tolerated. There were no AEs reported by the investigator as at least possibly related to 
IFX-1.  
An overview of known and potential risks and benefits of the IMP to human subjects is available 
in Section 1.4. 
Further details on IFX-1 are given in the Investigator’s Brochure, the current version of which 
is available in the investigator site file.  

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 31 of 109 
IFX-1 
InflaRx GmbH 
1.3 Rationale for the Phase II Study 
HS is diagnosed by its clinical features and its chronicity. It is recognized by the presence of 
recurrent, painful, deep-seated, rounded nodules usually ending in abscesses and sinus tracts 
with suppuration and hypertrophic scarring of apocrine gland-bearing skin and is likely to be 
an auto-inflammatory disease based on a defect in the hair follicle innate immunity  [13] 
(Section 1.1). As complement C5a is involved in the underlying acute inflammatory responses, 
this study is set up based on the hypothesis that IFX-1 might be able to block C5a induced 
pro-inflammatory effects such as neutrophil activation and cytokine generation, potentially 
contributing to the local skin inflammation and tissue damage.  
As the dose-response for IFX-1 has not been assessed to date in a chronic disease, the 
primary rationale of this Phase II study is to investigate a dose-response signal of IFX-1 in 
subjects with moderate to severe HS according to the HiSCR. 
Further important aims of the study are to investigate the PK, PD, and safety of IFX-1 in 
subjects with HS. The study will also collect data on clinical parameters that could be positively 
affected by a C5a blocking therapy (e.g., DLQI, Patient’s Global Assessment of Skin Pain 
[Numeric Rating Scale, NRS]).  
Rationale for Study Population 
Patients with HS show elevated serum levels of TNF-α [14, 18]. Additionally, CRP values and 
white blood cell count (WBC) are increased significantly in patients with moderate or severe 
HS compared with the mild manifestation of the disease [19]. Because these patients present 
signs of systemic inflammation, the administration of a compound such as IFX-1, with its multi-
faceted anti-inflammatory potential, may be a suitable agent for the management of HS, as 
shown in Study IFX-1-P2.3. The subjects with moderate to severe HS enrolled in the current 
study are considered to have a sufficiently severe disease status to evaluate the tolerability, 
PK, and PD of 4 dosing regimens of IFX-1, compared with placebo.  
In line with the conclusions of an HiSCR validation study [20], subjects with a total abscess 
and inflammatory nodule count (AN) of < 3 at baseline will be excluded to eliminate the 
possibility that a 1-unit reduction in AN count could lead to an HiSCR response. 
To keep the study population as homogenous as possible, subjects will not be enrolled into 
the study if they have been treated previously with any of the following for prespecified time 
periods before Screening (Section 4.2): IFX-1, adalimumab or other biologic products, 
non-stable doses of oral antibiotic treatment permitted for HS (doxycycline or minocycline 
only), systemic non-biologic therapies for HS with potential therapeutic impact for HS, any 
other systemic therapy for HS, any iv anti-infective therapy, phototherapy (ultra-violet B [UVB] 
or psoralen and ultra-violet A [UVA]), analgesics (including opioids) for HS-related pain, 
prescription-only topical therapies for HS, or oral anti-infectives for infections other than HS. 
Rationale for Dosing Regimen 
The aim of treatment with IFX-1 is to reach an almost complete blockade of the overall 
available C5a (existing and newly produced) in human whole blood during the entire treatment 
period. The rate at which consumed or activated C5 can be regenerated (the so-called C5 
turnover rate) is not known. It is plausible to assume that more C5 could be produced in 
settings of chronic inflammation than in healthy subjects, and thus more C5a could result from 
the ensuing activation. 
From clinical studies conducted so far (IFX-1-P1.1 and -P2.1), it is known that the peak IFX-1 
concentration upon administration of 4 mg/kg bw was approximately 100 µg/mL 
(approximately 650 nM), which could theoretically block approximately 1200 nM of C5a. The 
expected half-life of IFX-1 is 3 to 4 days, thus, a biweekly dosing interval with a dose range of 
400 to 800 mg in subjects with normal body weight is recommended.  

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 32 of 109 
IFX-1 
InflaRx GmbH 
In Study IFX-1-P2.3 in subjects with HS, IFX-1 administered at a weekly dose of 800 mg 
resulted in mean IFX-1 trough concentrations of 50.1 to 79.4 µg/mL. This dosing regimen was 
well tolerated, with no new safety signals, and clinical improvement of HS was demonstrated 
in the majority of subjects. The percentage of subjects achieving an HiSCR was higher than in 
the Phase III studies of adalimumab [11]. An effective dose of IFX-1 is unknown, as is the 
appropriate interval of administration. Therefore, 4 dosing regimens were selected for the 
current study to evaluate a dose-response signal for IFX-1 in subjects with HS according to 
the HiSCR at Week 16. All dosing regimens consist of a 2 weeks induction treatment to achieve 
blockade of C5a. After this induction treatment, a regular dosing schedule for maintenance 
treatment will start to maintain a blockade even in subjects on a low dose and in subjects in 
whom the entire C5 pool is enlarged and “turned over” several times. The toxicology 
development of IFX-1 is considered adequate to support the planned Phase II clinical study in 
subjects who will be treated at doses up to 1200 mg IFX-1 over a time period of 40 weeks. 
There were no relevant findings in the toxicology studies, which would preclude the continued 
clinical development of IFX-1. 
Exposures and safety margins are summarized in Table 1. 
Table 1 Exposure and Safety Margins 
 
NOAEL (26w Tox) 
1200 mg Dose (Extrapolated) 
Safety Margin 
Cmax [µg/mL] 
2,553 
ca. 260 
ca. 10 
AUCinf 
[µg*h/mL] 
464,737 
ca. 17,000 
ca. 27 
AUCinf = area under the curve to infinity; ca. = circa; Cmax = peak plasma concentration; NOAEL = No Observed 
Adverse Effect Level 
 
Rationale for Study Design 
This is a double-blind, placebo-controlled, multicenter Phase II study to determine the efficacy 
and safety of IFX-1 in subjects with moderate to severe HS. With the experience gained in an 
earlier, open-label study of IFX-1 in subjects with HS (Study IFX-1-P2.3), which demonstrated 
acceptable safety and potentially beneficial efficacy, the double-blind, placebo-controlled 
design of the current study is deemed appropriate for investigating the efficacy and safety of 
IFX-1 in subjects with moderate to severe HS. The study design is also deemed appropriate 
for generating PK and PD data to determine dose ranges for future studies.  
The study will be conducted in compliance with this study protocol, International Council for 
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) 
guidelines for Good Clinical Practice (GCP), and the applicable regulatory requirement(s) 
(Section 11). 
1.4 Risk-Benefit Assessment 
IFX-1 has been successfully investigated in an open-label Phase II study in subjects with 
moderate to severe HS. Further, considerations on risk-benefit-related aspects are derived 
from nonclinical data and clinical Phase I data in healthy subjects as well as from clinical data 
in 2 other Phase II studies conducted in subjects suffering from early, newly developing 
abdominal or pulmonary derived septic organ dysfunction and in subjects undergoing complex 
cardiac surgery. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 33 of 109 
IFX-1 
InflaRx GmbH 
1.4.1 Expected Benefits 
The subjects participating in this study who are treated with IFX-1 may benefit from an 
improvement in HS-related symptoms based on the rationale provided in the sections 1.3 
above. 
1.4.2 Potential Risks 
No obvious findings relevant to the safety of IFX-1 were detected during the extensive 
nonclinical in vitro/ex vivo and in vivo testing. In addition, IFX-1 has been demonstrated to be 
safe and well tolerated in healthy human subjects administered IFX-1 intravenously at single 
doses of up to 4 mg/kg bw.  
Furthermore, the safety of IFX-1 has been investigated in 3 Phase II studies, conducted in 
48 subjects with early septic organ dysfunction treated with up to 3 x 4 mg/kg bw IFX-1 given 
over 4 days, in 82 subjects undergoing complex cardiac surgery treated with single doses of 
up to 8 mg/kg bw IFX-1, and in 12 subjects with moderate to severe HS treated with 9 weekly 
infusions of 800 mg IFX-1. Overall, IFX-1 was safe and well tolerated in all these studies, and 
no additional risks associated with the administration of IFX-1 were observed. 
Thus, it has been demonstrated that IFX-1 was generally well tolerated when administered to 
subjects with HS.  
The potential risks associated with iv administration of IFX-1 due to its mode of action include 
the following: 
Infections: the mechanism of action for IFX-1 and the 3 known complement pathways 
(classical, alternative, and lectin pathway) do not suggest any significant impact on C5 
activation and MAC formation resulting from the presence of IFX-1 in blood. Data from an in 
vitro complement activation model and in vivo data from Phase I and II studies provide some 
evidences that IFX-1 does not interfere with the MAC formation. This is essential because 
MAC is the final step in the formation of complement activation elements leading to microbial 
elimination, especially for encapsulated bacteria. A theoretical risk of infection exists due to 
the inhibition of C5a, therefore, investigators (and other health care professionals) should be 
vigilant for signs and symptoms of infections in general. See Section 5.6 for the procedures to 
be followed in case of infections. 
Meningitis/meningococcal septicemia: current data do not suggest that subjects treated with 
IFX-1 are at significantly increased risk of infection with N. meningitides and to date, no cases 
of meningitis or meningococcal septicemia have been reported in clinical studies with IFX-1. 
Therefore, mandatory vaccination or concomitant broad spectrum antibiotic treatment is not 
warranted based on the mode of action for IFX-1. However, until a larger number of subjects 
have been exposed to IFX-1, investigators should be vigilant for signs of N. meningitides 
infection. 
See 
Section 5.6 
for 
the 
procedures 
to 
be 
followed 
in 
case 
of 
meningitis/meningococcal septicemia. 
Anaphylactic reactions and acute systemic allergic hypersensitivity: because IFX-1 is an 
antibody/protein, a general risk for anaphylactic reactions and acute systemic allergic 
hypersensitivity exists. Subjects who are included in this study are treated with IFX-1 at the 
study site so that adequate treatment and care is available in case of an anaphylactic reaction. 
To date, no anaphylactic reactions have been reported after administration of IFX-1 in clinical 
Phase I and II studies. See Section 5.6 for the procedures to be followed in case of 
anaphylactic reactions and acute systemic allergic hypersensitivity. 
1.4.3 Risk Associated with Lack of Efficacy 
With the administration of IFX-1 or placebo, no deterioration in health status is expected with 
respect to HS. Nevertheless, deterioration in HS can occur due to the fluctuating nature of the 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 34 of 109 
IFX-1 
InflaRx GmbH 
disease. In case of a lack of efficacy with IFX-1 treatment, or in case of placebo treatment, 
subjects will continue to experience their typical HS symptoms.  
Subjects who have a loss of response (see Definitions of Terms) during the Extension Period 
will have an optional visit 2 weeks later. Subjects who then have a loss of response at the 
subsequent (planned) visit will be discontinued from the study and will not switch to the non-
responder schedule. 
Subjects who experience WOAI (see Definitions of Terms) at 2 consecutive visits during the 
Extension Period will be discontinued from the study. 
1.4.4 Risk-Benefit Conclusion 
HS is a chronic inflammatory skin disease, which affects approximately 1% of the general 
population in the West, with women affected 2 to 5 times more commonly than men [21], and 
an average onset age of 23 years. This poorly understood disease is believed to be under-
reported by those who suffer from it.  
The disease is associated with significant morbidity. Given the pain and consequent physical 
impairment associated with the tender lesions that are symptomatic of this disease, it has been 
reported that health-related quality of life (HRQL) is lower in patients with HS than in patients 
with other dermatological diseases. Furthermore, a recent study estimated that up to 20% of 
patients with HS report the co-existence of depression, and patients with HS report a high level 
of stigmatization. Due to the significant physical and emotional burden of this disease, patients 
often aggressively seek treatment. 
The level of disease severity strongly influences the approach to the treatment of HS. Subjects 
with moderate to severe HS (Hurley Stage II or III disease) will be included in this study. 
Subjects with Hurley Stage II disease exhibit recurrent inflamed nodules and abscesses, which 
often lead to sinus tracts and scarring that may not resolve with antibiotic therapy. Subjects 
with Hurley Stage III disease require preventive and medical therapy, and efficacy in severe 
HS was shown for adalimumab, infliximab, and acitretin [3].  
It is hypothesized that treatment with IFX-1 could block the C5a-mediated inflammatory effect 
and thus reduce the pain and consequent physical impairment associated with the tender 
lesions of HS, and may even improve the disease status. During treatment with 9 weekly doses 
of IFX-1 in a proof-of-concept study in subjects with moderate to severe HS (IFX-1-P2.3), the 
AN count decreased, the HiSCR increased, and the Hidradenitis Suppurativa- Physician’s 
Global Assessment (HS-PGA) indicated a shift from very severe to moderate disease. This 
dosing regimen was well tolerated and, as seen in the other Phase I and II studies, IFX-1 had 
a favorable safety profile. 
In case of a lack of efficacy with IFX-1 treatment or in case of placebo treatment, subjects will 
continue to experience their typical HS symptoms, for which currently only limited treatment 
options are available. 
The hypothesized benefit of treatment with IFX-1, therefore, outweighs the potential risks for 
the subjects participating in this study. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 35 of 109 
IFX-1 
InflaRx GmbH 
2 OBJECTIVES 
2.1 Primary Objective 
The primary objective of the study is to evaluate a dose-response signal of IFX-1 in subjects 
with HS according to the HiSCR at Week 16.  
2.2 Secondary Objectives 
The secondary objectives of the study are: 
• 
To assess the efficacy of IFX-1 using additional outcome measures 
• 
To assess the safety and tolerability of IFX-1 
• 
To generate data for PK and PD modelling 
• 
To assess patient-reported outcomes 
• 
To evaluate the long-term efficacy and safety of IFX-1 
3 STUDY DESIGN 
3.1 Overall Design 
This is a prospective, randomized, 2-period, placebo-controlled and double-blind (Main Period) 
and open-label (Maintenance Phase of Extension Period) multicenter study. 
After establishing that the inclusion and exclusion criteria have been fulfilled at Screening 
(Sections 4.1 and 4.2), 175 subjects are planned to be randomized to receive double-blind 
treatment with IMP in 1 of 5 treatment cohorts in a ratio of 1:1:1:1:1.  
Subjects who give informed consent for participation in the PK substudy will be sequentially 
included in the PK substudy. 
Subjects will further be asked to consent to a photographical documentation of areas affected 
by HS. Subjects who consent will have photographs taken at prespecified times 
(Section 8.2.2.13). 
An independent, unblinded Data Monitoring Committee (DMC) will be established to allow 
regular monitoring of the study data in order to detect and report early evidence of 
unanticipated harm to subjects (Section 13.3). 
 
Main Period (16 Weeks) 
For each cohort, the Main Period starts at Week 0 (Day 1, immediately before first 
administration of IMP) and consists of a 2-week Induction Phase (ends immediately after 
administration of IMP at Week 2) followed by a 14-week Maintenance Phase through Week 16 
(ends immediately after administration of IMP at Week 16).  
During the Main Period, IMP (IFX-1 or placebo) will be administered in 5 treatment cohorts: 
placebo, IFX-1 400 mg q4w, IFX-1 800 mg q4w, IFX-1 800 mg q2w, and IFX-1 1200 mg q2w, 
as summarized in Table 2. 
The primary efficacy endpoint will be the percentage of subjects with a response on the basis 
of the HiSCR determined at Week 16, before administration of IMP (Section 8.2.2.2).  

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 36 of 109 
IFX-1 
InflaRx GmbH 
PK Substudy in Main Period 
A PK substudy will be conducted in approximately 50 of the 175 subjects participating in the 
Main Period. The subjects in Cohorts 1 to 5 will be sequentially included for participation in the 
PK substudy if consent for participation was given. The PK substudy assessments will be made 
on 2 visits during the Main Period, at Weeks 2 and 16. 
Extension Period (28 Weeks) – HiSCR Responders 
Subjects from all cohorts who are HiSCR responders at Week 16 (response on the basis of 
HiSCR is defined in Section 8.2.2.2) will receive IFX-1 at a dose of 800 mg q4w, starting at 
Week 20 through Week 40. Subjects who have a loss of response (see Definitions of Terms) 
during the Extension Period will have an optional visit 2 weeks later. Subjects who then have 
a loss of response at the subsequent (planned) visit will be discontinued from the study. 
A final visit at the study site for efficacy, PK, PD, and safety assessments will occur at Week 44. 
For subjects who discontinue early, a Post-Treatment Follow-Up visit will occur 3 months after 
the early discontinuation or when another HS therapy has been started, whichever occurs first. 
At the Post-Treatment Follow-Up visit the same parameters for efficacy, PK, PD and safety as 
at Week 44 or the early discontinuation visit will be assessed. 
Extension Period (28 Weeks) – HiSCR Non-Responders 
Subjects from all cohorts who are HiSCR non-responders at Week 16 (response on the basis 
of HiSCR is defined in Section 8.2.2.2) will receive IMP during an Induction Phase (Weeks 18 
and 19), followed by IFX-1 at a dose of 800 mg q2w during the Maintenance Phase from 
Week 20 through Week 40 (see also Table 3). Subjects who experience WOAI (see Definitions 
of Terms) at 2 consecutive visits during the Extension Period will be discontinued from the 
study. 
A final visit at the study site for efficacy, PK, PD, and safety assessments will occur at Week 44. 
For subjects who discontinue early, a Post-Treatment FUV will occur 3 months after the early 
discontinuation or when another HS therapy has been started, whichever occurs first. At the 
Post-Treatment Follow-Up visit the same parameters for efficacy, PK, PD and safety as at 
Week 44 or the early discontinuation visit will be assessed. 
3.2 Study Sites and Number of Subjects 
This multicenter study is planned to be conducted at approximately 50 sites in approximately 
8 countries.  
According to the sample size calculation (Section 10.2), 175 subjects are planned to be 
enrolled and randomized at Screening to 1 of 5 cohorts in the Main Period to ensure that 
approximately 145 subjects complete treatment with IFX-1 or placebo.  
3.3 Expected Duration of the Study 
The study start is defined as the date of the first visit of the first subject enrolled in the Main 
Period, and the end of the study is defined as the date of the last visit of the last subject 
participating in the Extension Period (Week 44), as recorded in the electronic Case Report 
Form (eCRF). 
The estimated recruitment period is approximately 9 months. 
The study duration for an individual subject will be up to 48 weeks and will include the following 
study periods: 
• 
Screening Period: up to 18 days before first administration of IMP (Week −4 to Week −2 
[Days -28 to Day -10]) 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 37 of 109 
IFX-1 
InflaRx GmbH 
• 
Main Period: starts with the first infusion of IMP on Week 0 (Day 1) and ends at Week 16 
(Day 113), after administration of IMP 
• 
Extension Period (open-label from Week 20 onwards): starts after administration of IMP 
at Week 16 and ends at Week 44 
4 STUDY POPULATION 
4.1 Inclusion Criteria 
Subjects must meet all of the following criteria to be enrolled into the study: 
Inclusion Criteria 
Rationale 
Criteria Checked at 
Screening 
Day 1 
1. Male or female, ≥ 18 years of age 
Safety concern 
X 
 
2. Written informed consent obtained from subject 
Administrative 
X 
 
3. Diagnosis of HS for at least 1 year 
Effectiveness 
X 
 
4. Moderate or severe HS, as indicated by HS 
lesions in at least 2 distinct areas, 1 of which 
must be at least Hurley Stage II or Stage III 
(Appendix 17.1) 
Effectiveness 
X 
X 
5. Stable HS for at least 2 months before 
Screening, as determined by the investigator 
through subject interview and review of medical 
history 
Effectiveness 
X 
 
6. Inadequate response to at least 3 months of 
oral antibiotics, or intolerance to antibiotics 
Effectiveness 
X 
 
7. Total abscess and inflammatory nodule count of 
≥ 3 
Effectiveness 
X 
X 
HS = hidradenitis suppurativa. 
 
4.2 Exclusion Criteria 
Subjects who fulfill any of the following criteria are not eligible to participate in the study: 
Exclusion Criteria 
Rationale 
Criteria Checked at 
Screening 
Day 1 
1. Body weight < 60 or > 130 kg 
Safety concern 
X 
 
2. Any other skin disease that may interfere with 
assessment of HS 
Effectiveness 
X 
X 
3. More than 20 draining fistulas 
Safety concern 
X 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 38 of 109 
IFX-1 
InflaRx GmbH 
Exclusion Criteria 
Rationale 
Criteria Checked at 
Screening 
Day 1 
4. Prior treatment with adalimumab or another 
biologic product during the 24 weeks before 
Screening 
Safety concern 
X 
 
5. Prior treatment with IFX-1 
Safety concern 
X 
 
6. Subjects on permitted oral antibiotic 
treatment for HS (doxycycline or minocycline 
only) who have not been on a stable dose 
during the 28 days before Screening 
Effectiveness 
X 
 
7. Subject received systemic non-biologic 
therapy for HS with potential therapeutic 
impact for HS during the 28 days before 
Screening (other than permitted oral 
antibiotics) 
Effectiveness 
X 
 
8. Prior treatment with any of the following 
medications during the 28 days before 
Screening: 
a. Any other systemic therapy for HS 
b. Any iv anti-infective therapy 
c. Phototherapy (UVB or psoralen and 
UVA) 
Effectiveness 
X 
 
9. Prior treatment with any of the following 
medications during the 14 days prior to IMP 
administration: 
a. Analgesics (including opioids) for 
HS-related pain 
b. Prescription-only topical therapies for HS 
c. Oral anti-infectives for infections other 
than HS 
Effectiveness 
X 
 
10. History of moderate to severe heart failure 
(NYHA Class III or IV), cerebrovascular 
accident during the 24 weeks before 
Screening, history of malignancy except for 
successfully treated non-metastatic basal cell 
or squamous cell carcinoma or in situ 
carcinoma of the cervix 
Safety concern 
X 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 39 of 109 
IFX-1 
InflaRx GmbH 
Exclusion Criteria 
Rationale 
Criteria Checked at 
Screening 
Day 1 
11. One of the following abnormal laboratory 
findings: 
a. WBC < 2500/mm3 
b. Neutrophil count < 1000/mm3 
c. Serum creatinine > 3 × UNL 
d. Total bilirubin > 3 × UNL 
e. Alanine aminotransferase > 5 × UNL 
f. 
Aspartate aminotransferase > 5 × UNL 
g. Positive Screening test for HIV-1 or 2, or 
hepatitis B or C virus 
For Canada only: One of the following abnormal 
laboratory findings: 
a. WBC < 2500/mm3 
b. Neutrophil count < 1000/mm3 
c. Serum creatinine > 3 × UNL 
d. Total bilirubin > 1.5 × UNL 
e. Alanine aminotransferase > 2.5 × UNL 
f. 
Aspartate aminotransferase > 2.5 × UNL 
g. Positive Screening test for HIV-1 or 2, or 
hepatitis B or C virus 
Safety concern 
X 
 
12. Chronic and/or recurring systemic infections, 
history of invasive infections with atypical 
pathogens (i.e., which normally do not cause 
invasive infection, such as listeriosis), or 
known primary immunodeficiency 
Safety concern 
X 
 
13. Subject is judged to be in poor general 
health, as determined by the investigator 
based upon medical history, physical 
examination, laboratory safety and, a 12-lead 
ECG 
Safety concern 
 
X 
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 40 of 109 
IFX-1 
InflaRx GmbH 
14. Female subjects of childbearing potential 
unwilling or unable to use a highly effective 
method of contraception (pearl index < 1%) 
such as complete sexual abstinence, 
combined oral contraceptive, vaginal 
hormone ring, transdermal contraceptive 
patch, contraceptive implant, or depot 
contraceptive injection in combination with a 
second method of contraception such as 
condom, cervical cap, or diaphragm with 
spermicide during the study and for at least 
1 month after last administration of IMP. 
For France only: the methods of 
contraception are applicable during the study 
and for at least 3 months after last 
administration of IMP. 
Safety concern 
X 
X 
15. History of drug or alcohol abuse during the 
24 weeks before Screening 
Safety concern 
X 
 
16. Pregnancy, as verified by a positive 
pregnancy test, or nursing woman 
Safety concern 
X 
X 
17. Evidence or suspicion that the subject might 
not comply with the requirements of the study 
protocol 
Safety concern 
X 
 
18. Any other factor which, in the investigator’s 
opinion, is likely to compromise the subject’s 
ability to participate in the study 
Safety concern 
X 
 
19. The subject is an employee or direct relative 
of an employee at the study site or sponsor 
Administrative 
X 
 
20. The subject is imprisoned or lawfully kept in 
an institution 
Administrative 
X 
 
21. The subject has participated in a clinical 
study during the 3 months before Screening, 
or plans to participate in a clinical study 
Administrative 
X 
 
22. For Denmark only: Hypersensitivity to any 
excipients of IFX-1  
Safety concern 
X 
 
ECG = electrocardiogram, HIV = human immunodeficiency virus, HS = hidradenitis suppurativa, IMP = 
investigational medicinal product, iv = intravenous, NYHA = New York Heart Association, UNL = upper normal limit, 
UVA = ultra-violet A, UVB = ultra-violet B, WBC = white blood cell count. 
 
4.3 Lifestyle Considerations 
No restrictions pertaining to lifestyle and/or diet will apply during the study. 
4.4 Screen Failures 
Screen failures are defined as participants who consent to participate in the study but are not 
subsequently randomly assigned to study intervention. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to meet 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 41 of 109 
IFX-1 
InflaRx GmbH 
the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes demography, 
screen failure details, eligibility criteria, and any non-treatment-emergent serious adverse 
event (SAE). 
Subjects who do not meet the criteria for participation in this study (screen failure) may be 
rescreened once. 
4.5 Rationale for Gender Distribution 
No randomization stratified by gender is planned. All potential subjects will be asked for 
informed consent for participation in the study regardless of their gender. Because more 
women than men are affected by HS, a 2:1 distribution of women and men is expected to be 
enrolled in the study. 
5 STUDY INTERVENTION 
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to 
the study protocol. 
All IMP supplied by the sponsor for use in this study will have been manufactured, tested, and 
released according to the standards of Good Manufacturing Practice. 
5.1 Investigational Medicinal Product 
5.1.1 IFX-1 
IFX-1 is a monoclonal anti-human C5a immunoglobulin as active pharmaceutical ingredient, 
which is formulated in a phosphate buffered saline and Polysorbate 80. 
IFX-1 will be supplied in 10 mL glass vials at a concentration of 10 mg/mL (i.e., 100 mg per 
vial) for iv administration and will have the following composition: 
Ingredient 
Strength 
IFX-1 
10 mg/mL 
Sodium chloride 
150 mM 
Sodium phosphate 
10 mM 
Polysorbate 80 
0.05% 
 
5.1.2 Placebo 
Placebo will be supplied in 10 mL glass vials for iv administration and will have the following 
composition: 
Ingredient 
Strength 
Sodium chloride 
150 mM 
Sodium phosphate 
10 mM 
Polysorbate 80 
0.05% 
 
The placebo vials and content have the same appearance as the IFX-1 vials and additives. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 42 of 109 
IFX-1 
InflaRx GmbH 
5.2 Packaging and Labeling 
The IMP will be packaged in cardboard boxes and labeled in accordance with all legal 
requirements. 
The cardboard boxes will be labeled with a unique number (“medcode”). The glass vials 
containing the IMP will be labeled with the same medcode as the cardboard box in which they 
are packed. 
The labels are part of the Clinical Trial Application documentation. 
5.3 Supply, Storage, and Accountability 
5.3.1 Supply 
The IMP will be supplied to study sites on behalf of the sponsor by Almac. The IMP should be 
shipped at a temperature of 2°C to 8°C, and should not be frozen. For each subject, the IMP 
will be sent from Almac to the study site after the subject has been enrolled into the study at 
Screening. Because it may take up to 10 days for the IMP to reach the study site, at least 10 
days should be allowed between Screening and first administration of IMP. 
At each study site, authorized personnel will check the IMP for any loss, damage, or tampering 
and confirm receipt. Records of the receipt of IMP have to be maintained. 
Any technical complaints arising from defects in the quality of the IMP, or defects in the 
packaging or labeling of the IMP, must be reported to the sponsor or the delegate at the earliest 
opportunity and the IMP should not be used.  
The authorized personnel will be responsible for adequate handling of the IMP and local drug 
accountability as well as recording of the accurate administration of the IMP (i.e., complete 
administration of IMP, including flushing of the infusion line) used for each subject.  
5.3.2 Storage 
The IMP must be stored between 2 and 8°C and should not be frozen.  
To record the temperature, an established and validated local temperature management 
system with temperature logs should be used. If this is not possible, the responsible site 
personnel will maintain temperature records for the entire duration of the study. A template for 
the temperature records will be provided by the Clinical Research Organization (CRO). At a 
minimum, the daily (working day) minimum and maximum temperatures must be documented. 
All IMP supplies must be stored separately from normal hospital inventories, in a locked facility 
with access limited to authorized personnel.  
5.3.3 Accountability 
During the study, all IMP vials will be reconciled against the current inventory and the 
dispensing records as a component of the monitoring visits.  
IMP administration data kept at the site will be monitored throughout the study by the monitor.  
After completion of the study, all records regarding the IMP will be provided to the sponsor, 
who will decide on the return or destruction of any unused IMP.  
In case any unused IMP should be destroyed at the site, this destruction must be documented 
on the form provided by the sponsor for this purpose. If unused IMP cannot be destroyed at 
the site, it needs to be returned to the depot. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 43 of 109 
IFX-1 
InflaRx GmbH 
5.4 Reconstitution and Administration of the Investigational 
Medicinal Product 
5.4.1 Reconstitution  
The IMP will be prepared in a blinded manner at the study site or site pharmacy, respectively. 
Depending on the dose to be administered (Table 2 and Table 3), the amount of IMP for a 
single infusion is 400, 800, or 1200 mg IFX-1, or placebo. IMP or placebo will be diluted in 
sterile sodium chloride. To keep the blinding of site personnel and subjects, the total volume 
in the infusion bag for each infusion should be 250 mL. Details of IMP preparation and 
application will be outlined in the respective IMP manual. 
5.4.2 Administration and Compliance 
Main Period: after Screening, subjects will be randomized to 1 of 5 treatment cohorts in a ratio 
of 1:1:1:1:1 (Section 5.5) and then receive IMP in the 16-week Main Period as shown in 
Table 2. 
Table 2 Dosing Schedule by Cohort in Main Period (Double-Blind) 
 
Induction Phase 
Maintenance Phase 
Visit 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
V9 
V10 
V11 
V12 
Week 
0 
0 
1 
2 
4 
6 
8 
10 
12 
14 
16 
Day 
1 
4 
8 
15 
29 
43 
57 
71 
85 
99 
113 
Cohort 1 
(Placebo) 
P 
P 
P 
P 
P 
P 
P 
P 
P 
P 
P 
Cohort 2  
(400 mg q4w) 
400 
400 
P 
P 
400 
P 
400 
P 
400 
P 
400 
Cumulative IFX-1 dose: 2000 mg 
 
Cohort 3  
(800 mg 
q4w) 
800 
800 
800 
P 
800 
P 
800 
P 
800 
P 
800 
Cumulative IFX-1 dose: 4800 mg 
 
Cohort 4  
(800 mg 
q2w) 
800 
800 
800 
800 
800 
800 
800 
800 
800 
800 
800 
Cumulative IFX-1 dose: 8000 mg 
 
Cohort 5  
(1200 mg 
q2w) 
800 
800 
800 
1200 
1200 
1200 
1200 
1200 
1200 
1200 
120
0 
Cumulative IFX-1 dose: 10,800 mg 
 
HiSCR = Hidradenitis Suppurativa Clinical Response; IMP = investigational medicinal product; P = infusion of 
placebo; q2w = every two weeks; q4w = every four weeks; V = scheduled visit for all subjects.  
400, 800, or 1200 = infusion of 400, 800, or 1200 mg IFX-1. 
NOTE: cumulative doses refer to the amount of IFX-1 (doses marked in bold) received at the time the primary 
efficacy endpoint is assessed at Week 16 (percentage of subjects with a response, as measured by HiSCR 
[Section 8.2.2.2]), before administration of IMP at Week 16. 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 44 of 109 
IFX-1 
InflaRx GmbH 
Extension Period: at Week 20 (Day 141) (HiSCR responders) or at Week 18 (Day 127) 
(HiSCR non-responders), subjects will receive the first administration of IMP during the 28-
week Extension Period, as shown in Table 3. 
Subjects who are HiSCR responders at Week 16 (response on the basis of HiSCR is defined 
in Section 8.2.2.2) will receive IFX-1 at a dose of 800 mg q4w during the Extension Period, 
starting at Week 20 through Week 40 (Day 141 to Day 281). If they have a loss of response 
(see Definitions of Terms) during the Extension Period, they will have an optional visit 2 weeks 
later. Subjects who still have a loss of response at the subsequent (planned) visit will be 
discontinued from the study and will not switch to the non-responder schedule.  
Subjects who are HiSCR non-responders at Week 16 (response on the basis of HiSCR is 
defined in Section 8.2.2.2) will receive IFX-1 at a dose of 800 mg during an Induction Phase 
at Weeks 18 and 19 (Day 127 and Day 130), followed by IFX-1 at a dose of 800 mg q2w during 
the remaining Extension Period starting from Week 20 through Week 40. The additional 
infusions will be administered during interim visits to the study site, starting at Week 22. 
Subjects who experience WOAI (see Definitions of Terms) at 2 consecutive visits during the 
Extension Period will be discontinued from the study.  

 
 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 45 of 109 
IFX-1 
InflaRx GmbH 
Table 3 Dosing Schedule by Cohort in Extension Period 
 
Induction Phase 
(Double-Blind) 
Maintenance Phase 
(Open-Label from Week 20 Onwards) 
HiSCR Responders at Week 16 (800 mg q4w) 
Visit 
– 
– 
– 
V1R 
– 
V2R 
– 
V3R 
– 
V4R 
– 
V5R 
– 
V6R 
Week 
18 
19 
20 
22 
24 
26 
28 
30 
32 
34 
36 
38 
40 
Day 
127 
130 
134 
141 
155 
169 
183 
197 
211 
225 
239 
253 
267 
281 
Cohort 1 
– 
– 
– 
800 
– 
800 
– 
800 
– 
800 
– 
800 
– 
800 
Cohort 2 
– 
– 
– 
800 
– 
800 
– 
800 
– 
800 
– 
800 
– 
800 
Cohort 3  
– 
– 
– 
800 
– 
800 
– 
800 
– 
800 
– 
800 
– 
800 
Cohort 4 
– 
– 
– 
800 
– 
800 
– 
800 
– 
800 
– 
800 
– 
800 
Cohort 5 
– 
– 
– 
800 
– 
800 
– 
800 
– 
800 
– 
800 
– 
800 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 46 of 109 
IFX-1 
InflaRx GmbH 
 
Induction Phase 
(Double-Blind) 
Maintenance Phase 
(Open-Label from Week 20 Onwards) 
HiSCR-Non-Responders at Week 16 (800 mg q2w) 
Visit 
V1NR 
V2NR 
V3NR 
V4NR 
V5NR 
V6NR 
V7NR 
V8NR 
V9NR 
V10NR 
V11NR 
V12NR 
V13NR 
V14NR 
Week 
18 
19 
20 
22 
24 
26 
28 
30 
32 
34 
36 
38 
40 
Day 
127 
130 
134 
141 
155 
169 
183 
197 
211 
225 
239 
253 
267 
281 
Cohort 1 
800 
800 
800 
800 
800 
800 
800 
800 
800 
800 
800 
800 
800 
800 
Cohort 2 
800 
P 
800 
800 
800 
800 
800 
800 
800 
800 
800 
800 
800 
800 
Cohort 3  
800 
P 
P 
800 
800 
800 
800 
800 
800 
800 
800 
800 
800 
800 
Cohort 4 
800 
P 
P 
800 
800 
800 
800 
800 
800 
800 
800 
800 
800 
800 
Cohort 5 
800 
P 
P 
800 
800 
800 
800 
800 
800 
800 
800 
800 
800 
800 
HiSCR = Hidradenitis Suppurativa Clinical Response; V = scheduled visit for all subjects; VxNR = scheduled visit for HiSCR non-responders at Week 16; VxR = scheduled visit 
for HiSCR responders at Week 16. 
800 = infusion of 800 mg IFX-1, P = infusion of placebo. 

 
 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 47 of 109 
IFX-1 
InflaRx GmbH 
During the Main Period and the Extension Period, the IMP (IFX-1 or placebo) will be 
administered by the responsible personnel at the site: 
• 
The IMP will be infused over a period of 30 to 60 min (± 10 min) via an iv line 
• 
At the end of the infusion, the iv line will be briefly flushed with approximately 10 mL of 
sterile sodium chloride to ensure that any IMP remaining in the iv line is administered 
After each of the first 2 infusions of IMP administered in the Induction Phases of the Main and 
Extension Periods, subjects must remain at the study site for at least 30 min after end of IMP 
administration; appropriate treatment for potential infusion-related reactions must be available 
during this time.  
For France: After each infusion of IMP administered in the Induction Phases of the Main and 
Extension Periods, subjects must remain at the study site for at least 60 min after end of IMP 
administration; appropriate treatment for potential infusion-related reactions must be available 
during this time.  
Each administration of IMP will be recorded in detail in the source documentation and in the 
eCRF. 
If a subject misses a visit for a scheduled infusion of IMP for any reason, the infusion must be 
administered as soon as possible after the scheduled time of infusion. If the scheduled infusion 
cannot be administered within 3 days after the scheduled time of infusion, then that infusion 
should be omitted and the subsequent infusion must be administered as planned.  
If a subject appears at the study center for a scheduled infusion but the infusion cannot be 
administered due to any reason, the visit can be repeated within 3 days (if the investigator 
thinks that the IMP can be administered within 3 days). Otherwise, the infusion will be omitted 
and is documented accordingly in the eCRF. 
Subjects who omit more than 2 scheduled (consecutive or non-consecutive) infusions during 
the Main Period will be discontinued from the study and will have a Post-Treatment FUV 3 
months after discontinuation or when another HS therapy has been started (Section 6.2). 
The number of unused, partially used, and empty vials will be documented and the vials will 
be kept until the drug accountability documentation has been checked by the monitor. 
5.5 Randomization and Blinding 
The randomization can occur at every time point between Screening and Day 1 or at Day 1 
after confirmation of the Principal Investigator that the patient fulfills the eligibility criteria. 
If the investigator randomizes the patient between Screening Visit and Day 1 and recognizes 
that the patient did not fulfill the eligibility criteria anymore at Day 1, the patient should not be 
treated and will be classified as early discontinuation. 
For treatment during the double-blind Main Period, subjects will be centrally assigned to 
randomized IMP in 1 of 5 cohorts in a ratio of 1:1:1:1:1 (Section 3.1) using an Interactive 
Response Technology (IRT) at Day 1 stratified by Hurley Stage II and III. Complete data from 
the clinical HS examination must be available before randomization can occur. 
The double-blind will be maintained through the Main Period and, for HiSCR non-responders, 
in the Induction Phase of the Extension Period. 
  
Emergency Identification of Investigational Medicinal Product 
The IRT will be programmed with blind-breaking instructions. In case of an emergency, the 
investigator has the sole responsibility for determining if unblinding of a subject’s treatment 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 48 of 109 
IFX-1 
InflaRx GmbH 
assignment is warranted. Subject safety must always be the first consideration in making such 
a determination.  
If the investigator decides that unblinding is warranted, he or she should make every effort to 
contact the sponsor before unblinding a subject’s treatment assignment unless this could delay 
emergency treatment. If a subject’s treatment assignment is unblinded, the sponsor will be 
notified via the IRT and the subject should discontinue treatment. The date and reason why 
the blind was broken must be recorded in the source documentation and in the eCRF, as 
applicable. 
5.6 Procedures in Case of Specific Side Effects 
To date, IFX-1 has been tested in healthy subjects and subjects with early septic organ 
dysfunction, complex cardiac surgery, and HS. An overview of side effects (i.e., ADRs that 
occurred in these studies) is provided in the Investigator’s Brochure.  
If a side effect occurs or is suspected after administration of IMP, subjects must be closely 
monitored and carefully observed, and as applicable the side effect must be reported as an 
AE (Section 9). Any treatment deemed as medically appropriate should be initiated. 
In case of the following specific types of side effects, the procedures reported below must be 
applied.  
Infections: because IFX-1 blocks C5a, there is a theoretical risk of an increased rate of 
infections. Therefore, the investigator (and other health care professionals who take care of 
the subjects) should be alert to signs and symptoms of infections in general. In case a subject 
develops a clinical picture that is difficult to distinguish from that associated with invasive 
infection, routine blood cultures and early start of antibiotic treatment is recommended. In 
subjects with bacterial infection, depending on the severity of the infections, it is important that 
concomitant antibiotic therapy be administered during treatment with IFX-1 to ensure 
appropriate control of the source of the infection. The investigator should pay close attention 
to the choice of an appropriate broad spectrum antibiotic treatment according to applicable 
guidelines. The IMP can be temporarily or permanently interrupted at the investigator’s 
discretion. Any invasive infection has to be reported as an adverse event of special interest 
(AESI) (Section 9.3).  
Meningitis/Meningococcal Sepsis: in case of signs of meningitis at any time during the study 
period, the subject must be carefully observed and the guideline for “ambulatory acquired 
bacterial meningoencephalitis”[22] should be followed. This includes lumbar puncture, blood 
culture testing, immediate start of treatment with dexamethasone and iv antibiotics 
(combination therapy with ampicillin and 3rd generation cephalosporin), and search for 
infectious focus (e.g., computed tomography or magnetic resonance tomography). The IMP 
should be interrupted immediately in case of signs and symptoms of meningitis and withdrawn 
if meningitis is confirmed. 
Infusion-Related Reactions/Anaphylactic Reactions and Acute Systemic Allergic 
Hypersensitivity: In case of any severe, acute systemic hypersensitivity reaction during, or 
shortly after, infusion of IFX-1, the infusion should be stopped immediately and the subject 
discontinued from further dosing. In such cases, subjects should be closely monitored for any 
changes in blood pressure, heart rate, metabolic conditions, or organ function, and appropriate 
measures should be taken to stabilize all vital signs. Fluid resuscitation may be needed, as 
well as vasopressor therapy or other measures to treat changes in blood pressure, vital signs, 
or metabolic conditions in general. In cases of emergency with immediate life-threatening 
potential such as cardiac arrest or similar life-threatening changes, appropriate cardio-
pulmonary resuscitation should be started immediately according to applicable guidelines, or 
as established at the study sites through existing standard operating procedures or other 
algorithms for cardio-pulmonary resuscitation according to current recommended resuscitation 
guidelines. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 49 of 109 
IFX-1 
InflaRx GmbH 
For any potential infusion-related event, the physician should check for a potentially developing 
or existing anaphylactic reaction. In case an anaphylactic reaction is anticipated, appropriate 
immediate actions should be taken according to the severity or stage of the detected 
anaphylactic reaction as recommended by existing guidelines for the treatment of anaphylactic 
reactions or, if established at the study sites, according to available standard operating 
procedures or algorithms. 
If the investigator abstains from further dosing, the subject should be discontinued from the 
study and handled as drop-out.  
In case of an emergency or other situation in which it is medically imperative for the investigator 
to identify the IMP that a subject has received or is receiving during the Main Period and during 
the Induction Phase of the Extension Period, the procedure for emergency identification of IMP 
described in Section 5.5 must be followed. 
5.7 Overdose 
The consequences of an overdose with IFX-1 are not known. 
If overdosing occurs or is suspected, subjects must be closely monitored and carefully 
observed for any symptoms. In case of any symptoms, treatment as deemed medically 
appropriate by the investigator should be initiated. Overdoses must be recorded as treatment-
emergent adverse events (TEAEs). 
5.8 Prior and Concomitant Therapy 
Any medication, vaccine (including, but not limited to, over-the-counter or prescription 
medicines such as aspirin, antacids, vitamins, mineral supplements, and/or herbal 
supplements), or procedure (e.g., phototherapy or laser-surgical therapy) that the subject 
received during 3 months before Screening, at Screening, or receives during the study, must 
be recorded in the source documentation and in the eCRF, with details on the reason for use, 
date(s) of administration (with start and end dates), and dosing information, including dose, 
route, and frequency of administration. 
5.8.1 Prior Therapy 
Any prior treatment with phototherapy, laser-surgical therapy, or antibiotics (see 
Section 5.8.2.2) during at least the 3 months before Screening will be documented in the 
eCRF. Subjects must have been on a stable dose of doxycycline or minocycline during the 28 
days before Screening (“as needed” dosing is not considered stable).   
Any prior treatment with oral corticosteroids, immunosuppressive drugs, biologics, biosimilars, 
investigational treatment, any other systemic therapy for HS, any iv anti-infective therapy, 
analgesics (including opioids) for HS-related pain (see Section 5.8.2.3), prescription-only 
topical therapies for HS, and oral anti-infectives for infections other than HS during the 28 days 
before Screening will be documented. 
Any biologic treatment for HS used previously, including details on reason for discontinuation 
will be documented. 
All information on the use of prior medication will be recorded in the source documentation and 
in the eCRF. 
Prior therapy should also include a detailed history of prior therapies used to treat HS. 
All medications will be documented in the eCRF by verbatim name, dosing regimen, route of 
administration, start and end date of administration, and indication. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 50 of 109 
IFX-1 
InflaRx GmbH 
5.8.2 Concomitant Therapy 
All concomitant therapy (including topical treatments for HS) taken during the study will be 
documented.  
5.8.2.1 Wound Care 
Concomitant use of wound care dressings on HS wounds is permitted but is limited to 
alginates, hydrocolloids, and hydrogels. 
5.8.2.2 Antibiotic Therapy 
Concomitant use of permitted oral antibiotic therapy for treatment of HS is permitted provided 
the dosing regimen (dose and frequency) has been stable during the 28 days before Screening 
(refer to exclusion criterion #6, Section 4.2). The dosing regimen must remain stable 
throughout study participation. Antibiotics taken on an “as needed” basis are not considered a 
stable dose. 
Permitted oral concomitant antibiotics include: 
• 
Doxycycline (at an oral dose of up to 100 mg twice daily) 
• 
Minocycline (at an oral dose of up to 100 mg twice daily) 
An adequate test of oral antibiotic therapy is considered to be at least 90 days in duration. If, 
after ≥ 90 days of oral antibiotic therapy, any of the following has occurred, the subject will be 
considered to have had an inadequate response, or loss of response, to oral antibiotics: 
• 
Progression of Hurley Stage (i.e., the Hurley Stage of at least 1 affected anatomic region 
has progressed from II to III or, after having improved to I during the study [inclusion 
criterion #4, Section 4.1], progressed from I to II or from I to III) 
• 
Subject requires at least 1 intervention (e.g., incision and drainage or intralesional 
injection of corticosteroid) 
• 
Subject experiences pain interfering with activities of daily living, with unsatisfactory relief 
from over-the-counter analgesics (e.g., ibuprofen or acetaminophen) 
• 
Subject experiences pain requiring opioids, including tramadol 
• 
Subject experiences drainage interfering with activities of daily life (e.g., requires multiple 
dressing changes and/or change of clothes daily) 
• 
Subject experiences an increase in the number of anatomic regions affected by HS 
• 
Subject experiences at least 1 new abscess or 1 new draining fistula 
A subject is defined as intolerant to oral antibiotic therapy when the therapy has been 
discontinued by a physician as a result of a significant adverse reaction to the therapy in 
question. 
An adverse reaction is considered significant if it is at least moderately severe (i.e., the reaction 
causes discomfort and interrupts the subject's usual activities or functions). Examples of 
significant adverse reactions include, but are not limited to, the following: 
• 
Nausea resulting in decreased oral intake 
• 
Macular or papular eruption or erythema with pruritus or other associated symptoms 
• 
Dizziness, disequilibrium, lightheadedness, or vertigo interfering with function 
• 
Allergic reaction manifesting as rash, flushing, urticaria, dyspnea, or fever ≥ 38°C 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 51 of 109 
IFX-1 
InflaRx GmbH 
• 
Diarrhea with a stool frequency of at least 4 stools per day 
• 
The inadequate response, loss of response, or intolerance to antibiotics is decided upon 
at the discretion of the investigator.  
5.8.2.3 Analgesic Therapy 
Subjects who received prior analgesic therapy will be required to washout all analgesics during 
the 14 days before starting treatment with IMP on Day 1. This includes analgesics for HS-
related pain and other pain (non-HS-related).  
If a subject’s pain (HS-related or non-HS-related) worsens after Day 1, they may initiate 
analgesic therapy at any time during the study as follows: 
For HS-related pain, permitted analgesics are limited to: 
• 
Ibuprofen (at an oral dose of up to 800 mg every 6 h), not to exceed 3.2 g/24 h, or lower, 
according to the maximum dose allowed per local requirements  
• 
Acetaminophen as per local labeling 
• 
Tramadol (at an oral dose of up to 100 mg every 4 h), not to exceed 400 mg/24 h, in case 
of HS-related pain that remains uncontrolled with ibuprofen or acetaminophen given 
according to the dosing regimens above after Day 1 
Dose adjustments of ibuprofen, acetaminophen, or tramadol and use of these analgesics as 
needed for HS-related pain up to the maximum permitted dose and frequency are permitted 
during the study. 
Subjects will be required to report taking any analgesics. All use of analgesics and any dose 
adjustments will be recorded in the source documentation and in the eCRF. 
For non-HS-related pain: 
• 
Oral opioid analgesics are prohibited 
• 
All other analgesics (including tramadol) are allowed at the recommended or prescribed 
dose 
5.8.2.4 Lesion Intervention 
In case an acutely painful lesion occurs that requires immediate intervention, physicians may 
perform either of the following permitted interventions: 
• 
Injection with intralesional triamcinolone acetonide suspension (at a concentration of up 
to 5 mg/mL, up to 1 mL), and incision and drainage 
• 
If incision and drainage are performed, an over-the-counter antiseptic wash should be 
used. New systemic and topical therapies following incision and drainage (including 
antibiotics) are not permitted. Concomitant use of wound care dressings is allowed, but 
limited to alginates, hydrocolloids, and hydrogels 
Subjects should continue using any ongoing oral and topical treatment (with the constraints 
described in Section 5.8.3) during the study. 
The use of concomitant therapy associated with the lesion intervention(s) must be captured in 
the source documentation and in the eCRF. 
Main Period: a total of 2 permitted interventions are allowed during the Main Period. An 
intervention can be applied to a maximum of 2 different lesions at the same visit to the study 
site, or to the same lesion at 2 different visits. The same lesion cannot be treated twice at the 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 52 of 109 
IFX-1 
InflaRx GmbH 
same visit. If a subject requires more than 2 interventions within the first 16 weeks of the study, 
then they must be discontinued from the study. 
Extension Period: a maximum of 2 interventions are permitted every 4 weeks during the 
Extension Period. An intervention can be applied to a maximum of 2 different lesions at the 
same visit to the study site, or to the same lesion at 2 different visits. Within each 4-week 
period, the same type of intervention cannot be applied twice on the same lesion. If a subject 
requires more than 2 interventions within a 4-week period, or has 2 of the same interventions 
for the same lesion within a 4-week period, then they must be discontinued from the study. 
All the assessments and procedures scheduled for a given visit to the study site must occur 
before any interventions are applied. Any lesion that undergoes an intervention will be 
documented. The site will be required to count any lesion that undergoes an intervention as 
permanently present from the date of intervention, and must account for it in the source 
documentation and in the eCRF. 
5.8.3 Prohibited Therapy 
The following therapies are prohibited for all subjects during the study: 
• 
Phototherapy (UVB or psoralen and UVA) 
• 
All biologic therapy with a potential therapeutic impact on the disease being studied 
including, but not limited to, the following: 
o Abatacept (Orencia®) 
o Anakinra (Kineret®) 
o Belimumab (Benlysta®) 
o Certolizumab pegol (Cimzia®) 
o Efalizumab (Raptiva®) 
o Etanercept (Enbrel®) 
o Golimumab (Simponi®) 
o Infliximab (Remicade®) 
o Natalizumab (Tysabri®) 
o Rituximab (Rituxan®) 
o Tocilizumab (Actemra®) 
o Ustekinumab (Stelara®) 
• 
Any investigational agent 
• 
Any other systemic medication for HS, including, but not limited to, antibiotics (except as 
specified in Section 5.8.2.2), methotrexate, cyclosporine, retinoids, and fumaric acid 
esters 
• 
Oral or injectable corticosteroids 
• 
Oral analgesics for HS not listed in Section 5.8.2.3 
• 
Oral opioid analgesics for non-HS-related pain (for HS-related pain, see Section 5.8.2.3) 
• 
New prescription topical therapies for HS 
• 
Over-the-counter topical antiseptic washes, creams, soaps, ointments, gels, and liquids 
containing antibacterial agents to treat HS, not listed in Section 5.8.2 
• 
Surgical or laser intervention for an HS lesion 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 53 of 109 
IFX-1 
InflaRx GmbH 
The investigator should contact the sponsor if there are any questions regarding prior or 
concomitant therapy. 
6 DISCONTINUATION OF STUDY INTERVENTION 
6.1 Discontinuation of Study 
The study may be discontinued by the sponsor at any site in case any of the following criteria 
are met: 
• 
The study protocol is not adequately adhered to (protocol violations) despite training of 
the study site personnel 
• 
The data quality is deficient 
• 
The recruitment is inadequate  
Additionally, the entire study can be discontinued at all sites by the sponsor at any time for 
medical or ethical reasons.  
The investigator(s) will be notified in writing, outlining the reasons for discontinuation, and the 
investigator(s) must promptly inform all participating subjects. Detailed instructions on further 
assessments will be provided. 
All study materials, except documents needed for archiving requirements, will be returned to 
the sponsor, including all records regarding the IMP, and the sponsor will decide on whether 
any unused IMP should be returned or destroyed. The clinical monitor will ensure that any 
outstanding data clarification issues and queries are resolved and that all study records at the 
study site are complete. 
In accordance with applicable regulatory requirements, the sponsor will promptly inform the 
competent regulatory authorities of the discontinuation and its reason(s), and the investigator 
or sponsor will promptly inform the Institutional Ethics Committee. 
The approval of the study can be rescinded, or the study can be discontinued by a competent 
authority or a responsible Ethics Committee. 
6.2 Discontinuation of Individual Subject Participation 
Each early discontinuation of individual subject participation, irrespective of the reason for 
discontinuation, must be documented by the investigator. If possible, the date, circumstances, 
and reason for discontinuation should be documented.  
The investigator will attempt to complete all procedures usually required at the end of the study 
(i.e., at Week 44) at the time when the subject’s participation in the study is discontinued. 
Subjects who have been discontinued from the study will have a Post-Treatment FUV 3 months 
after discontinuation or when another HS therapy has been started. 
6.2.1 Withdrawal of Informed Consent 
Subjects may discontinue their participation in the study by withdrawing their consent at any 
time without giving reasons. Nevertheless, they should be asked about the reason for 
discontinuation after being informed that they do not need to do so. Information as to when 
they withdrew consent must be documented. 
Subjects are to be informed that when consent is withdrawn, the stored and captured data as 
well as blood samples taken until the time of termination may be used further to: 
• 
Assess effects of the IMP being tested 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 54 of 109 
IFX-1 
InflaRx GmbH 
• 
Guarantee that the subject’s personal interests are not adversely affected 
• 
Comply with the requirement to provide complete documentation when seeking 
marketing authorization 
6.2.2 Discontinuation of Treatment With Investigational Medicinal Product 
Subjects must be discontinued from treatment with the IMP under any of the following 
circumstances: 
• 
Unacceptable toxicity or TEAE, as determined by the investigator 
• 
Anaphylactic or other serious allergic reaction 
• 
Serious infection, including meningitis and sepsis 
• 
If, in the investigator’s opinion, continued administration of IMP could be detrimental to 
the subject’s well-being 
• 
Use of prohibited treatment that in the opinion of the investigator or sponsor necessitates 
the subject being removed 
• 
Application of lesion interventions exceeding the permitted number (see section 5.8.2.4) 
• 
Biopsy confirmation of any malignancy 
• 
Pregnancy 
• 
Subjects who receive 800mg q4w and have a loss of response (see Definition of Terms) 
during the Extension Period will have an optional visit 2 weeks later. Subjects who still 
have a loss of response at the subsequent (planned) visit will be discontinued from the 
study and will not switch to the non-responder schedule 
• 
Subjects who receive 800mg q2w and experience WOAI (see Definition of Terms) at 2 
consecutive visits in the Maintenance Period of the Extension Period will be discontinued 
from the study 
Subjects who have been discontinued will have a Post-Treatment FUV 3 months after 
discontinuation or when another HS therapy has been started. 
6.2.3 Omitted Investigational Medicinal Product Infusions 
Subjects who omit more than 2 scheduled infusions during either the Main Period or during the 
Extension Period will be discontinued from the study. 
6.2.4 Lost to Follow-Up 
Lost to follow-up is defined as an unsuccessful attempt at contacting a subject after that subject 
has withdrawn consent and/or discontinued from treatment with the IMP.  
At least 3 phone calls at 3 different times on consecutive days, and a further phone call a week 
later, should be performed, and if all are unsuccessful at contacting the subject then that 
subject is to be declared as lost to follow-up.  
The date of being lost to follow-up is defined as the last date with any assessment of the 
subject. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 55 of 109 
IFX-1 
InflaRx GmbH 
7 STUDY ASSESSMENTS AND PROCEDURES 
7.1 Screening 
Screening is the predetermined series of procedures with which each investigator selects an 
appropriate and representative sample of subjects for enrollment into the study.  
The Screening procedures will be conducted between 28 days and 10 days before first 
administration of IMP. The findings from the Screening procedures will be documented in the 
Subject Screening/Enrollment Log. 
For each subject, the IMP will be sent from Almac to the study site after the subject has been 
enrolled into the study at Screening. Because it may take up to 10 days for the IMP to reach 
the study site, at least 10 days should be allowed for between Screening and first 
administration of IMP. 
The investigator may pre-screen subjects for study inclusion and exclusion criteria without first 
obtaining written informed consent for participation in the current study on the basis of 1 or 
both of the following situations: 
• 
Pre-existing data (e.g., for study inclusion and exclusion criteria, as available in medical 
records held by the investigator) 
• 
Initial contact (e.g., routine visit, phone call) where only routine and/or non-study specific 
questions are allowed 
After subjects have provided written informed consent, potentially eligible subjects will be 
assessed at the Screening visit to determine if all inclusion criteria and no exclusion criteria 
are met. All subjects must provide written informed consent before any study specific 
assessments or procedures are performed. The following procedures will be conducted and 
documented at the Screening visit:  
• 
Initiate and complete informed consent procedure and document process 
• 
Review all inclusion and exclusion criteria (see Sections 4.1 and 4.2) 
• 
Serum pregnancy test, required for all women of childbearing potential 
• 
Blood sample for analysis of safety laboratory parameters 
• 
Blood sample to test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), 
and hepatitis C virus (HCV) 
• 
Medical and surgical history during the 6 months before Screening 
• 
Review and record prior therapy for chronic diseases taken during the 3 months before 
Screening 
• 
Review and record prior and concomitant therapy as specified in the exclusion criteria 
(Section 4.2)  
• 
Demographics and baseline characteristics 
• 
HS medical and surgical history 
• 
Physical examination 
• 
12-lead Electrocardiogram (ECG) 
• 
Vital signs 
• 
HS clinical parameters 
• 
Erythema assessment 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 56 of 109 
IFX-1 
InflaRx GmbH 
• 
Initiate documentation of patient-reported outcomes: 
o Patient’s Global Assessment of Skin Pain (NRS) (daily documentation in e-diary) 
o Analgesic therapy (daily documentation in e-diary) 
o Patient’s Assessment of Drainage (daily documentation in e-diary) 
o DLQI (documentation at prespecified visits) 
o Hospital Anxiety and Depression Scale (HADS [documentation at prespecified 
visits]) 
o 36-Item Short Form Survey (version 2; SF-36v2 [documentation at prespecified 
visits]) 
o EuroQol-5 Dimensions survey (EQ-5D-5L [documentation at prespecified visits]) 
• 
Initiate documentation of AEs 
• 
Initiate documentation of concomitant medications 
If the subject fulfills all of the inclusion criteria, does not meet any of the exclusion criteria, and 
written informed consent is available, the subject will be randomized to 1 of the 5 cohorts. The 
maximum time between signing informed consent at Screening and randomization should be 
3 weeks, and the maximum time between randomization and first administration of IMP should 
be 3 weeks. The maximum time between Screening and first administration of IMP should be 
4 weeks. Because it may take up to 10 days for the IMP to reach the study site, at least 10 
days should be allowed for between Screening and first administration of IMP. 
Subjects who give informed consent for participation in the PK substudy will be sequentially 
included in the PK substudy. 
Subjects will further be asked to consent to a photographical documentation of affected areas 
at prespecified visits. 
Subjects enrolled into the study will be issued a subject card with relevant contact details, 
including emergency contact details. 
If the subject meets an exclusion criterion or another reason for non-inclusion in the study is 
present after obtaining informed consent, the subject will not be enrolled into the study and will 
be deemed as screen failure. 
7.2 Main Period (16 Weeks) 
The following section describes all study assessments and procedures that have to be 
performed in the Main Period (double-blind). For each cohort, the Main Period starts at Week 0 
(Day 1, immediately before first administration of IMP) and consists of a 2-week Induction 
Phase (ends immediately after administration of IMP at Week 2) followed by a 14-week 
Maintenance Phase through Week 16 (ends immediately after administration of IMP at 
Week 16). An overview of the visit schedule is available in the Schedule of Assessments - 
Screening and Main Period (All Subjects). 
Before administration of IMP, the following assessments and procedures will be performed at 
the visits to the study site, as indicated:  
• 
Review all relevant inclusion and exclusion criteria (see Section 4.1 and 4.2) to confirm 
eligibility for participation in the study (Week 0 [Day 1]) 
• 
Review and record concomitant therapy, as specified in the exclusion criteria 
(Section 4.2), to confirm eligibility for participation in the study (Week 0 [Day 1]) 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 57 of 109 
IFX-1 
InflaRx GmbH 
• 
Urine pregnancy test, required for all women of childbearing potential (Weeks 0 [Day 1], 
4 [France only], 8 [France only], 12 [France only], 16) 
• 
Blood sample for analysis of safety laboratory parameters (Weeks 4, 8 [France only], 12 
[France only], 16) 
• 
Review medical and surgical history to confirm eligibility for participation in the study 
(Week 0 [Day 1]) 
• 
HS medical and surgical history (Week 0 [Day 1]) 
• 
Physical examination (Weeks 0 [Day 1], 16) 
• 
ECG (Week 16) 
• 
Vital signs (Weeks 0 [Days 1 and 4], 1, 2, 4, 6, 8, 10, 12, 14, 16) 
• 
HS clinical parameters (Weeks 0 [Day 1], 2, 4, 6, 8, 10, 12, 14, 16) 
• 
Erythema assessment (Weeks 0 [Day 1], 2, 4, 6, 8, 10, 12, 14, 16) 
• 
Continue documentation of patient-reported outcomes: 
o Patient’s Global Assessment of Skin Pain (NRS) (daily in e-diary throughout Main 
Period) 
o Analgesic therapy (daily in e-diary throughout Main Period) 
o Patient’s Assessment of Drainage (daily in e-diary throughout Main Period) 
o DLQI (Weeks 0 [Day 1], 16) 
o HADS (Weeks 0 [Day 1], 16) 
o SF-36v2 (Weeks 0 [Day 1], 16) 
o EQ-5D-5L (Week 0 [Day 1], 16) 
• 
Citrate plasma sample for analysis of: 
o IFX-1 (Weeks 0 [Day 4], 1, 2, 4, 6, 8, 10, 12, 14, 16) 
• 
Plasma sample for analysis of: 
o C3a (Weeks 0 [Day 1], 2, 16)  
o C5a (Weeks 0 [Days 1 and 4], 2, 6, 16) 
• 
Serum and plasma biomarker sample (Weeks 0 [Day 1], 2, 16), not applicable for 
Denmark 
• 
Serum sample for analysis of: 
o CH50 (Weeks 0 [Day 1], 2, 16) 
o CRP (Weeks 0 [Day 1], 2, 4 [France only], 8 [France only], 12 [France only],16) 
o Antidrug antibodies (ADAs) (Weeks 0 [Day 1], 4, 16) 
• 
Photographic documentation of affected areas (Weeks 0 [Day 1], 4, 16) 
• 
Documentation of AEs (Weeks 0 [Days 1 and 4], 1, 2, 4, 6, 8, 10, 12, 14, 16) 
• 
Documentation of concomitant therapy (Weeks 0 [Days 1 and 4], 1, 2, 4, 6, 8, 10, 12, 14, 
16) 
After the assessments and procedures listed above have been completed: 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 58 of 109 
IFX-1 
InflaRx GmbH 
• 
Administration of IMP according to the dosing schedule shown in Table 2 (Weeks 0 
[Days 1 and 4], 1, 2, 4, 6, 8, 10, 12, 14, 16) 
After administration of IMP: 
• 
Citrate plasma sample for analysis of IFX-1, to be taken after end of IMP administration 
(+ 10 min) using a separate infusion line (Weeks 0 [Day 4], 2) 
• 
For subjects participating in the PK substudy: citrate plasma samples for analysis of 
IFX-1 will be taken after end of IMP administration (+ 10 min), and at 2 h (± 10 min), 6 h 
(± 10 min), 24 h (± 2 h), and 48 h (± 2 h) after start of IMP administration, in all cases 
using a separate infusion line (Weeks 2, 16) 
7.3 Extension Period (28 Weeks) 
Subjects from all cohorts who are HiSCR responders at Week 16 (response on the basis of 
HiSCR is defined in Section 8.2.2.2) will receive IFX-1 at a dose of 800 mg q4w, starting at 
Week 20 through Week 40. Subjects who have a loss of response (see Definitions of Terms) 
during the Extension Period will have an optional visit 2 weeks later. Subjects who still have a 
loss of response at the optional visit will be discontinued from the study and will not switch to 
the non-responder schedule. 
Subjects from all cohorts who are HiSCR non-responders at Week 16 (response on the basis 
of HiSCR is defined in Section 8.2.2.2) will receive IMP during an Induction Phase (Weeks 18 
and 19), followed by IFX-1 at a dose of 800 mg q2w during the Maintenance Phase from 
Week 20 through Week 40 (see also Table 3). Subjects who experience WOAI (see Definitions 
of Terms) at 2 consecutive visits during the Extension Period will be discontinued from the 
study. 
Subjects who have been discontinued will have a Post-Treatment FUV 3 months after 
discontinuation or when another HS therapy has been started. 
Due to the distinction between subjects according to their HiSCR responder status at Week 16, 
separate Schedules of Assessments are available for HiSCR responders (Schedule of 
Assessments - Extension Period (HiSCR Responders at Week 16)]) and HiSCR 
non-responders (Schedule of Assessments - Extension Period (HiSCR Non-Responders at 
Week 16)]). 
HiSCR Responders at Week 16 
Before administration of IMP, the following assessments and procedures will be performed at 
the visits to the study site, as indicated:  
• 
Urine pregnancy test, required for all women of childbearing potential (Weeks 20, 24, 28, 
32, 36, 40), only applicable for France 
• 
Blood sample for analysis of safety laboratory parameters (Weeks 20 [Denmark and 
France], 24 [France only], 28 [France only], 32, 36 [France only], 40 [France only]) 
• 
Physical examination (Week 32) 
• 
ECG (Week 32) 
• 
Vital signs (Weeks 20, 24, 28, 32, 36, 40, and at optional visits) 
• 
HS clinical parameters (Weeks 20, 24, 28, 32, 36, 40, and at optional visits) 
• 
Erythema assessment (Weeks 20, 24, 28, 32, 36, 40, and at optional visits) 
• 
Continue documentation of patient-reported outcomes: 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 59 of 109 
IFX-1 
InflaRx GmbH 
o Patient’s Global Assessment of Skin Pain (NRS) (daily in e-diary throughout 
Extension Period) 
o Analgesic therapy (daily in e-diary throughout Extension Period) 
o Patient’s Assessment of Drainage (daily in e-diary throughout Extension Period) 
o DLQI (Week 32) 
o HADS (Week 32) 
o SF-36v2 (Week 32) 
o EQ-5D-5L (Week 32) 
• 
Citrate plasma sample for analysis of: 
o IFX-1 (Weeks 20, 24, 28, 32, 36, 40) 
• 
Plasma sample for analysis of: 
o C3a (Week 32) 
o C5a (Weeks 24, 32) 
• 
Serum and plasma biomarker sample (Week 32), not applicable for Denmark 
• 
Serum sample for analysis of: 
o CH50 (Week 32) 
o CRP (Weeks 20 [France only], 24 [France only], 28 [France only], 32, 36 [France 
only], 40 [France only]) 
o ADAs (Weeks 24, 32) 
• 
Photographic documentation of affected areas (Weeks 24, 32) 
• 
Documentation of AEs (Weeks 20, 24, 28, 32, 36, 40, and at optional visits) 
• 
Documentation of concomitant therapy (Weeks 20, 24, 28, 32, 36, 40, and at optional 
visits) 
After the assessments and procedures listed above have been completed: 
• 
Administration of IMP according to the dosing schedule shown in Table 3 (Weeks 20, 24, 
28, 32, 36, 40 for q4w dosing) 
HiSCR Non-Responders at Week 16 
Before administration of IMP, the following assessments and procedures will be performed at 
the visits to the study site, as indicated:  
• 
Urine pregnancy test, required for all women of childbearing potential (Weeks 20, 24, 28, 
32, 36, 40), only applicable for France 
• 
Blood sample for analysis of safety laboratory parameters (Weeks 20 [Denmark and 
France], 24 [France only], 28 [France only], 32, 36 [France only], 40 [France only]) 
• 
Physical examination (Week 32) 
• 
ECG (Week 32) 
• 
Vital signs (Weeks 18 [Days 127 and 130], 19, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40) 
• 
HS clinical parameters (Weeks 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40) 
• 
Erythema assessment (Weeks 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40) 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 60 of 109 
IFX-1 
InflaRx GmbH 
• 
Continue documentation of patient-reported outcomes: 
o Patient’s Global Assessment of Skin Pain (NRS) (daily in e-diary throughout 
Extension Period) 
o Analgesic therapy (daily in e-diary throughout Extension Period) 
o Patient’s Assessment of Drainage (daily in e-diary throughout Extension Period) 
o DLQI (Week 32) 
o HADS (Week 32) 
o SF-36v2 (Week 32) 
o EQ-5D-5L (Week 32) 
• 
Citrate plasma sample for analysis of: 
o IFX-1 (Weeks 18 [Days 127 and 130], 19, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 
40) 
• 
Plasma sample for analysis of: 
o C3a (Week 32) 
o C5a (Weeks 18 [Day 127], 24, 32) 
• 
Serum and plasma biomarker sample (Week 32), not applicable for Denmark 
• 
Serum sample for analysis of: 
o CH50 (Week 32) 
o CRP (Weeks 20 [France only], 24 [France only], 28 [France only], 32, 36 [France 
only], 40 [France only]) 
o ADAs (Weeks 18 [Day 127], 24, 32) 
• 
Photographic documentation of affected areas (Weeks 18 [Day 127], 24, 32) 
• 
Documentation of AEs (Weeks 18 [Days 127 and 130], 19, 20, 22, 24, 26, 28, 30, 32, 34, 
36, 38, 40) 
• 
Documentation of concomitant therapy (Weeks 18 [Days 127 and 130], 19, 20, 22, 24, 
26, 28, 30, 32, 34, 36, 38, 40) 
After the assessments and procedures listed above have been completed: 
• 
Administration of IMP according to the dosing schedule shown in Table 3 (Weeks 18 
[Days 127 and 130], 19, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40) 
After administration of IMP: 
• 
Citrate plasma sample for analysis of IFX-1, to be taken after end of IMP administration 
(+ 10 min) using a separate infusion line (Week 18 [Day 130]) 
Follow-Up Visit at Week 44 (Safety Follow-Up)/3-Month Post-Treatment Follow-Up Visit 
The following assessments and procedures will be performed at the FUV to the study site at 
Week 44, as indicated:  
• 
Blood sample for analysis of safety laboratory parameters 
• 
Serum pregnancy test, required for all women of childbearing potential 
• 
Physical examination 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 61 of 109 
IFX-1 
InflaRx GmbH 
• 
ECG 
• 
Vital signs 
• 
HS clinical parameters 
• 
Erythema assessment 
• 
Conclude documentation of patient-reported outcomes: 
o Patient’s Global Assessment of Skin Pain (NRS) (e-diary) 
o Analgesic therapy (e-diary) 
o Patient’s Assessment of Drainage (e-diary) 
o DLQI 
o HADS 
o SF-36v2 
o EQ-5D-5L 
• 
Citrate plasma sample for analysis of: 
o IFX-1 
• 
Plasma sample for analysis of: 
o C3a 
o C5a 
• 
Serum and plasma biomarker sample, not applicable for Denmark 
• 
Serum sample for analysis of: 
o CH50 
o CRP 
o ADAs  
• 
Photographic documentation of affected areas 
• 
Conclude documentation of AEs 
• 
Conclude documentation of concomitant therapy 
For subjects who discontinue early, a Post-Treatment FUV will occur 3 months after the early 
discontinuation or when another HS therapy has been started, whichever occurs first. The 
subjects will be asked about any AEs and any concomitant therapy used since the previous 
visit to the study site.  
7.4 Unscheduled Visits 
Unscheduled visits (USVs) to the study site will be arranged as needed for subjects who 
require unscheduled follow-up assessments (e.g., due to an SAE, abnormal laboratory safety 
findings, loss of response, or WOAI).  
The following assessments and procedures will be performed at USVs to the study site, as 
indicated:  
• 
Vital signs 
• 
HS clinical parameters 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 62 of 109 
IFX-1 
InflaRx GmbH 
• 
Erythema assessment 
• 
Continue documentation of patient-reported outcomes: 
o Patient’s Global Assessment of Skin Pain (NRS) (e-diary) 
o Analgesic therapy (e-diary) 
o Patient’s Assessment of Drainage (e-diary) 
• 
Documentation of AEs 
• 
Documentation of concomitant therapy 
8 STUDY VARIABLES AND METHODS OF ASSESSMENT 
8.1 Study Subjects 
8.1.1 Demographic Data and Baseline Characteristics 
The following demographic data and baseline characteristics will be documented at Screening: 
• 
Age 
• 
Sex 
• 
Race and ethnicity 
• 
Body weight 
• 
Height 
• 
Smoking status 
• 
Prior HS-related surgeries (i.e., if prior surgeries have been performed and number and 
type of prior surgeries). Subjects with prior HS-related surgery will be identified during a 
medical review before database lock 
8.1.2 Medical and Surgical History 
A complete medical history (including non-HS-related surgical history), with details of tobacco 
and alcohol use, will be obtained from each subject at Screening. The medical history will be 
reviewed and updated on Day 1 to ensure that the subject remains qualified for the study. 
8.1.3 Hidradenitis Suppurativa Medical and Surgical History 
The diagnosis of HS is based on the following criteria, set by the 2nd Conference of the HS 
Foundation in San Francisco [13]:  
• 
Disease onset after puberty 
• 
Involvement of at least 2 areas of skin rich in apocrine glands 
• 
History of recurrent drainage of pus from the affected areas 
The HS medical history will be documented in terms of: 
• 
Duration of HS (years) 
• 
Family history of HS 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 63 of 109 
IFX-1 
InflaRx GmbH 
• 
Allocation of affected areas to the Hurley Stage gradation of disease severity [13]. 
Subjects with Hurley Stage II and III, indicating moderate and severe HS, will be enrolled 
into the study (Appendix 17.1)  
All surgical interventions for HS before Screening will be documented in the eCRF 
8.1.4 Prior and Concomitant Therapy 
All prior therapy taken during the 3 months before Screening and all concomitant therapy will 
be documented. For details, refer to Section 5.8. 
8.2 Efficacy Variables 
8.2.1 Overview of Variables 
Efficacy will be assessed on the basis of the following variables: 
• 
HS clinical parameters 
• 
HiSCR, based on HS clinical parameters 
• 
HS-PGA, based on HS clinical parameters 
• 
Modified Sartorius Score (mSS), based on HS clinical parameters 
• 
Lesions, based on HS clinical parameters 
• 
Erythema assessment 
• 
Patient’s Assessment of Drainage 
• 
Use of analgesic therapy 
• 
Patient’s Global Assessment of Skin Pain (NRS) 
• 
DLQI 
• 
HADS 
• 
SF-36v2 
• 
EQ-5D-5L 
• 
Photographic documentation of affected areas 
8.2.2 Methods of Assessment 
8.2.2.1 
Hidradenitis Suppurativa Clinical Parameters 
To evaluate the severity of illness, the following HS clinical parameters will be assessed and 
documented at Screening, at Week 0 (Day 1), and at prespecified times during the study, as 
outlined in the Schedules of Assessments through Week 44 or an early discontinuation visit 
and the 3-month Post-Treatment Follow-Up visit, if the subject discontinues before Week 44:  
• 
Affected area (i.e., left and right axilla, left and right sub/inframammary area, 
intermammary area, left and right buttock, left and right inguino-crural fold, perianal, 
perineal area, other [to be specified]), as described in guidance provided to the 
investigator 
NOTE: lesions in each affected area will be counted. The identification of lesions will be 
performed according to standard definitions of elementary cutaneous lesions. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 64 of 109 
IFX-1 
InflaRx GmbH 
• 
Number and type of lesions (i.e., abscesses, inflammatory nodules, non-inflammatory 
nodules, non-draining fistulas, draining fistulas, hypertrophic scars, other lesions 
[folliculitis, pustules]) 
• 
Longest distance between 2 relevant lesions (mm) 
• 
Are lesions clearly separated by normal skin? (yes/no) 
8.2.2.2 
Hidradenitis Suppurativa Clinical Response (HiSCR) 
The HiSCR is defined by the status of 3 types of lesions [20]:  
• 
Abscesses 
• 
Inflammatory nodules 
• 
Draining fistulas 
The definition for response to treatment based on HiSCR relative to Day 1 is:  
• 
At least 50% reduction in AN count 
• 
No increase in number of abscesses 
• 
No increase in number of draining fistulas 
A subject is considered to be a HiSCR responder only if all 3 criteria above are fulfilled. If any 
1 of the 3 criteria is missing, the HiSCR response will be recorded as missing. 
Additionally, the HiSCR25 response will be calculated. The definition of a HiSCR25 responder 
relative to Day 1 is: 
• 
An at least 25% reduction in AN count 
• 
No increase in number of abscesses 
• 
No increase in number of draining fistulas  
A subject is considered to be a HiSCR25 responder only if all 3 criteria above are fulfilled. 
The HiSCR will be assessed at each of the prespecified times when the HS clinical parameters 
are scheduled to be assessed during the study after Day 1, as outlined in the Schedules of 
Assessments. The score will be calculated using data recorded for HS clinical parameters in 
the eCRF (Section 8.2.2.1). 
8.2.2.3 
Hidradenitis Suppurativa-Physician’s Global Assessment (HS-PGA) 
The HS-PGA is a physician-rated HS disease severity scale with a score ranging from 0 (least 
severe) to 5 (most severe) based on counts of abscesses, draining fistulas, inflammatory 
nodules, and non-inflammatory nodules measured as HS clinical parameters (Appendix 17.2). 
The HS-PGA will be calculated based on the HS clinical parameters at each of the prespecified 
times when the HS clinical parameters are scheduled to be assessed during the study, as 
outlined in the Schedules of Assessments. Lesions are counted by considering all anatomical 
regions. 
A further efficacy endpoint is the achievement of clear or minimal severity among subjects with 
at least 2 grades of improvement (reduction) from Day 1 to each time point. 
8.2.2.4 
Modified Sartorius Score (mSS) 
The mSS is a summation of HS lesions based on a number of factors including anatomical 
region, number and type of lesions, and distance between relevant lesions measured as HS 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 65 of 109 
IFX-1 
InflaRx GmbH 
clinical parameters [23]. The mSS has a minimum value of 0 and no upper limit and is 
calculated using data recorded for HS clinical parameters in the eCRF (Section 8.2.2.1) 
according to the algorithm in Appendix 17.3. 
The mSS and the corresponding change from Day 1 will be assessed at each of the 
prespecified times when the HS clinical parameters are scheduled to be assessed during the 
study, as outlined in Schedules of Assessments. 
8.2.2.5 
Lesions  
Lesion counts are defined as the number of all abscesses, inflammatory nodules, 
non-inflammatory nodules, non-draining fistulas, draining fistulas, hypertrophic scars, and 
other lesions. Lesion counts will be recorded at each of the prespecified times when the HS 
clinical parameters are scheduled to be assessed during the study (as outlined in the 
Schedules of Assessments). 
8.2.2.6 
Erythema Assessment 
For each anatomic region affected by HS, the investigator will assess the overall degree of 
erythema using a 4-point ordinal scale ranging between 0 and 3 (0 = no redness, 1 = faint but 
discernible pink coloration, 2 = moderate red coloration, 3 = very red or bright red coloration) 
(Appendix 17.4) through Week 44 (as outlined in the Schedules of Assessments) or early 
discontinuation visit and the 3-month Post-Treatment Follow-Up visit if the subject discontinues 
before Week 44.  
The erythema assessment will be used to assess the worst and average degree of erythema 
for each affected anatomic region and overall. 
8.2.2.7 
Patient’s Assessment of Drainage 
The Patient’s Assessment of Drainage (Appendix 17.5) will be assessed daily by subjects in 
an e-diary from Screening through the FUV at Week 44  
The Patient’s Assessment of Drainage will be used to assess the amount of drainage due to 
HS. Ratings affected by HS will range from 0 (no drainage) to 10 (drainage as bad as you can 
imagine). 
8.2.2.8 
Analgesic Therapy 
Subjects will be required to report taking any analgesics. All use of analgesics and any dose 
adjustments will be recorded in the source documentation and in the eCRF. For further details 
refer to section 5.8.2.3.  
8.2.2.9 
Patient’s Global Assessment of Skin Pain (NRS) 
The Patient’s Global Assessment of Skin Pain (NRS) (Appendix 17.6) will be assessed by 
subjects every day in an e-diary from Screening through the FUV at Week 44.  
The NRS will be used to assess the worst and average skin pain due to HS. Ratings for these 
2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). 
Subjects should be instructed to respond to the items based on a recall period of the “last 
24 h”. They should also document any analgesic therapy in the e-diary. 
8.2.2.10 
Dermatology Life Quality Index (DLQI) 
The DLQI is an established and widely used patient-reported outcome instrument for 
assessing the impact on health-related quality of life due to dermatological conditions in clinical 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 66 of 109 
IFX-1 
InflaRx GmbH 
studies. The DLQI will be assessed by subjects on Day 1 (Week 0) and during the study at 
prespecified times through Week 44 (as outlined in the Schedules of Assessments) or an early 
discontinuation visit and the 3-month Post-Treatment Follow-Up visit if the subject discontinues 
before Week 44. 
A score is documented for each of the 10 DLQI items, ranging from 0 to 3 for each item. The 
total score is the sum of the responses to all 10 DLQI items, ranging from 0 to 30. A higher 
score corresponds to worse HRQL [20]. Guidelines with regard to the scoring of each question 
and the handling of incorrectly completed questionnaires are taken from the DLQI manual 
(http://sites.cardiff.ac.uk/dermatology/quality-of-life/dermatology-quality-of-life-index-dlqi/dlqi-
instructions-for-use-and-scoring/). Details of the subject questionnaire and the evaluation of 
the total DLQI score are available in Appendix 17.7. 
The DLQI score yields an efficacy endpoint.  
To avoid biasing the subject’s response, the subject should complete the questionnaire at the 
study site before study site personnel perform any other assessments and before any 
interaction with the study site personnel has occurred. 
8.2.2.11 
Hospital Anxiety and Depression Scale (HADS) 
Subjects will complete the HADS questionnaire (Appendix 17.8) on Day 1 (Week 0) and during 
the study at prespecified times through Week 44 (as outlined in the Schedules of 
Assessments) or an early discontinuation visit and the 3-month Post-Treatment Follow-Up visit 
if the subject discontinues before Week 44. The HADS is a subject-rated scale designed to 
screen for anxiety and depressive states. It consists of 2 sub-scales: the D-scale measures 
depression and the A-scale measures anxiety. Each sub-scale contains 7 items and each item 
is rated from 0 (absent) to 3 (maximum severity). The score of each sub-scale ranges from 0 
to 21. 
To avoid biasing the subject’s response, the subject should complete the questionnaire at the 
study site before study site personnel perform any other assessments and before any 
interaction with the study site personnel has occurred. 
8.2.2.12 
36-Item Short Form Survey (SF-36v2) 
Subjects will complete the SF-36v2 questionnaire (Appendix 17.9) on Day 1 (Week 0) and 
during the study at prespecified times through Week 44 (as outlined in the Schedules of 
Assessments) or an early discontinuation visit and the 3-month Post-Treatment Follow-Up visit 
if the subject discontinues before Week 44. The SF-36v2 is a subject-reported generic 
measurement of health status that has proven useful in studies of both general and specific 
populations, comparing the relative burden of diseases and the health benefits produced by 
different treatments [24].  
The SF-36v2 consists of 36 questions from the following 8 domains: vitality, physical 
functioning, bodily pain, general health perceptions, physical role functioning, emotional role 
functioning, social role functioning, and mental health.  
Each domain is directly transformed into a scale from 0 to100 on the assumption that each 
question carries equal weight. A lower score indicates a poorer health status; a higher score 
indicates a better health status (i.e., a score of 0 is equal to maximum disability and a score of 
100 is equal to no disability). The 8 domains are summarized to form 2 distinct higher-ordered 
clusters (physical health and mental health). 
To avoid biasing the subject’s response, the subject should complete the questionnaire at the 
study site before study site personnel perform any other assessments and before any 
interaction with the study site personnel has occurred. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 67 of 109 
IFX-1 
InflaRx GmbH 
8.2.2.13 
EuroQol-5L Dimensions Survey (EQ-5D-5L) 
Subjects will complete the EQ-5D-5L questionnaire (Appendix 17.10) on Day 1 (Week 0), and 
during the study at prespecified times through Week 44 (as outlined in the Schedules of 
Assessments) or an early discontinuation visit and the 3-month Post-Treatment Follow-Up visit 
if the subject discontinues before Week 44. The EQ-5D-5L is a standardized subject-reported 
measure of health status in terms of quality-of-life parameters, such as the subject’s mobility, 
self-care, usual activities, pain and discomfort, and anxiety and depression. There are 
5 categorical response choices for each of the 5 measures. In addition, subjects are asked to 
indicate “the state of your health today” on a visual analog scale of 0 to 100 (0 = worst 
imaginable health state, 100 = best imaginable health state) [25]. 
The EQ-5D-5L relates to the respondent’s situation at the time the assessment is completed, 
therefore the subject does not need to recall their health status over the preceding days or 
weeks. 
To avoid biasing the subject’s response, the subject should complete the questionnaire at the 
study site before study site personnel perform any other assessments and before any 
interaction with the study site personnel has occurred. 
8.2.2.14 
Photographic Documentation of Affected Areas 
Subjects at prospectively selected sites may be asked to have photographs taken of the 
affected areas during the study. Subjects who consent will have photographs taken at 
prespecified times through Week 44 (as outlined in the Schedules of Assessments) or an early 
discontinuation visit and the 3-month Post-Treatment Follow-Up visit if the subject discontinues 
before Week 44. No formal analysis is foreseen. 
8.3 Safety Variables 
8.3.1 Overview of Variables 
Safety will be assessed on the basis of the following variables: 
• 
AEs 
• 
Physical examination 
• 
Vital signs 
• 
ECG 
• 
Laboratory safety parameters 
• 
Pregnancy test 
• 
Status of HIV, HBV, and HCV status at Screening 
• 
ADA status 
8.3.2 Methods of Assessment 
8.3.2.1 
Adverse Events 
The incidence, severity, and causality of AEs will be assessed at every visit from signature of 
the informed consent form at Screening to the subject’s last evaluation according to the 
procedures described in Section 9. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 68 of 109 
IFX-1 
InflaRx GmbH 
8.3.2.2 
Physical Examination 
A physical examination will be performed at Screening and during the study at prespecified 
times through Week 44 (as outlined in the Schedules of Assessments) or an early 
discontinuation visit and the 3-month Post-Treatment Follow-Up visit if the subject discontinues 
before Week 44. Physical examination findings that are related to the medical history will be 
recorded in the source documentation and in the eCRF. 
A symptom-directed physical examination should be performed at all other visits, as warranted. 
An abnormality noted after starting treatment with IMP (Day 1) will be evaluated by the 
investigator for whether it constitutes an AE. 
8.3.2.3 
Vital Signs 
Vital sign determinations of systolic and diastolic blood pressure, pulse rate (counted for at 
least 30 seconds after 5 min in a sitting position), respiratory rate, and body temperature will 
be obtained at each visit to the study site. Blood pressure and pulse rate should be measured 
before blood draws are performed. Height and body weight will only be measured at Screening. 
8.3.2.4 
Electrocardiogram 
A resting 12-lead ECG will be performed at Screening and during the study at prespecified 
times through Week 44 (as outlined in the Schedules of Assessments).  
Subjects who had a 12-lead ECG with normal findings performed during the 90 days before 
Screening will not be required to have a repeat ECG at Screening, provided all the relevant 
documentation specified in the protocol is available. If there are other findings that are clinically 
significant (CS), the investigator must contact the medical monitor at the CRO before enrolling 
the subject into the study. 
Subjects will have a repeat ECG at Week 44 or at an early discontinuation visit and the 3-
month Post-Treatment Follow-Up visit if the subject discontinues before Week 44.  
Subjects can have a repeat ECG examination at any time during the study if considered 
warranted by the investigator. 
An appropriately certified physician will interpret, sign, and date each ECG. Any clinical 
significant (CS) and non-clinical significant (NCS) findings will be recorded in the source 
documentation and in the eCRF. Each signed, original ECG will be reviewed by the clinical 
monitor for correctness (date, time, and clinically relevant abnormal findings, if applicable) and 
stored with the source documentation at the study site. 
8.3.2.5 
Laboratory Safety Parameters 
Laboratory safety parameters will be assessed at Screening and during the study at 
prespecified times through Week 44 (as outlined in the Schedules of Assessments) or an early 
discontinuation visit and the 3-month Post-Treatment Follow-Up visit if the subject discontinues 
before Week 44. 
Blood samples should be obtained after the subjects have provided responses to 
questionnaires and after vital sign determinations have been completed, but before 
administration of IMP.  
Analyses will be conducted by a certified central laboratory.  
Instructions regarding the collection, processing, and shipping of samples for analysis of 
laboratory safety parameters will be available in the laboratory manual provided by the 
responsible CRO. Instructions for urine pregnancy testing are also provided in the laboratory 
manual. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 69 of 109 
IFX-1 
InflaRx GmbH 
The following parameters will be assessed using standard validated methods:  
Clinical chemistry: 
serum creatinine, urea, alanine transaminase, aspartate transaminase, 
gamma-glutamyltransferase, total bilirubin, lactate dehydrogenase, 
alkaline phosphatase, sodium, potassium, calcium, albumin 
Hematology:  
red blood cells (erythrocytes), platelets, hemoglobin, white blood cells 
(including differential blood count) 
Coagulation:  
partial thromboplastin time, international normalized rate  
All abnormal laboratory values will require a comment in the eCRF according to the following 
classification: 
• 
Not CS 
• 
CS 
• 
Error (e.g., laboratory error, improper sample preparation, hemolysis, or delayed transit to 
laboratory) 
At Screening, any laboratory value that deviates from the reference range and is considered 
by the investigator to be CS, or considered as a result of a disease noted in the medical history, 
must be documented on the medical history page of the eCRF. Any deviation outside of the 
reference range considered by the investigator as CS at any later visit must be documented in 
the eCRF as an AE if not previously documented as an ongoing medical condition or as an 
ongoing AE. Follow-up laboratory investigations due to an AE will be performed at a local 
laboratory at the discretion of the investigator. 
8.3.2.6 
Pregnancy Testing 
Pregnancy testing will be conducted in all women of childbearing potential.  
A serum pregnancy test will be performed at Screening, at Week 44 or an early discontinuation 
visit and the 3-month Post-Treatment Follow-Up visit if the subject discontinues before 
Week 44. 
An urine pregnancy test will be performed at Weeks 0 (Day 1) and 16.  
For France: an urine pregnancy test will be performed in addition at Weeks 4, 8, 12, 20, 24, 
28, 32, 36, 40). 
If any pregnancy test is positive, the subject will not be eligible for participation or continuation 
in the study.  
Lactating women will not be eligible for participation or continuation in the study. 
8.3.2.7 
Human Immunodeficiency Virus (HIV) and Hepatitis Virus (HBV or HCV) 
Testing 
Tests for HIV-1 or 2 and HBV or HCV will be conducted at Screening. 
Analyses for HIV-1 or 2 antibodies will be conducted by the central laboratory. Subjects will 
not be eligible for participation in the study if they test positive for HIV infection.  
Analyses for the presence of HBV surface antigen (HBsAg) will be conducted by a central 
laboratory. Subjects will not be eligible for participation in the study if they test positive for 
HBsAg. Subjects who test negative for HBsAg will be tested for the presence of HBV surface 
antibody (HBsAb) and IgM-antibody against hepatitis B core antigen (IgM anti HBc). If test 
results are positive for HBsAb or IgM anti HBc, then an HBV DNA PCR test will be conducted. 
If "target is not detected” for the DNA PCR, the patient is eligible to enter the study. If test 
results are negative for HBsAB and IgM anti HBcA, patient is eligible to enter the study. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 70 of 109 
IFX-1 
InflaRx GmbH 
Analyses for the presence of anti-hepatitis C antibodies in serum will be conducted by a central 
laboratory using a standard chemiluminescence assay. 
8.3.2.8 
Antidrug Antibodies 
ADAs will be assessed on Day 1 (before first administration of IMP) and during the study at 
prespecified times through Week 44 (as outlined in the Schedules of Assessments). A portion 
of the samples will be collected for possible future analysis; this is not applicable for patients 
in Denmark. 
In addition, serum samples for future research taken at Week 2 (Day 15) will be used for ADA 
measurement.  
ADAs will be measured in serum samples at a specialized laboratory using a validated 
homogeneous electrochemiluminescence-based bridging enzyme-linked immunosorbent 
assay  for initial detection as well as an additional confirmatory assay in case of positive 
findings detected in the initial test. Samples that are confirmed as ADA-positive will be quasi-
quantified by titration.  
8.4 Pharmacokinetics and Pharmacodynamics 
8.4.1 Overview of Variables 
PK will be assessed on the basis of IFX-1 concentrations. 
PD will be assessed on the basis of the following variables: 
• 
Complement factors C3a and C5a 
• 
CH50 
• 
CRP 
8.4.2 Methods of Assessment 
8.4.2.1 
Pharmacokinetic Variables 
Concentrations of IFX-1 in citrate plasma will be analyzed on Day 4 and during the study at 
prespecified times through Week 44 (as outlined in the Schedules of Assessments) or an early 
discontinuation visit and the 3-month Post-Treatment Follow-Up visit if the subject discontinues 
before Week 44.  
In the PK substudy, the PK of IFX-1 will be assessed in approximately 10 subjects from each 
Cohort at Weeks 2 and 16 of the Main Period. At these times, blood samples will be obtained 
for the analysis of IFX-1 in citrate plasma before IMP infusion (0 h) and at after end of IMP 
administration (+10 min), and at 2 h (± 10 min), 6 h (± 10 min), 24 h (± 2 h), and 48 h (± 2 h) 
after start of IMP administration, in all cases using a separate infusion line. 
IFX-1 will be analyzed by a specialized laboratory with an ELISA test system. 
8.4.2.2 
Pharmacodynamic Variables 
The PD variables will be assessed on Day 1 and during the study at prespecified times through 
Week 44 (as outlined in the Schedules of Assessments) or an early discontinuation visit and 
the 3-month Post-Treatment Follow-Up visit if the subject discontinues before Week 44. 
Complement factor C3a will be analyzed in plasma samples by a specialized laboratory with 
an ELISA test system. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 71 of 109 
IFX-1 
InflaRx GmbH 
Complement factor C5a will be analyzed in plasma samples by the specialized laboratory at 
InflaRx with an ELISA test system. 
Total complement hemolytic activity CH50 will be analyzed in serum samples by the central 
laboratory with a liposome immunoassay. 
CRP will be analyzed in serum samples by the central laboratory with a standard assay. 
 
8.4.2.3 
Serum and Plasma Biomarker Variables 
Samples to assess serum and plasma biomarkers will be taken on Day 1 and during the study 
at prespecified times through Week 44 (as outlined in the Schedules of Assessments) or an 
early discontinuation visit and the 3-month Post-Treatment Follow-Up visit if the subject 
discontinues before Week 44. 
The collection of serum and plasma biomarker samples are not applicable for Denmark. 
Samples may be analyzed for plasma and serum proteins, peptides, and non-protein soluble 
factors such as lipids that could help predict disease behavior or help determine more severe 
disease phenotypes. The samples may be analyzed as part of a multi-study assessment of 
factors involved in the response to IFX-1. The samples may also be used for the development 
of diagnostic tests related to IFX-1. The results of any such analyses may be reported 
separately. 
Serum samples taken at Week 2 (Day 15) will be used for ADA measurement (Section 8.3.2.8). 
9 
ADVERSE EVENTS 
9.1 Adverse Events 
9.1.1 Definition of Adverse Events  
An AE is any untoward medical occurrence in a subject administered an IMP; an AE does not 
necessarily have to have a causal relationship with this treatment. 
AEs encompass any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease that arises or worsens after the inclusion of the subject into the 
study. 
AEs may include: 
• 
The significant worsening of the disease or symptoms of the disease under investigation 
following administration of an IMP 
• 
Illnesses that coincide with an onset after administration of an IMP 
• 
Exacerbation (i.e., increase in frequency or severity) of a pre-existing condition. Chronic 
illnesses present prior to study entry, other than the indication being investigated, should 
be recorded in the medical history page of the eCRF and only be reported as AEs if there 
is an increase in the frequency or severity of the condition during the study 
• 
For laboratory safety parameters, any absolute values outside of the reference range or 
changes after initial administration of the IMP that are considered by the investigator as 
CS must be recorded in the eCRF as AEs if not previously documented as ongoing 
medical conditions or as ongoing AEs. Examples of laboratory abnormalities that should 
be considered as AEs include those that result in discontinuation of treatment with the 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 72 of 109 
IFX-1 
InflaRx GmbH 
IMP, withholding treatment with the IMP pending some investigational outcome, reduction 
of IMP dose, or additional concomitant treatment 
• 
Laboratory abnormalities do not need to be listed as separate AEs if they are considered 
to be part of a clinical syndrome that is being reported as an AE 
Laboratory findings do not need to be reported as AEs in the following cases: 
• 
Laboratory parameters already beyond the reference range at baseline 
• 
Abnormal laboratory parameters caused by mechanical or physical influences on the 
blood sample (e.g., hemolysis) and flagged as such by the laboratory in the laboratory 
report 
• 
Abnormal parameters that are obviously biologically implausible (e.g., values that are 
incompatible with life) 
• 
An abnormal laboratory value that cannot be confirmed after repeated analysis, 
preferably in the same laboratory (i.e., the previous result could be marked as not valid 
and should not necessarily be reported as an AE) 
In addition, at the investigator’s discretion, any changes or trends over time in laboratory 
parameters can be recorded in the eCRF as AEs, if such changes or trends are considered to 
be clinically relevant, even if the absolute values are within the reference range. 
AEs do not include: 
• 
Medical or surgical procedures; the condition that leads to the procedure is an AE 
• 
Untoward medical findings that occur before initial administration of the IMP if they occur 
in the scope of investigations that are performed for assessing inclusion and exclusion 
criteria (e.g., results of laboratory tests conducted at Screening) 
• 
Situations where an untoward medical occurrence has not occurred, e.g., planned 
hospitalization due to a pre-existing condition that has not worsened, hospitalization that 
occurs for a procedure not associated with an AE (e.g., elective surgery or social 
admission), or hospitalization for a diagnostic procedure that takes less than 24 h 
• 
Overdose of an IMP or any concomitant therapy that does not result in any adverse signs 
or symptoms. Details of the dosing (volume, location of infusion, and infusion rate) of the 
IMP will be recorded in the eCRF 
At each visit to the study site, the investigator will determine whether any AEs have occurred. 
If known, the medical diagnosis of an AE should be recorded in preference to the listing of 
individual signs and symptoms. 
9.1.2 Documentation and Reporting of Adverse Events 
The observation period for AEs will start with confirmation of signed informed consent at 
Screening (i.e., at Day -28 to Day -10) and ends at Week 44. 
All AEs reported from the time the subject gives written informed consent to participate in the 
study until 28 days after the last administration of IMP will be recorded, irrespective of whether 
they were solicited or reported spontaneously by the subject. AE information will be collected 
and recorded in the eCRF. 
For subjects who discontinue early, a Post-Treatment FUV will occur 3 months after the early 
discontinuation or when another HS therapy has been started, whichever occurs first.  

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 73 of 109 
IFX-1 
InflaRx GmbH 
Any AEs judged by the investigator to be at least possibly related to treatment with the IMP 
should be reported to the sponsor regardless of the length of time that has passed since the 
subject has completed the study. 
Every attempt should be made to describe AEs in terms of a diagnosis. If appropriate, 
component symptoms should be listed in addition to the diagnosis. If only nonspecific signs or 
symptoms are present, then these should be recorded as separate diagnoses in the eCRF. 
All subjects who experience AEs, irrespective of whether they are considered by the 
investigator to be at least possibly related to treatment with the IMP, must be monitored to 
determine the outcome. The clinical course of each AE will be followed up according to 
accepted standards of medical practice, even after the subject has completed participation in 
the study, until a satisfactory explanation is found or the investigator considers it medically 
justifiable to terminate the follow-up. Should the AE result in death, a full pathologist’s report 
should be provided, if possible. 
AEs will be classified according to their severity, causal relationship to the IMPs, and 
seriousness. 
If the AE is serious or of special interest, as defined in Section 9.3, the investigator or other 
authorized medical personnel at the study site must be notified and complete the paper “SAE 
form” at the time the SAE is detected. SAE reporting should occur within 24 h (Section 9.2.2).  
Severity of Adverse Events 
The severity of AEs will be assessed according to the following criteria: 
Mild  
• 
Transient or mild discomfort 
• 
No limitation in activity 
• 
No medical intervention or therapy required 
Moderate  
• 
Marked limitation in activity 
• 
Some assistance usually required 
• 
Medical intervention or therapy required  
• 
Hospitalization possible 
Severe  
• 
Extreme limitation in activity 
• 
Significant assistance required 
• 
Significant medical intervention or therapy required 
• 
Hospitalization or hospice care probable  
 
Causal Relationship of Adverse Events 
The investigator must assess whether or not the AE is causally related to administration of the 
IMP. Even if the investigator considers that there is no causal relationship to the IMP, the AE 
must still be reported.  
The causal relationship of AEs to administration of the IMP will be assessed according to the 
following criteria: 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 74 of 109 
IFX-1 
InflaRx GmbH 
Not related 
• 
Event or laboratory test abnormality with a time to administration of the 
IMP that makes a relationship impossible 
• 
Is most likely explained by concurrent disease or other drugs or 
chemicals (either pathophysiologically or clinically) 
• 
Has occurred before administration of the IMP in comparable severity 
and/or frequency 
Unlikely 
related 
• 
Event or laboratory test abnormality with a time to administration of the 
IMP that makes a relationship improbable (but not impossible) 
• 
Disease or other drugs provide plausible explanations 
Possibly 
related 
• 
Event or laboratory test abnormality with reasonable time relationship to 
administration of the IMP  
• 
Could also be explained by disease or other drugs 
• 
Information on IMP withdrawal may be lacking or unclear 
Probably 
related 
• 
Event or laboratory test abnormality with reasonable time relationship to 
administration of the IMP  
• 
Unlikely to be attributed to disease or other drugs 
• 
Response to withdrawal clinically reasonable 
• 
Rechallenge not required 
Certainly 
related 
• 
Event or laboratory test abnormality with plausible time relationship to 
administration of the IMP  
• 
Cannot be explained by disease or other drugs 
• 
Response to withdrawal plausible (pharmacologically or pathologically) 
• 
Event definitive pharmacologically or phenomenologically (i.e., an 
objective and specific medical disorder or a recognized pharmacological 
phenomenon) 
• 
Rechallenge satisfactory, if necessary 
 
All AEs classified as “possibly”, “probably”, or “certainly” related will be considered as “at least 
possibly related to the IMP”. All AEs classified as “not related” or “unlikely related” will be 
considered as “not related” to the IMP. 
The degree of certainty with which an AE is attributed to administration of the IMP or an 
alternative cause (e.g., natural history of the underlying disease, concomitant therapy, etc.) 
must be determined on the basis of how well the AE can be understood in terms of: 
• 
Known pharmacology of the IMP 
• 
Clinically and/or pathophysiologically plausible context 
• 
Reaction of a similar nature previously observed with similar products, or reported in the 
literature for similar products as being product-related (e.g., headache, facial flushing, 
pallor) 
• 
Plausibility supported by the temporal relationship (e.g., the event being related by time 
to administration or termination of treatment with the IMP, drug withdrawal, or reproduced 
on rechallenge) 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 75 of 109 
IFX-1 
InflaRx GmbH 
9.2 Serious Adverse Events 
9.2.1 Definition of Serious Adverse Events 
An AE is defined as serious (i.e., as an SAE) according to the ICH E2A guideline if any of the 
following criteria are fulfilled: 
• 
Results in death 
• 
Is life-threatening 
NOTE: the term “life-threatening” in the definition of “serious” refers to an event in which 
the subject was at risk of death at the time of the event; it does not refer to an event 
which hypothetically might have caused death had it been more severe 
• 
Requires in-patient hospitalization or prolongation of existing hospitalization 
• 
Results in persistent or significant disability/incapacity 
• 
Is a congenital anomaly/birth defect 
• 
Is an important medical event that may not be immediately life-threatening or result in 
death or hospitalization, but may jeopardize the subject or may require intervention to 
prevent one of the other outcomes listed above 
Medical and scientific judgement should be exercised in deciding whether expedited reporting 
is appropriate in other situations, such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization but may jeopardize the subject 
or may require intervention to prevent one of the other outcomes listed in the definition above. 
These should also usually be considered serious. 
The following hospitalizations are not considered to be serious AEs because there is no 
“adverse event” (i.e., there is no untoward medical occurrence) associated with the 
hospitalization: 
• 
Hospitalization for respite care 
• 
Hospitalization planned prior to informed consent (where the condition requiring the 
hospitalization has not changed after administration of IMP) 
9.2.2 Documentation and Reporting Obligations of Serious Adverse Events 
The observation period for SAEs starts with confirmation of signed informed consent at 
Screening (i.e., at Day -28 to Day -10) and ends at Week 44. 
Any SAE judged by the investigator to be at least possibly related to treatment with the IMP 
should be reported to the sponsor regardless of the length of time that has passed since study 
completion. 
SAEs have to be documented on “SAE forms” and the investigator must report them 
immediately to the CRO, or no later than 24 h after becoming aware of the SAE. If more 
information about the SAE becomes available later, this must also be reported immediately or 
no later than 24 h after becoming aware of the SAE. 
In case of a subject’s death, the investigator will provide the applicable Ethics Committee(s) 
and the applicable responsible authorities with any further information requested. 
In all reports, personal data are to be anonymized by using the subject identification number. 
It must be possible to relate the initial and all follow-up reports to each other by means of the 
subject identification number, or name and address, or the like. 
The investigator must report all SAEs to the following address: 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 76 of 109 
IFX-1 
InflaRx GmbH 
 
Fax: + 353 1 809 9501 
QLS_IFX1@iqvia.com 
 
9.3 Adverse Events of Special Interest 
An AESI is an AE of scientific and medical concern specific to the sponsor’s product or 
program, for which ongoing monitoring and rapid communication by the investigator to the 
sponsor could be appropriate. Such an event might require further investigation in order to 
characterize and understand it. 
For this study, the following AEs are defined as AESIs: 
• 
Acute systemic hypersensitivity reaction 
• 
Meningitis 
• 
Meningococcal septicemia 
• 
Invasive infection 
All AESIs will be recorded and reported as SAEs, and subject narratives will be generated. 
9.4 Suspected Unexpected Serious Adverse Reactions 
9.4.1 Definition of Suspected Unexpected Serious Adverse Reactions 
Suspected Unexpected Serious Adverse Reactions (SUSARs) are side effects whose nature 
or severity is inconsistent with the information available about the product in the Investigator’s 
Brochure. 
9.4.2 Reporting of Suspected Unexpected Serious Adverse Reactions 
The sponsor will submit all available information on a SUSAR immediately to the applicable 
Ethics Committee, the applicable regulatory authority, and the investigators in this study, at the 
latest within 15 calendar days after the event becomes known. 
For every SUSAR that results in death or a life-threatening condition, the responsible Ethics 
Committee, the applicable regulatory authority, and the investigators in this study must be 
informed by the sponsor within 7 calendar days after the event becomes known. Additional 
information has to be given within 8 further calendar days. 
9.5 Therapeutic Procedures 
If a subject requires treatment as a result of an AE, the treatment must meet the recognized 
standards of medical care in order to restore the subject’s health. Appropriate resuscitation 
devices and medication must be available in order to treat the subject as quickly as possible 
in the event of an emergency. 
The actions taken to treat the AE/SAE must be documented by the investigator either in the 
appropriate eCRF and/or using additional documents. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 77 of 109 
IFX-1 
InflaRx GmbH 
9.6 Pregnancy 
Pregnancy, by definition, is not considered as an AE unless it results in a complication (such 
as a maternal complication during pregnancy) that meets the definition of an AE, results in 
spontaneous abortion or stillbirth, or is associated with a congenital anomaly or birth defect in 
the fetus. Any such complication must then be reported accordingly as an SAE. 
A female subject who becomes pregnant while participating in the study, or up to and including 
28 days after the last dose of IMP, must notify the investigator immediately and, if appropriate, 
discontinue treatment with the IMP. The subject may continue other study procedures at the 
discretion of the investigator.  
The sponsor must be notified within 5 days of the investigator becoming aware of the 
pregnancy, using the following address. 
Fax: + 353 1 809 9501 
QLS_IFX1@iqvia.com 
 
Whenever possible, a pregnancy in subjects exposed to IMP should be followed to term so as 
to assess any potential occurrence of congenital anomalies or birth defects. Any follow-up 
information, including premature termination and the status of the mother and child after 
delivery, should be reported by the investigator. 
In certain situations, it may be necessary to monitor the development of the child for an 
appropriate period after birth. If this is the case, details should be included in this section.  
Severe side effects and complications during a pregnancy as well as congenital birth defects 
are SAEs per definition and, therefore, have to be reported additionally as SAEs according to 
the reporting procedures described above. 
10 
STATISTICAL METHODS AND DETERMINATION OF SAMPLE 
SIZE  
10.1 General Considerations 
A detailed statistical analysis plan will be developed and finalized (approved with signatures) 
before the Blind Data Review Meeting (BDRM), and may be amended after the BDRM and 
before unblinding the study database if the need arises.  
The statistical analysis plan will include the exact definition of endpoints and variables to be 
analyzed, extensive details of the statistical analysis methods to be used together with the 
structure of tables and figures to be included as end-of-text tables and figures as well as 
appended listings for the clinical study report. 
All endpoints and variables will be adequately evaluated. Individual data will be listed. Data will 
be summarized using suitable descriptive statistics; depending on the structure of the data, 
either sample statistics or frequency tables will be used. Data will be analyzed by cohort and 
study period (Main Period and Extension Period) and might be further differentiated (e.g., by 
visit or by study site).   
10.2 Determination of Sample Size 
The primary efficacy endpoint will be analyzed using the multiple comparisons 
procedure-modelling (MCP-Mod) procedure [26-28]. A total of 175 subjects are planned to be 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 78 of 109 
IFX-1 
InflaRx GmbH 
enrolled into the study (i.e., 35 subjects per cohort) to achieve at least 29 subjects per cohort 
available for the primary analysis of the primary efficacy endpoint. 
The sample size is selected in a way that the multiple contrast test exceeds a power of 90%. 
With the planned sample size, the power criterion of the multiple contrast test is fulfilled 
because 29 subjects per cohort would yield a power of at least 90% to detect a dose-response 
signal if present. In this context, the HiSCR at Week 16 is assumed to be 25% in the placebo 
group, as shown in earlier HS studies [15], and 30%, 45%, 55%, and 60% in the active cohorts 
(Cohorts 2 to 5), with cumulative doses of 2000 mg, 4800 mg, 8000 mg, and 10,800 mg, 
respectively. A 1-sided significance level of 𝛼𝛼 = 0.025 will be used.  
Additionally, simulations were conducted to investigate the expected length of the 2-sided 90% 
confidence intervals (CIs) for the minimum effective dose (MED) and the median effective dose 
(ED50). Definitions of MED and ED50 can be found in Section 10.5. Based on the planned 
sample size of at least 29 evaluable subjects per cohort, wide 90% CIs can be expected for 
the MED and the ED50. The expected length of the 90% CIs was determined by simulations of 
the modelling step of the MCP-Mod procedure. To determine the true HiSCR at Week 16, a 
maximum possible effect for the agonist (Emax) model and a logistic model were selected, which 
are the same models that will be used as candidate models in the MCP-Mod procedure. A 
guesstimate of ED50 = 3000 was used for the Emax model and guesstimates of ED50 = 3500 
and 𝛿𝛿 = 1100 was used for the logistic model.   
10.3 Analysis Sets 
Full analysis set (FAS): the FAS will consist of all subjects who will receive at least 1 infusion 
of IMP. The analysis will be based on the cohort the subjects are randomized to (intention-to-
treat principle). 
Per protocol set (PPS): the PPS will be a subset of the FAS and will exclude all subjects with 
major protocol violations that affect the evaluation of the primary endpoint of the study. 
Subjects who will receive treatment from a cohort that they are not randomized to for the 
complete treatment course until Week 16 will not be excluded from the PPS and will be 
analyzed based on the actual treatment they will receive. 
Safety analysis set (SAS): the SAS will consist of all subjects who will receive at least 1 infusion 
of IMP. Subjects will be analyzed according to the treatment they actually received. Actual 
treatment refers to the individual dosing schedule. The allocation of single subjects to the 
actual dosing groups will be performed under blinded conditions during the blinded data 
review. 
Safety analyses will be based on the SAS. Efficacy analyses will be provided for the FAS and 
the PPS.  
More detailed specifications of the analysis sets and analyses will be provided in the statistical 
analysis plan.  
10.4 Endpoints 
10.4.1 Efficacy Endpoints 
The primary efficacy endpoint is the percentage of subjects with a response on the basis of 
the HiSCR (Section 8.2.2.2) determined at Week 16, before administration of IMP. 
The secondary efficacy endpoints are:  
• 
Percentage of subjects with a response on the basis of the HiSCR determined at 
Week 12, before administration of IMP 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 79 of 109 
IFX-1 
InflaRx GmbH 
• 
Number of subjects with flares analyzed in terms of ≥ 25% increase in AN count among 
subjects with a minimum increase of 2 in AN count relative to Day 1  
• 
Absolute values and absolute and relative change in mSS from Day 1 by time point 
• 
Absolute value and absolute and relative change in Patient’s Global Assessment of Skin 
Pain (NRS) from Day 1 by time point 
• 
Percentage of subjects achieving, by time point: 
o At least a 30% reduction and at least 1 unit reduction from Day 1 among subjects 
with baseline NRS ≥ 3 in Patient’s Global Assessment of Skin Pain (NRS30) 
o At least a 50% reduction and at least 2 units reduction from Day 1 among 
subjects with baseline NRS ≥ 3 in Patient’s Global Assessment of Skin Pain 
(NRS50) 
• 
Absolute values and absolute and relative change in DLQI score from Day 1 by time point 
Exploratory efficacy endpoints: 
• 
Percentage of subjects with ≥ 50% reduction in AN count compared to Day 1 by time 
point 
• 
Percentage of subjects with no increase in number of abscesses compared to Day 1 by 
time point 
• 
Percentage of subjects with no increase in number of draining fistulas compared to Day 1 
by time point 
• 
Percentage of (partial) responders measured by HiSCR and HiSCR25 by time point 
• 
Percentage of subjects with ≥ 25% relative and ≥ 2 absolute increase in counts, using 
the abscess count, the inflammatory nodule count, and the draining fistula count by time 
point 
• 
Achievement of clear or minimal severity of HS-PGA among subjects with at least 2 
grades of improvement (reduction) from Day 1 to each time point. 
 
The endpoints that are evaluated by time point will be analyzed in a similar way during the 
Extension Period. Summary tables for the Extension Period will be grouped by HiSCR 
responders and non-responders.  
In addition, the percentage of subjects with loss of response, defined as a loss of at least 50% 
of the improvement (reduction) in the AN count achieved from baseline to Week 16 [AN > ½ × 
(Baseline AN count + Week 16 AN count)] based on the number of subjects with HiSCR at 
Week 16 will be analyzed for the Extension Period. 
Descriptive subgroup analyses will be performed on selected efficacy endpoints. Relevant 
subgroups are defined by subjects with and without previous exposure to adalimumab or other 
biologic products, and with and without response to adalimumab or other biologic products, 
Hurley Stage, antibiotic treatment, and baseline demographics. The subgroup analyses will be 
exploratory. Details on subgroup analyses and further subgroup analyses (if deemed 
necessary) will be provided in the statistical analysis plan. 
Other efficacy endpoints (e.g., erythema assessment, Patient’s Assessment of Drainage and 
analgesic therapy) will be exploratory, as defined in detail in the statistical analysis plan. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 80 of 109 
IFX-1 
InflaRx GmbH 
10.4.2 Safety Endpoints 
The number and percentage of subjects who had a TEAE as well as the number of TEAEs will 
be assessed for all TEAEs and SAEs. 
Furthermore, the number and percentage of subjects who have a TEAE as well as the number 
of TEAEs will be assessed for all causally related TEAEs, related SAEs, AESIs, TEAEs leading 
to study discontinuation, related TEAEs leading to study discontinuation, TEAEs leading to 
IMP discontinuation, and related TEAEs leading to IMP discontinuation. 
For the analysis of severity and causal relationship of AEs, the worst severity and the strongest 
relationship per subject and class of AE will be considered. 
Laboratory safety parameters, especially the change in inflammatory markers and differential 
blood cell counts, will be assessed by time point and changes in routine laboratory parameters 
from baseline will be determined. Shifts in safety laboratory parameters outside of normal 
ranges compared with baseline will be investigated. 
Immunogenicity will be assessed by determining the number and percentage of subjects with 
detection of ADAs (before and after administration of IMP). 
Other safety endpoints will be exploratory, as defined in detail in the statistical analysis plan. 
Non-treatment-emergent AEs will be listed. 
10.4.3 Pharmacokinetic Endpoints 
The exposure to IFX-1 in all subjects will be measured as the plasma concentration of IFX-1 
determined on Day 4 and at all subsequent scheduled visits to the study site through Week 44 
before administration of IMP, and at Weeks 0 (Day 4), 2, and 16 after administration of IMP 
using a separate infusion line. Actual PK sampling times will be determined and the plasma 
concentration of IFX-1 will be assessed by time point.  
A PK substudy will be conducted during the Main Period, at Weeks 2 and 16, in 
approximately50 of the 175 subjects participating in the Main Period (8 to 10 subjects per 
cohort). At these times, blood samples will be obtained for the analysis of IFX-1 in citrate 
plasma before IMP administration (0 h), after end of IMP administration (+ 10 min), and at 2 h 
(± 10 min), 6 h (± 10 min), 24 h (± 2 h), and 48 h (± 2 h) after start of IMP administration, in all 
cases using a separate infusion line. 
The analysis of derived PK parameters will be described in a separate PK analysis plan. 
10.4.4 Pharmacodynamic Endpoints 
The PD of IFX-1 are primarily measured by plasma concentration of C5a, which is determined 
at prespecified times after administration of IFX-1.  
Plasma concentrations of C5a and C3a and serum concentrations of CH50 will be assessed 
by time point and as change from Day 1. 
Serum concentrations of CRP will be assessed by time point and as change from Day 1. 
10.5 Analysis of Endpoints 
10.5.1 Efficacy  
The primary efficacy endpoint HiSCR at Week 16 will be analyzed using the MCP-Mod 
procedure. The MCP-Mod approach will include Hurley Stage at baseline, concomitant use of 
antibiotic therapy, and AN count at baseline as covariates. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 81 of 109 
IFX-1 
InflaRx GmbH 
Multiple contrast tests, which are part of the MCP-Mod procedure, will be used to test for a 
dose-response signal using the placebo cohort and the cohorts based on cumulative doses of 
2,000 mg, 4,800 mg, 8,000 mg, and 10,800 mg as dose levels.  
In the MCP-Mod procedure, dose-response models can be consistently considered as:  
f(d, 𝛉𝛉) = θ0 + θ1 ∙f 0(d, 𝛉𝛉∗),  
where d denotes the respective dose, and f 0(d, 𝛉𝛉∗) denotes the standardized dose-response 
model parametrized by the vector 𝛉𝛉∗. In this parametrization, θ0 denotes the location 
parameter, θ1 denotes the scale parameter, and 𝛉𝛉∗ determines the shape of the model 
function. For this study, a candidate set of 2 dose-response models are prespecified, m = 1,2, 
which both characterize a monotonically increasing dose-response relationship: 
1. Emax model 
2. Logistic model 
For each of the standardized dose-response models fm0 (d, θ∗), (m = 1,2) in the candidate set, 
the null hypothesis H0
m:   cm
T  µ = 0 will be tested against the 1-sided alternative H1
m:  cm
T  µ > 0 
using a multiple contrast test with significance level α/2 = 0.025, where cm = (cm1, … , cm5)T is 
the optimal contrast vector representing model m and µ = (µ1, … , µ5)T denotes the HiSCR at 
Week 16 for the applied doses. 
Single contrast tests will be used to test the null hypotheses that there is no dose-response 
signal for candidate model m = 1,2. By combining the single test statistics to a multivariate test 
statistic and comparing this test statistic to a multivariate normal-distribution, the single tests 
are multiplicity adjusted and the multiple test problem is adequately considered. The maximum 
of the 2 test statistics will be used as a combined test statistic. 
Only if a dose-response signal can be detected for at least 1 of the candidate models in terms 
of the multiple contrast tests, the shape of the dose-response curve and the target dose(s) of 
interest will be estimated.  
The estimated dose-response curve will be used to estimate the MED and ED50. The MED is 
defined as the minimum dose, at which the HiSCR at Week 16 is at least 15% higher than the 
HiSCR at Week 16 in the placebo group. An improvement of 15% over placebo in HiSCR at 
Week 16 is considered as clinically relevant [15]. The ED50 is defined as the minimum dose 
that achieves 50% of the maximum achievable effect over placebo. Standard formulas for the 
estimation of ED50 will be used and will be explicitly stated in the statistical analysis plan. 
Multiple imputations will be performed for subjects with missing data on HiSCR at Week 16 
who did not discontinue before Week 16 because of one of the following reasons: 
• 
Disease relapse 
• 
Progressive disease 
• 
Lack of efficacy 
Subjects who discontinued before Week 16 because of one of the above mentioned reasons 
will be treated as not having achieved HiSCR at Week 16. All further specifications for 
multiple imputations are based on the assumption that the number of subjects that need to 
have the HiSCR at Week 16 imputed, will be relatively small. 
Multiple imputations will be performed based on the assumption that HiSCR response at 
Week 16 is missing at random, i.e. missingness will not depend on the HiSCR at Week 16 
itself but will only depend on the factors in the imputation model. The factors that will be used 
in the multiple imputation model for HiSCR at Week 16 are HiSCR at prior visits, cohort, 
baseline Hurley Stage, baseline AN count, and concomitant use of antibiotics. We anticipate 
that baseline Hurley Stage, baseline AN count and concomitant use of antibiotics will not be 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 82 of 109 
IFX-1 
InflaRx GmbH 
missing for subjects in the intent-to-treat population. The multiple imputation model will be 
using fully conditional specification logistic regression. We will perform 20 imputations using 
a random seed of 122007 using SAS PROC MI. 
The MCP-Mod approach as outlined above will be applied to all 20 imputed datasets. If the 
MCP step results in a non-significant dose-response signal for more than one of the 
20 datasets, the results will be considered as not robust enough for dose-response estimation. 
In this case, the Mod step will not be performed. For the estimation of the dose-response curve 
for each candidate model (Mod step), the individual model parameters (ED50 for the Emax model 
and ED50 and 𝛿𝛿 for the logistic model) from the analysis on each imputed dataset will be 
combined using Rubin’s rule. 
The percentage of subjects with a response on the basis of the HiSCR (Section 8.2.2.2) 
determined at Week 12 before administration of IMP will be analyzed in the same way as the 
primary endpoint. 
For all other continuous efficacy endpoints, the absolute values and changes from baseline 
(absolute and relative) will be summarized by display of basic descriptive statistics (e.g., 
number of observations (n), mean, standard deviation, minimum, median, maximum, lower 
quartile, upper quartile, and upper and lower boundary of the 95% CI for the mean) by time 
point.  
Model-based analyses (e.g. analysis of covariance [ANCOVA], Poisson, and logistic 
regression models) for continuous, count, and binary endpoints will be defined in the statistical 
analysis plan as deemed necessary and possible. 
All categorical efficacy endpoints will be summarized by time point using absolute and relative 
frequencies including 95% exact CIs based on the binomial distribution. 
Sensitivity analyses will be defined for all efficacy endpoints if deemed necessary. 
10.5.2 Safety  
Treatment-emergent AEs will be analyzed according to the number and percentage of subjects 
who had a TEAE, as well as the number of TEAEs with the respective MedDRA System Organ 
Class and Preferred Term. Additionally, the number and percentage of subjects with TEAEs 
will be further grouped by severity and causal relationship. The number and percentage of 
subjects with SAEs and AESIs and the number of SAEs and AESIs will be analyzed. Where 
AEs are grouped by severity or relationship, the maximum severity/relationship per subject and 
class of AE will be considered. If the number of subjects discontinuing treatment or 
discontinuing the study is substantial, further analyses taking into account the time of AE onset 
and cumulative dose may be considered. 
Safety laboratory, physical examination, and vital signs parameters will be analyzed by 
summary statistics (e.g., number of observations, mean, standard deviation, minimum, 
median, maximum, lower quartile, upper quartile) for absolute values and changes from 
baseline by visit. 
Categorical safety parameters will be summarized by absolute and relative frequencies by time 
point. 
10.5.3 Pharmacokinetics 
The analysis of derived PK parameters will be described in a separate PK analysis plan.  
10.5.4 Pharmacodynamics 
Where applicable, the absolute values and changes from baseline of PD endpoints will be 
summarized using descriptive statistics (e.g., number of observations (n), mean, standard 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 83 of 109 
IFX-1 
InflaRx GmbH 
deviation, minimum, median, maximum, lower quartile, upper quartile, geometric mean) by 
time point. 
All PD parameters will be analyzed based on the FAS with all values and assessments 
available. Some analyses may be repeated for the PPS.  
10.6 Demographics and Baseline Characteristics 
Baseline characteristics and demographic information (including medical/HS history and 
surgeries) will be summarized by cohort and overall. A baseline measurement will be defined 
as the latest measurement obtained prior to the first administration of IMP, if applicable. 
10.7 Prior and Concomitant Therapies 
Prior and concomitant therapies will be summarized by absolute and relative frequencies by 
cohort and overall. Therapies will be defined as concomitant if the start or end date is later 
than the date of first IMP administration, or if no end date is available (ongoing therapy).  
 
10.8 Subject Disposition 
The disposition of subjects who were enrolled (i.e., signed the informed consent form) in the 
study as well as reasons for discontinuation from study and from treatment will be summarized 
for each cohort. 
10.9 Treatment Exposure 
The administration of IMP will be summarized by cohort and will include the number and 
percentage of subjects completing each treatment visit. The actually received cumulative dose 
in mg relative to the planned cumulative dose will be calculated per subject and will be 
summarized for each cohort.  
10.10 Handling of Missing Data 
Data imputation rules are defined for missing values for the primary efficacy endpoint of 
percentage of subjects with a response, as measured by HiSCR at Week 16. Subjects with 
missing baseline assessments (baseline assessments might be obtained at Screening or at 
Day 1 before first infusion of IMP) necessary for the calculation of the HiSCR at Week 16 will 
not be randomized (i.e., there shall be no missing baseline values for HiSCR). Missing values 
for assessments at Week 16 necessary for the calculation of HiSCR at Week 16 will be 
replaced by multiple imputation, as described in section 10.5.1. 
All other missing data will not be replaced. 
Sensitivity analyses will be conducted based on the PPS. Further sensitivity analyses (e.g., 
evaluating patients with missing HiSCR at Week 16 as non-responders) will be defined in the 
statistical analysis plan if deemed necessary. 
10.11 Interim Analysis 
No formal interim analysis is planned for this study. The database will be locked for the analysis 
of the Main Period when all data up to and including Week 16 have been collected and cleaned, 
and the BDRM has taken place. All endpoints in the Main Period will be analyzed after 
unblinding, which will take place after all subjects have completed the assessments at Week 
20 due to operational reasons. A database snapshot will be performed during the Extension 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 84 of 109 
IFX-1 
InflaRx GmbH 
Period. A second database lock will be performed after all data of the Extension Period have 
been collected and cleaned, and the corresponding analyses of endpoints will be performed.  
An independent, unblinded Data Monitoring Committee (DMC) will receive data for safety 
reviews at prespecified time points in order to detect and report early evidence of unanticipated 
harm to subjects (see Section 13.3). To maintain the blind, the data for the safety reviews will 
be delivered by an unblinded CRO biostatistics team located at a different geographical site to 
the blinded CRO biostatistics personnel involved in the study. 
11 ETHICAL, LEGAL, AND ADMINISTRATIVE ASPECTS 
11.1 Good Clinical Practice Statement 
All persons participating in the conduct of the study (sponsor, investigators, etc.) commit 
themselves to observe the Declaration of Helsinki (version Fortaleza 2013) as well as all 
pertinent national laws and the ICH guidelines for GCP issued in June 1996 and 
CPMP/ICH/135/95 from September 1997. 
11.2 Submission to the Ethics Committee and Responsible 
Regulatory Authority  
The protocol and other associated documents will be submitted to the applicable Ethics 
Committee for approval. The study documents will be submitted to the applicable regulatory 
authority. 
The study can only start after obtaining a positive evaluation by the applicable Ethics 
Committee and approval from the applicable regulatory authority. The written approval of the 
applicable Ethics Committee and the responsible regulatory authority must be filed in the trial 
master file. Additionally, each study site must receive a copy of these documents to be filed in 
the investigator site file. 
11.3 Subject Information and Informed Consent 
The investigator must explain to each study subject the nature of the study, the purposes, the 
procedures involved, the expected duration, the potential risks and benefits involved, and any 
discomfort it may entail to each study subject. They must be informed that participation in the 
study is voluntary, that they may withdraw their consent to participate at any time, and that 
withdrawal of consent will not affect the subsequent medical treatment of the study subject or 
the relationship to the treating physician. 
The informed consent must be given by means of standard written statements, written in 
non-technical language. The subjects should read the informed consent form and consider 
their decision before signing and dating the document. A copy of the signed document must 
be given to the subject. No subject can be involved in the study if he/she is related to the 
investigator, any member of the team at the study site, or the sponsor. 
The informed consent of the subject must also refer specifically to the assessment and 
processing of data on the subject’s health. The subject is to be informed explicitly on the 
purpose and extent of the assessment and the use of their personal data, especially the 
health-related data.  
Subjects may also be asked to provide informed consent to have photographs taken of their 
disease response during the study. 
An additional informed consent form respecting the principles described above will be used for 
subjects participating in the PK substudy. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 85 of 109 
IFX-1 
InflaRx GmbH 
11.4 Protocol Amendments 
Changes made to the protocol that was appraised positively by the Ethics Committee and 
approved by the responsible federal authority must be positively reappraised and approved by 
the Ethics Committee and the responsible federal authority if the changes: 
• 
Are such that they may affect the subjects’ safety 
• 
Are fundamental to the therapeutic procedures 
• 
Result in further data collection that necessitates changes to the subject information 
and/or informed consent form 
• 
Affect the interpretation of the scientific documents upon which the study is based or the 
significance of the results of the study 
• 
Significantly affect the leadership or conduct of the study 
• 
Concern the quality or the innocuousness of the investigational drug 
Protocol amendments need the authorization of the sponsor, the coordinating investigator, and 
the responsible biostatistician, if applicable. All protocol amendments will be: 
• 
Submitted to the Ethics Committee and, where applicable, to the responsible federal 
authority 
• 
Provided in written form to the responsible parties 
• 
Filed in the trial master file 
12 DOCUMENTATION 
12.1 Electronic Case Report Forms 
All data beside ePRO required by this clinical study protocol will be collected in an eCRF and 
entered into a database validated by the CRO for eCRFs. 
The sponsor or its designee will supply the study site with eCRFs. The sponsor or its designee 
will make arrangements to train appropriate study site personnel in the use of the eCRF. 
These eCRFs are used to transmit information collected on the performance of this study to 
the sponsor and regulatory authorities. eCRFs must be completed in English.  
Data entered in the eCRF will be stored in a centralized database on a remote server. Data 
will be entered by study site personnel who can access the system through a personal user 
identification and password assigned by the system administrator.  
Data will be entered directly into the eCRF via a single data entry process. In the eCRF, 
subjects will be identified by their subject numbers. The eCRF is to be dated and signed by the 
investigator or a qualified person who has been delegated by the investigator to do so on 
his/her behalf, as documented on a signature delegation log filed in the investigator site file. 
After completion of the entry process, computer logic checks will be run to identify items, such 
as inconsistent dates, missing data and questionable values. Queries may be issued by 
sponsor personnel (or designees) and will be answered by the site.  
Corrections to the eCRF database are recorded in an audit trail that captures a complete record 
of all information. The new information, identification of the person making the correction, the 
date the correction was made, and the reason for change are captured in a new record.  

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 86 of 109 
IFX-1 
InflaRx GmbH 
The principal investigator must review the eCRFs for completeness and accuracy and must 
sign and date the appropriate eCRFs as indicated. Furthermore, the principal investigator must 
retain full responsibility for the accuracy and authenticity of all data entered into the eCRFs. 
The eCRFs will be reviewed for completeness and acceptability at the study site during periodic 
visits by the clinical monitor. The sponsor and/or its designee will be permitted to review the 
subject’s medical and hospital records pertinent to the study to ensure accuracy of the eCRFs. 
The completed eCRFs are the sole property of the sponsor and should not be made available 
in any form to third parties, except for authorized representatives of appropriate governmental 
health or regulatory authorities, without written permission of the sponsor. 
Further information on handling of the eCRF data (e.g., data entry, clarification, and validation) 
will be defined in the data management plan. 
12.2 Archiving 
Because the study is being conducted to obtain marketing authorization, the requirements of 
ICH Guideline E6 section 5.5.11 and 5.5.12 shall be taken into account. 
The investigator is responsible for archiving the investigator site file, the subject’s records, and 
the source data according to applicable regulatory requirements. These documents have to be 
archived for at least 10 years, but should be retained for longer if required by regulatory 
stipulations or by agreement with the sponsor. 
If the investigator can no longer maintain the archive of study records (e.g., due to retirement 
or relocation), the sponsor must be informed in writing about any change in responsibility for 
record retention, including the name of the new responsible party, contact information, and 
location of the study records. Records must not be destroyed without prior written consent from 
the sponsor. 
13 SUPERVISION OF THE CLINICAL STUDY 
13.1 Access to Source Data 
According to ICH guidelines for GCP and the applicable laws, the investigator must permit all 
authorized third parties access to the study site and the medical records of the study subjects 
(source data). These include the clinical monitors, auditors, and other authorized employees 
of the sponsor as well as members of the local or federal authorities. All these persons are 
bound to strict confidentiality. 
13.2 Monitoring 
Monitoring of the study sites will be performed by a CRO designated by the sponsor and will 
be based on the CRO’s monitoring standard operating procedures (SOPs) as well as the study 
specific monitoring manual.  
The clinical monitor, as a representative of the sponsor, has the obligation to follow the study 
closely. The monitor will visit the study site at periodic intervals in addition to maintaining 
necessary telephone calls and written contact as appropriate. The monitor will maintain a 
working knowledge of the study through observation, review of study records and source 
documentation, and discussion of the conduct of the study with the investigator and study site 
personnel. Source data verification of the eligibility criteria as described in the monitoring 
manual will be performed for all subjects. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 87 of 109 
IFX-1 
InflaRx GmbH 
The monitor will report via the project manager of the sponsor designated CRO to the sponsor 
who carefully monitors all aspects of the study for compliance with applicable government 
regulations, with respect to current ICH guidelines for GCP and current SOPs. 
As part of the responsibilities assumed by participating in the study, the investigator agrees to 
maintain adequate case histories for the subjects treated under this protocol. The investigator 
agrees to maintain accurate source documentation and eCRFs as part of the case histories. 
Study records are comprised of source documents, eCRFs, and all other administrative 
documents (e.g., correspondence, clinical study materials, supply shipping manifests, or 
monitoring logs). An investigator site file will be provided with instructions for the maintenance 
of study records. 
13.3 Independent Data Monitoring Committee 
An independent, unblinded DMC will be established to allow regular monitoring of the study 
data in order to detect and report early evidence of unanticipated harm to subjects. The 
Independent DMC will meet after a defined number of subjects have completed the Main 
Period. The number of subjects is defined in the Independent DMC Charta. Further ad hoc 
reviews may be arranged and conducted if deemed necessary. 
The reviews will focus on safety data from the double-blind treatment phases, including but not 
limited to TEAEs, drug exposure, laboratory test results, and vital sign measurements. Further 
details of the data and outputs to be provided to the DMC will be described in the DMC SAP. 
A DMC charter will provide further details on the DMC membership, the responsibilities of the 
DMC, the purpose and timing of the reviews, and the procedures for ensuring confidentiality 
and proper communication. The charter will also outline the required content of the written 
report to be provided by the DMC after each safety review, including their recommendations 
for the future conduct of the study. 
To maintain the blind, the data for the safety reviews will be delivered by an unblinded CRO 
biostatistics team located at a different geographical site to the blinded CRO biostatistics 
personnel involved in the study. Apart from the actual decisions, these data will not be shared 
with anyone outside of the attendees of the safety review meeting until after the double-blind 
treatment phase database lock. A detailed blinding and communication plan will be agreed 
upon by InflaRx and the responsible CRO to clarify the distribution of the unblinded information 
and the level of blinding (eg, summary data, individual data). 
13.4 Audits 
In order to guarantee that the conduct of the study is in accordance with ICH guidelines for 
GCP and the national laws, audits may be performed at the study sites to be carried out by an 
independent auditor. In addition, for-cause audits may be scheduled. 
The investigator agrees to give the auditor access to all relevant documents for review. 
13.5 Inspections 
According to the corresponding ICH guidelines for GCP, inspections of the study sites may be 
performed by the local or federal authorities at any time during or after completion of the study. 
The investigator agrees to give the inspectors access to all relevant documents for review. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 88 of 109 
IFX-1 
InflaRx GmbH 
14 DATA PROTECTION AND CONFIDENTIALITY 
Within this study, personal data from the study subjects and data regarding the treatment and 
the course of subject’s welfare will be collected. 
The data will be stored and processed in anonymized form (i.e., without reference to the 
subject’s name) with the aid of a unique subject identification number. 
Data will be managed by a sponsor designated CRO (data entry, data cleaning, and data 
exports). The safety concept ensures among other things that data access is limited to 
authorized persons, that measures are taken to prevent loss of data, and that the applicable 
laws pertaining to data protection are observed. The data are protected from third party access 
and only members of the study team are permitted access. These members are bound to strict 
confidentiality. 
Personal data will be stored in an anonymous manner after reaching finishing completion 
status of all concomitant scientific projects for at least 15 years, if no other or new regulatory 
requirements come into effect warranting different time periods for archiving. 
14.1 Declaration Regarding Data Protection 
During data entry, processing, and analysis by a sponsor designated CRO, all requirements 
of the data protection act will be taken into account. Access to data is strictly limited to 
authorized persons. Data are protected against unauthorized access. 
14.2 Declaration Regarding the Anonymized Transfer of Personal 
Data  
The sponsor certifies herewith that the transfer of anonymized personal data will take place 
according to the applicable local laws. Moreover, the sponsor certifies that study subjects who 
do not permit the transfer of data will not be admitted to the study. 
15 ADMINISTRATIVE AGREEMENTS 
15.1 Adherence to the Protocol/Protocol Violations 
The clinical study described here will be conducted and analyzed in accordance with local laws 
and ICH guidelines for GCP. 
After a subject has been enrolled, it is the investigator’s responsibility to avoid protocol 
violations in order to obtain unbiased data for the analysis of the study. 
All protocol violations will be documented and discussed with the responsible biostatistician 
before closing the database and carrying out the statistical analyses.  
15.2 Financing and Insurance 
The study is financed by the sponsor. 
The subjects are covered by an applicable insurance policy for participation in a clinical study. 
A copy of the insurance policy and the insurance conditions will be filed in the investigator site 
file. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 89 of 109 
IFX-1 
InflaRx GmbH 
15.3 Notification of the Local Authorities 
The sponsor, their contractors, and all investigators and their deputies are responsible for 
notifying the local regulatory authority of their participation in the study prior to enrollment of 
the first subject in the study. Responsibility for notification to the local authorities has been 
delegated to a sponsor designated CRO. 
This extends also to amendments, discontinuation of study arms or of the entire study, and the 
regular conclusion of the study. 
15.4 Publication Policy and Registration 
15.4.1 Publication Policy 
The rights and obligations of investigators and the sponsor concerning any formal presentation 
or publication of data collected as a direct or indirect result of this study will be addressed 
specifically in the Clinical Study Agreement for the study.  
The first publication must be based upon all data obtained from all analyses, as stipulated in 
the study protocol. 
The sponsor must receive a copy of any intended communications in advance of the proposed 
submission date. This is to allow the sponsor time to review the communication for accuracy 
(thus avoiding potential discrepancies with submissions to regulatory authorities), to verify that 
confidential and/or proprietary information is not inadvertently divulged, to provide any relevant 
supplementary information, and to allow establishment of co-authorship (as appropriate). The 
authorship of communications arising from pooled data will include investigators from study 
sites that contributed data as well as relevant personnel from the sponsor. Ownership of all 
data will remain with the sponsor.  
Furthermore, the publication policy will follow the recommendations of Good Scientific Practice 
of the Deutsche Forschungsgemeinschaft (www.dfg.de) and will meet the criteria of the 
International Committee of Medical Journal Editors (http://www.icmje.org).  
15.4.2 Registration 
The sponsor will provide the relevant study protocol information in a public database (e.g., 
ClinicalTrials.gov, https://clinicaltrials.gov/) before or at commencement of the study. The 
sponsor may also provide study information for inclusion in national registries according to 
local regulatory requirements.  
If a potential subject contacts the sponsor regarding participation in the study, the investigator 
agrees that the sponsor may forward the study site and contact details to the subject. Based 
on the inclusion and exclusion criteria for the study, the investigator will assess the suitability 
of the subject for enrollment into the study. 
Results of this study will be disclosed according to the relevant regulatory requirements. All 
publications in peer-reviewed medical journals resulting from this study will be listed in the 
original study protocol registration record (e.g., on ClinicalTrials.gov).  

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 90 of 109 
IFX-1 
InflaRx GmbH 
16 REFERENCES 
1. 
Jemec, G.B., Medical treatment of hidradenitis suppurativa. Expert Opin 
Pharmacother, 2004. 5(8): p. 1767-70. 
2. 
Forum., E.D., “Guideline on hidradenitis suppurativa”. (Expiry date: 07/2017). 
3. 
JR., I., Hidradenitis suppurativa (acne inversa): Treatment. Dellavalle RP, Dahl MV, 
eds. UpToDate. Waltham, MA: UpToDate Inc. 
4. 
von der Werth, J.M. and G.B. Jemec, Morbidity in patients with hidradenitis 
suppurativa. Br J Dermatol, 2001. 144(4): p. 809-13. 
5. 
Cosmatos, I., et al., Analysis of patient claims data to determine the prevalence of 
hidradenitis suppurativa in the United States. J Am Acad Dermatol, 2013. 68(3): p. 412-
9. 
6. 
Revuz, J.E., et al., Prevalence and factors associated with hidradenitis suppurativa: 
results from two case-control studies. J Am Acad Dermatol, 2008. 59(4): p. 596-601. 
7. 
Jemec, G.B., M. Heidenheim, and N.H. Nielsen, The prevalence of hidradenitis 
suppurativa and its potential precursor lesions. J Am Acad Dermatol, 1996. 35(2 Pt 1): 
p. 191-4. 
8. 
Kurzen, H., et al., What causes hidradenitis suppurativa? Exp Dermatol, 2008. 17(5): 
p. 455-6; discussion 457-72. 
9. 
Slade, D.E., B.W. Powell, and P.S. Mortimer, Hidradenitis suppurativa: pathogenesis 
and management. Br J Plast Surg, 2003. 56(5): p. 451-61. 
10. 
Giamarellos-Bourboulis, E.J., et al., Altered innate and adaptive immune responses in 
patients with hidradenitis suppurativa. Br J Dermatol, 2007. 156(1): p. 51-6. 
11. 
Kanni, T., et al., Compartmentalized Cytokine Responses in Hidradenitis Suppurativa. 
PLoS One, 2015. 10(6): p. e0130522. 
12. 
van der Zee, H.H., et al., Elevated levels of tumour necrosis factor (TNF)-alpha, 
interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting 
TNF-alpha and IL-1beta. Br J Dermatol, 2011. 164(6): p. 1292-8. 
13. 
Revuz, J., Hidradenitis suppurativa. J Eur Acad Dermatol Venereol, 2009. 23(9): p. 
985-98. 
14. 
Wollina, U., et al., Acne inversa (Hidradenitis suppurativa): A review with a focus on 
pathogenesis and treatment. Indian Dermatol Online J, 2013. 4(1): p. 2-11. 
15. 
Kimball, A.B.O.M.M.W., D.A.; Gottlieb A.B.; Papp, K.A.; Zouboulis, C.C.; Armstrong, 
A.W.; Kerdel, F.; Gold, M.H.; Forman, S.B.; Korman, N.J.; Giamarellos-Bourboulis, 
E.J.; Crowley, J.J.; Lynde, C.; Reguiai, Z.; Prens, E.-P.; Alwawi, E.;  Mostafa, N.M.; 
Pinsky, B.; Sundaram, M.; Gu, Y.; Carlson, D.M.; Jemec, G.B.E, Two Phase 3 Trials of 
Adalimumab for Hidradenitis Suppurativa. The New England Journal of Medicine, 
2016. 375(5): p. 14. 
16. 
Forneris, F., et al., Regulators of complement activity mediate inhibitory mechanisms 
through a common C3b-binding mode. EMBO J, 2016. 35(10): p. 1133-49. 
17. 
Bubeck, D., The making of a macromolecular machine: assembly of the membrane 
attack complex. Biochemistry, 2014. 53(12): p. 1908-15. 
18. 
Matusiak, L., A. Bieniek, and J.C. Szepietowski, Increased serum tumour necrosis 
factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-
tumour necrosis factor-alpha agents? Acta Derm Venereol, 2009. 89(6): p. 601-3. 
19. 
Hessam, S., et al., Correlation of inflammatory serum markers with disease severity in 
patients with hidradenitis suppurativa (HS). J Am Acad Dermatol, 2015. 73(6): p. 998-
1005. 
20. 
Kimball, A.B., et al., Assessing the validity, responsiveness and meaningfulness of the 
Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for 
hidradenitis suppurativa treatment. Br J Dermatol, 2014. 171(6): p. 1434-42. 
21. 
Dhaou, B.B.B., F.; Aydi, Z.; Baili, L.; Rokbani, L.; , Hidradenitis suppurativa (Verneuil’s 
disease). Recent Journal of the Saudi Society of Dermatology and Dermatologic 
Surgery Articles, 2013. 17(1): p. 5. 
22. 
Pfister, H., Ambulant erworbene bakterielle (eitrige) Meningoenzephalitis. 2012. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 91 of 109 
IFX-1 
InflaRx GmbH 
23. 
Sartorius, K., et al., Suggestions for uniform outcome variables when reporting 
treatment effects in hidradenitis suppurativa. Br J Dermatol, 2003. 149(1): p. 211-3. 
24. 
Ware, J.E., Jr. and B. Gandek, Overview of the SF-36 Health Survey and the 
International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol, 1998. 
51(11): p. 903-12. 
25. 
Rabin, R. and F. de Charro, EQ-5D: a measure of health status from the EuroQol 
Group. Ann Med, 2001. 33(5): p. 337-43. 
26. 
Bretz, F., J.C. Pinheiro, and M. Branson, Combining multiple comparisons and 
modeling techniques in dose-response studies. Biometrics, 2005. 61(3): p. 738-48. 
27. 
EMA, Qualification Opinion of MCP-Mod as an efficient statistical methodology for 
model-based design and analysis of Phase II dose finding studies under model 
uncertainty. 2014. 
28. 
Pinheiro, J., et al., Model-based dose finding under model uncertainty using general 
parametric models. Stat Med, 2014. 33(10): p. 1646-61. 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 92 of 109 
IFX-1 
InflaRx GmbH 
17  APPENDIX 
17.1 Hurley Stages 
Evaluation of disease severity after Hurley [13]. 
Grade I 
Abscess formation, single or multiple, without sinus tracts or cicatrization 
Grade II 
Recurrent abscesses, with sinus tract formation and cicatrization; single or multiple, 
widely separated lesions 
One or more widely separated recurrent abscesses with tract formation and 
cicatrization 
Grade III 
Diffuse or near-diffuse involvement, or multiple interconnected tracts and abscesses 
across entire area  
Multiple interconnected tracts and abscesses across the entire area, with diffuse or 
near-diffuse involvement 
 
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 93 of 109 
IFX-1 
InflaRx GmbH 
17.2 Hidradenitis Suppurativa-Physician’s Global Assessment  
 
The HS-PGA disease severity scale includes the following definitions [20]: 
Severity 
Score 
Definition 
Clear 
0 
0 abscesses, 0 draining fistulas, 0 inflammatory nodules, 
and 0 non-inflammatory nodules 
Minimal 
1 
0 abscesses, 0 draining fistulas, 0 inflammatory nodules, 
and presence of non-inflammatory nodules 
Mild 
2 
0 abscesses, 0 draining fistulas, and 1 to 4 inflammatory 
nodules 
or  
1 abscess or draining fistula (sum of abscesses and 
draining fistulas is 1) and 0 inflammatory nodules 
Moderate 
3 
0 abscesses, 0 draining fistulas, and ≥ 5 inflammatory 
nodules 
or  
1 abscess or draining fistula and ≥ 1 inflammatory 
nodule 
or  
2 to 5 abscesses or draining fistulas (sum of abscesses 
and draining fistulas is 2 to 5) and < 10 inflammatory 
nodules 
Severe 
4 
2 to 5 abscesses or draining fistulas and ≥ 10 
inflammatory nodules 
Very severe 
5 
> 5 abscesses or draining fistulas (sum of abscesses 
and draining fistulas > 5) 
 
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 94 of 109 
IFX-1 
InflaRx GmbH 
17.3 Modified Sartorius Score  
Algorithm for calculating the mSS [23]. 
Calculate several regional scores for each valid local anatomical region. The total mSS is 
obtained by adding together the single regional mSS. 
The following algorithm is used for calculating the regional score based on lesion counts in 
12 anatomic regions: 
• 
Left axilla 
• 
Right axilla 
• 
Left sub/inframammary area 
• 
Right sub/inframammary area 
• 
Intermammary area 
• 
Left buttock 
• 
Right buttock 
• 
Left inguino-crural fold 
• 
Right inguino-crural fold 
• 
Perianal 
• 
Perineal area 
• 
Other (to be specified) 
For each anatomic region, calculate the regional score as follows: 
1. Count 3 points for each regional mSS to account for the identified local region involved 
2. For each regional mSS, add points per number and score of lesions (abscesses, 
nodules, fistulas, scars) within the respective identified local anatomical region: 
o + 2 * Number of inflammatory nodules 
o + 2 * Number of non-inflammatory nodules 
o + 4 * Number of abscesses 
o + 4 * Number of draining fistulas 
o + 4 * Number of non-draining fistulas 
o + 1 * Number of hypertrophic scars 
3. For each regional score, add the following points for the longest distance between 
2 relevant lesions (i.e., nodules and fistulas) in each identified local anatomical region, or 
size of lesion: 
o 0 points, if no active lesions 
o 2 points, if the longest distance between 2 relevant lesions or size (if only 1 lesion 
is present, the diameter of the corresponding lesion is measured) is < 50 mm 
o 4 points, if the longest distance between 2 relevant lesions or size is ≥ 50 mm and 
< 100 mm 
o 6 points, if the longest distance between 2 relevant lesions or size is > 100 mm 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 95 of 109 
IFX-1 
InflaRx GmbH 
4. Are lesions clearly separated by normal skin? 
o Yes: 0 points 
o No: 6 points 
If this question was left unanswered and is thus missing for 1 identified local anatomical 
region, the score will be recorded as missing for the corresponding subject and time 
point. 
The total mSS is the sum of the 12 regional scores. 
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 96 of 109 
IFX-1 
InflaRx GmbH 
17.4 Erythema Assessment 
At every visit, for each anatomic region affected by HS, the investigator will assess the overall 
degree of erythema using a 4-point ordinal scale ranging between 0 and 3. 
Region (Assessed at Every Visit) 
Degree of Erythema 
Left axilla 
 
Right axilla 
 
Left sub/inframammary area 
 
Right sub/inframammary area 
 
Intermammary area 
 
Left buttock 
 
Right buttock 
 
Left inguino-crural fold 
 
Right inguino-crural fold 
 
Perianal 
 
Perineal area 
 
Other (to be specified) 
 
0 = no redness; 1 = faint but discernible pink coloration; 2 = moderate red coloration; 3 = very red or bright red 
coloration 
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 97 of 109 
IFX-1 
InflaRx GmbH 
17.5 Patient’s Assessment of Drainage 
Please answer the questions before you go to bed. Mark an “X” in the box that describes the 
severity of drainage affected by HS: 
In the last 24 hours, which number best describes the worst severity of drainage due to 
HS? 
Severity of Drainage due to HS 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 98 of 109 
IFX-1 
InflaRx GmbH 
17.6 Patient’s Global Assessment of Skin Pain  
 
 
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 99 of 109 
IFX-1 
InflaRx GmbH 
17.7 The Dermatology Life Quality Index  
The aim of this questionnaire is to measure how much the subjects’ skin problem has affected their 
life OVER THE LAST WEEK.  
1. Over the last week, how itchy, sore, painful, or stinging has your skin 
been? 
Very much 
A lot 
A little 
Not at all 
 
 
 
 
2. Over the last week, how embarrassed or self-conscious have you been 
because of your skin? 
Very much 
A lot 
A little 
Not at all 
 
 
 
 
 
3. Over the last week, how much has your skin interfered with you going 
shopping or looking after your home or yard? 
Very much 
A lot 
A little 
Not at all 
 
 
 
 
 
 
 
Not relevant  
4. Over the last week, how much has your skin influenced the clothes you 
wear? 
Very much 
A lot 
A little 
Not at all 
 
 
 
 
 
 
 
Not relevant  
5. Over the last week, how much has your skin affected any social or leisure 
activities? 
Very much 
A lot 
A little 
Not at all 
 
 
 
 
 
 
 
Not relevant  
6. Over the last week, how much has your skin made it difficult for you to do 
any sport? 
 
Very much 
A lot 
A little 
Not at all 
 
 
 
 
 
 
 
Not relevant  
7. Over the last week, has your skin prevented you from working or 
studying? 
yes 
no 
 
 
 
Not relevant  
If "No", over the last week how much has your skin been a problem at work 
or studying? 
A lot 
A little 
Not at all  
 
 
 
 
 
 
8. Over the last week, how much has your skin created problems with your 
partner or any of your close friends or relatives?   
Very much 
A lot 
A little 
Not at all 
 
 
 
 
 
 
 
Not relevant  
9. Over the last week, how much has your skin caused any sexual 
difficulties? 
 
Very much 
A lot 
A little 
Not at all 
 
 
 
 
 
 
 
Not relevant  
10. Over the last week, how much of a problem has the treatment for your skin 
been, for example by making your home messy, or by taking up time? 
Very much 
A lot 
A little 
Not at all 
 
 
 
 
 
 
 
Not relevant  
© AY Finlay, GK Khan, April 1992. This must not be copied without the permission of the authors. 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 100 of 109 
IFX-1 
InflaRx GmbH 
The total DLQI Score is classified as follows [20]: 
0-1 
No effect on subject’s life 
2-5 
Small effect on subject’s life 
6-10 
Moderate effect on subject’s life 
11-20 
Very large effect on subject’s life 
21-30 
Extreme effect on subject’s life 
 
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 101 of 109 
IFX-1 
InflaRx GmbH 
17.8 The Hospital Anxiety and Depression Scale  
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 102 of 109 
IFX-1 
InflaRx GmbH 
17.9 The 36-Item Short Form Survey  
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 103 of 109 
IFX-1 
InflaRx GmbH 
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 104 of 109 
IFX-1 
InflaRx GmbH 
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 105 of 109 
IFX-1 
InflaRx GmbH 
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 106 of 109 
IFX-1 
InflaRx GmbH 
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 107 of 109 
IFX-1 
InflaRx GmbH 
 
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 108 of 109 
IFX-1 
InflaRx GmbH 
17.10 
The EuroQol-5 Dimensions Survey  
 
 

 
IFX-1-P2.4 
Global Amendment 1.1 [Final V2.0, 16 November 2018] 
page 109 of 109 
IFX-1 
InflaRx GmbH